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Abstract 
 
Forward genetics is the process of identifying the genotype responsible for a particular 
phenotype. This thesis project stemmed from the investigation of two mutants presenting 
with lymphatic defect during embryonic life. Both were isolated during the first forward 
genetic screen aimed at identifying novel regulators of lymphangiogenesis using zebrafish, 
which was performed between 2007 and 2009 at the Hubrecht Institute in Utrecht, The 
Netherlands. The mutants were isolated based on a visible reduction, or complete 
absence, of the thoracic duct, one of the major collecting lymphatic vessels in the 
zebrafish trunk.  
 
Chapter 2 provides a first look at how post-translational modification can affect 
angiogenesis. Although the zebrafish mutant reported in this chapter was isolated based 
on a lymphatic phenotype, we quickly focused our attention on the visible blood vascular 
hyper branching phenotype exhibited by mutant embryos. We successfully linked this 
phenotype to a loss-of-function mutation in the gene carbamoyl-phosphate synthetase2, 
aspartate transcarbamylase, and dihydroorotase (cad), a known regulator of post-
translational glycosylation. We provide evidence suggesting that this gene acts within the 
NOTCH mediated inhibition of VEGFC/VEGFR3 signaling in arteries. We demonstrate that 
the hyperbranching phenotype can be specifically rescued with a targeted knock-down of 
the VEGFC/VEGFR3 pathway.  
 
Chapter 3 is the core of this thesis and reports our work on a second zebrafish mutant 
dubbed lymphatic and cardiac defects 1 (lyc1). This mutant was linked to a loss of function 
mutation in the gene polycystic kidney disease 1a (pkd1a). We show that the lyc1 
lymphatic phenotype is characterised by a defect in the migration of lymphatic precursors 
cells to form the thoracic duct. Using Pkd1 knock-out mice, we show that Pkd1 regulates 
cell-to-cell junction integrity, which is consistent with the gross morphological defect of 
knock-out lymphatic endothelial cells, and altered morphogenesis of maturing lymphatic 
vessels. We provide evidence both in vitro and in vivo that the loss of Pkd1 reduces 
lymphatic endothelial cells exploratory behaviour. This work represents an entirely new 
facet of Pkd research, and presents a novel role for an extremely well studied protein, in a 
new cellular context. 
 
 In Chapter 4, we examined the intriguing possibility that intravascular flow might control 
secondary angiogenesis, with a particular emphasis on the lymphatic vasculature. We 
provide evidence supporting the idea that an alteration of flow, prior to the initiation of 
secondary angiogenesis, significantly reduces the number of angiogenic sprouts. We also 
show that the morphology of the vascular system, as well as the reported physical property 
of the circulating blood, are predicted to expose vascular endothelial cells to a degree of 
mechanical stimulation that is compatible with a physiological response. We provide clues 
as to which genes might mediate this vascular endothelial cell response, demonstrating 
that a knock-down of klf2a and nfatc1 expression, two genes previously reported to play a 
key role in flow-dependent developmental processes, results in a decrease of the number 
of lymphatic precursor cells forming during secondary angiogenesis.  
Declaration by author 
 
This thesis is composed of my original work, and contains no material previously published 
or written by another person except where due reference has been made in the text. I 
have clearly stated the contribution by others to jointly authored works that I have included 
in my thesis. 
 
I have clearly stated the contribution of others to my thesis as a whole, including statistical 
assistance, survey design, data analysis, significant technical procedures, professional 
editorial advice, and any other original research work used or reported in my thesis. The 
content of my thesis is the result of work I have carried out since the commencement of 
my research higher degree candidature and does not include a substantial part of work 
that has been submitted to qualify for the award of any other degree or diploma in any 
university or other tertiary institution. I have clearly stated which parts of my thesis, if any, 
have been submitted to qualify for another award. 
 
I acknowledge that an electronic copy of my thesis must be lodged with the University 
Library and, subject to the General Award Rules of The University of Queensland, 
immediately made available for research and study in accordance with the Copyright Act 
1968. 
 
I acknowledge that copyright of all material contained in my thesis resides with the 
copyright holder(s) of that material. Where appropriate I have obtained copyright 
permission from the copyright holder to reproduce material in this thesis. 
 
 
 
 
 
 
Baptiste Coxam 
November 2014
 
Publications during candidature 
 
1. Coxam B*, Sabine A, Bower NI, Smith KA, Pichol-Thievend C, Skoczylas R, Astin 
JW, Frampton E, Jaquet M, Crosier PS, Parton RG, Harvey NL, Petrova TV, 
Schulte-Merker S, Francois M, Hogan BM (2014) Pkd1 regulates lymphatic vascular 
morphogenesis during development. Cell reports 7: 623-633 
 
2. Coxam B*, Neyt C*, Le Guen L, Grassini DR Smith KA, Schulte-Merker S, Hogan 
BM,  
carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and 
dihydroorotase (cad) regulates Notch signaling and vascular development in 
zebrafish. Developmental Dynamics (accepted October 2014) *Equal first authors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Publications included in this thesis 
carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and 
dihydroorotase (cad) regulates Notch signaling and vascular development in 
zebrafish.  
Baptiste Coxam, Christine Neyt, Ludovic Le Guen, Daniela R. Grassini, Kelly A. Smith, Stefan Schulte-
Merker, Benjamin M. Hogan,  
Incorporated as Chapter 2.  
Contributor Statement of contribution 
Baptiste Coxam Designed and performed experiments (47%), prepared figures, wrote paper (50 %) 
Christine Neyt Designed and performed experiments (40%) 
Daniela R. Grassini Designed and performed experiments ( 3%) 
Ludovic Le Guen Designed and performed experiments (10%) 
Kelly A. Smith Provided reagents and material  
Stefan Schulte-Merker Provided reagents and material  
Benjamin M. Hogan PhD supervision, wrote paper (50 %) 
 
Pkd1 regulates lymphatic vascular morphogenesis during development.  
Baptiste Coxam, Amélie Sabine, Neil I. Bower, Kelly A. Smith, Cathy Pichol-Thievend, Renae Skoczylas, 
Jonathan W. Astin, Emmanuelle Frampton, Muriel Jaquet, Philip S. Crosier, Robert G. Parton1, Natasha L. 
Harvey, Tatiana V. Petrova, Stefan Schulte-Merker, Mathias Francois and Benjamin M. Hogan 
Incorporated as Chapter 3.  
Contributor Statement of contribution 
Baptiste Coxam Designed and performed experiments (68%), prepared figures, wrote paper (50 %) 
Amélie Sabine Designed and performed experiments (14%), prepared figures 
Neil I. Bower Designed and performed experiments (2%) 
Kelly A. Smith Designed and performed experiments (3%) 
Cathy Pichol-Thievend Designed and performed experiments (4.5%) 
Renae Skoczylas Provided assistance with reagents and material  
Johnathan W.Astin Provided assistance with reagents and material  
Emmanuelle Frampton Designed and performed experiments (1.7%) 
Muriel Jacquet Provided assistance with reagents and material  
Philip S. Crosier Provided reagents and material  
Rober G. Parton Designed and performed experiments (1.7%) 
Nathan L. Harvey Provided assistance with reagents and material  
Tatiana V. Petrova Provided assistance with reagents and material  
Stefan Schulte-Merker Provided reagents and material  
Mathias Francois Designed and performed experiments (5.1%) 
Benjamin M. Hogan PhD supervision, wrote paper (50 %) 
 
Contributions by others to the thesis  
 
Significant contributions include: 
 
Chapter 2-3: 
Contributions are detailed previously.  
 
Chapter 4: 
The model presented in figure 4.4 and 4.5 was designed and built by Tim Lamberton. 
 
 
Statement of parts of the thesis submitted to qualify for the award of another degree 
 
NONE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acknowledgements 
First and foremost, I would like to thank Ben for giving me a place in this very special place 
that is his lab. As he always compelled me to try new approaches, I tried to innovate and 
decided to present my acknowledgments to him in an unorthodox format:  
 
 
 
 
I would like to thank all the members of the Hogan lab over the last 4 years for the 
constant help, support, joking around, and the large sprinkles of fun they poured over 
these PhD years. Particular thanks go to Neil and Scott for ever-fruitful discussions about 
sport and other things (and kudos to Scott for helping me understand the rules of almighty 
cricket), and Christine for being a constant help and providing all the assistance a young 
PhD student would ever need. 
 
My thanks go to all the members of the cardiovascular division, for making lab meeting 
and collaborative research so much more entertaining. And for making up the numbers 
during Christmas beach cricket. Many thanks to Kelly for nice random life/science chats 
and to Mat for nice random life/science chats late at night. Thanks also go to Amanda 
Carozzi and the post-graduate team at the IMB for their constant support and help 
throughout the administrative challenges of my PhD life. I would also like to thank my 
parents for the life-long sponsoring of my private and academic career, and for always 
supporting me through all my choices.  
 
I also would like to thank Redbull, instant noodles and the 7th floor vending machine for 
always being there for me. 
 
Obviously, a huge thank you goes to Ash for her constant support, understanding, and not 
minding me skipping social life to go in the lab and science hard at the most socially 
inappropriate times. Also for being the best argument I have seen so far that Science 
might not be the most awesome aspect of my life.  
 
  
Keywords 
vascular development, lymphangiogenesis, forward genetic,  glycosylation, 
morphogenesis, cell polarity, shear stress, secondary angiogenesis, primary cilia, 
mechanosensor. 
 
 
Australian and New Zealand Standard Research Classifications 
(ANZSRC) 
 
ANZSRC code: 060403 DEVELOPMENTAL GENETICS, 100% 
 
 
Fields of Research (FoR) Classification 
 
FoR code:  0604 GENETICS, 100% 
 
 Table of content: 
 
Non-standard Abbreviations and Acronym .................................................................................. 4 
 
List of figures ................................................................................................................................... 5 
 
1.Review of the literature ................................................................................................................ 8 
1.1 Structure and function of the lymphatic system vasculature in vertebrates ............................... 10 
1.1.1 Cellular structure of adult lymphatic endothelial cells ............................................... 10 
 
1.2 Lymphatic vessels in disease .................................................................................................... 12 
1.2.1 Diseases of reduced lymphatic function. .................................................................... 12 
1.2.1.1 Lymphedema ............................................................................................... 12 
1.2.1.2 Inflammatory response/disorders ................................................................. 12 
1.2.1.3 Lymphatic dysfunction and obesity .............................................................. 12 
                        
            1.2.2 Diseases of excess lymphatic function ....................................................................... 14 
1.2.2.1 Cancer metastasis ....................................................................................... 14 
 
1.3 The cellular process of lymphatic vessel development ............................................................. 14 
1.3.1 The venous origin of lymphatic vessels ...................................................................... 14 
1.3.2 Migration of lymphatic precursor cells and maturation of the lymphatic network ........ 18 
            1.3.2.1 Francois (2012) and Yang (2012) model ..................................................... 18 
            1.3.2.2 Hagerling model (2013)  .............................................................................. 18 
 
 
1.4 Zebrafish: a model for the study of vascular development ........................................................ 22 
1.4.1 Identification of the zebrafish lymphatic vasculature .................................................. 22 
1.4.2 Development of the zebrafish lymphatic vasculature ................................................. 23 
 
1.5 Genetic regulation of lymphangiogenesis .................................................................................. 25 
1.5.1 Specification and early maintenance .......................................................................... 25 
1.5.1.1 PROX1. ........................................................................................................ 25 
1.5.1.2 SOX18 ......................................................................................................... 25 
1.5.1.3 COUP-TFII ................................................................................................... 26 
1.5.1.4 Retinoic acid ................................................................................................ 27 
          1.5.2 Migration and maturation of LECs ................................................................................ 27 
1.5.2.1 VEGFC /VEGFR3 ........................................................................................ 27 
1.5.2.2 TBX1 ............................................................................................................ 28 
1.5.2.3 CCBE1 ......................................................................................................... 28 
1.5.2.4 FOXC2 ......................................................................................................... 30 
1.5.2.5 NFATC1 ....................................................................................................... 30 
1.5.2.6 ANGIOPOIETIN/TIE pathway ...................................................................... 31 
 
 
1.5.3 External factors regulating lymphangiogenesis .......................................................... 33 
1.5.3.1 Chemokine signaling .................................................................................... 33 
1.5.3.2 Neurons ....................................................................................................... 33 
1.5.3.3 Tissue fluid pressure .................................................................................... 34 
 
 
Background to the project ............................................................................................................ 36 
 
Aim of the project .......................................................................................................................... 38 
 
1
 
2 carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase 
(cad) regulates Notch signaling and vascular development in zebrafish ............................... 40 
Foreword ......................................................................................................................................... 42 
 
 
 
 
3 Pkd1 regulates lymphatic vascular morphogenesis during development ........................... 54 
Foreword ......................................................................................................................................... 56 
 
4 Blood flow induced shear stress regulates secondary angiogenesis in zebrafish ............. 96 
 
4.1 Introduction ................................................................................................................................ 98 
4.2 Results ..................................................................................................................................... 101 
4.3 Discussion ............................................................................................................................... 112 
4.4 Experimental procedures ......................................................................................................... 115 
4.5 Acknowledgments ................................................................................................................... 117 
 
5 Concluding remarks ................................................................................................................. 118 
 
Supplementary material .............................................................................................................. 126 
References ................................................................................................................................... 136 
 
 
 
 
2
Non-standard Abbreviations and Acronyms 
ADPKD    Autosomal dominant polycystic kidney disease  
ANG1    Angiopoietin 1 
ANG2    Angiopoietin 2 
CAD               Carbamoyl-phosphate synthetase2, aspartate transcarbamylase,  
                       and dihydroorotase 
CCBE1       Collagen- and calcium-binding EGF domains 1  
CYP26B1   Cytochrome P450, Family 26, subfamily B, polypeptide 1 
DA                  Dorsal Aorta 
DCC       Deleted in colorectal cancer 
DLAV      Dorsal longitudinal anastomosis vessel 
DLLV             Dorsal longitudinal lymphatic vessels 
DOCK180     Dedicator of cytokinesis 180 
ECM        Extracellular matrix  
ELMO1         Engulfment and cell motility protein 1 
FLT4             fms-like tyrosine kinase 4 (VEGFR-3) 
FOXC2         Forkhead box protein C2 
HUVECS    Human umbilical vein endothelial cells 
IFT88       Intraflagellar transport protein 88 homolog 
iLECs        Initial lymphatic endothelial cells 
KLF2A        Kruppel-like factor 2a 
LEC     Lymphatic endothelial cell  
LYVE-1     Lymphatic vessel endothelial hyaluronan receptor 1  
NFATC1       Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 
3
PCV             Posterior Cardinal Vein 
PECAM-1    Platelet endothelial cell adhesion molecule 1  
PKD1    Polycystic Kidney Disease 1 
PKD2     Polycystic Kidney Disease 2 
PL      Parachordal lymphangioblast 
PLLV           Peripheral longitudinal lymphatic vessel 
PROX-1   Prospero homeobox 1 
pTD             Primordial thoracic duct 
RAC1    Ras-related C3 botulinum toxin substrate 1  
sLECs    Superficial lymphatic endothelial cells 
TBX1    T-box protein 1 
TD              Thoracic duct 
TIE1           Tyrosine kinase with immunoglobulin-like and EGF-like domains 1 
TIE2           Tyrosine kinase with immunoglobulin-like and EGF-like domains 2 
UNC5b   UNC5 homolog BDCC 
VEGF-C    Vascular endothelial growth factor C  
VEGFR-3  Vascular endothelial growth factor receptor 3 
VS              Venous sprout 
 
 
 
 
 
4
List of figures incorporated in this thesis: 
 
Figure 1.1 – Organisation of the lymphatic vasculature .................................................................. 11 
Figure 1.2 – Diseases of reduced lymphatic function ..................................................................... 13 
Figure 1.3 – Cancer Metastasis ...................................................................................................... 15 
Figure 1.4 – Lymphatic development in mice ................................................................................. 17 
Figure 1.5 – Lymphangiogenesis model – Francois and Yang ....................................................... 19 
Figure 1.6 – Lymphangiogenesis model – Hagerling ..................................................................... 21 
Figure 1.7 – Lymphangiogenesis in zebrafish ................................................................................ 24 
Figure 1.8 - Transcription factors regulating lymphangiogenesis ................................................... 32 
Figure 1.9 – Chemokine signaling during lymphatic vascular development in zebrafish ................ 35 
Figure 1.10 – Forward genetic screen for lymphatic mutants ......................................................... 37 
Figure 4.1 – Abolition of blood flow in zebrafish embryos reduces the number of secondary 
angiogenic sprouts……………... ................................................................................................... 101 
Figure 4.2 – A decrease in intravascular shear stress reduces the formation of parachordal 
lymphangioblasts ........................................................................................................................... 102 
Figure 4.3 – Increased intravascular shear stress reduces the formation of parachordal 
lymphangioblasts ........................................................................................................................... 103 
Figure 4.4 – Construction of a physical model to predict shear stress intensity in the posterior 
cardinal vein .................................................................................................................................. 105 
Figure 4.5 – The intensity of shear stress is patterned along the dorso-ventral and longitudinal axis 
at the time of secondary angiogenesis from the posterior cardinal vein ........................................ 106 
Figure 4.6 – Disruption of primary cilia formation and maintenance does not impair secondary 
angiogenesis ................................................................................................................................. 107 
Figure 4.7 – Ca2+ and NO signaling are dispensable for the initiation of secondary angiogenesis ....  
 ....................................................................................................................................................... 108 
Figure 4.8 – klf2a expression is flow-dependent and its knock-down reduces the formation of 
parachordal lymphangioblasts ....................................................................................................... 110 
5
Figure 4.9 – Specific knock-down of nfatc1 expression in zebrafish reduces the formation of 
parachordal lymphangioblasts and the thoracic duct .................................................................... 111 
Supplementary Figure 1 – Knock-down of ift88 transcription results in a secondary angiogenic 
defect ............................................................................................................................................. 128 
 
Chapter 2 is presented as published online by Developmental Dynamics from page 40 
 
Chapter 3 is presented as published online by Cell Reports from page 54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7
Chapter 1 – Review of the literature 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9
In this literature review, I will investigate our current understanding of the role of the lymphatic 
vasculature in human physiology, the cellular origins of lymphatic vascular development, the major 
components involved in the molecular regulation of this process and the role of the zebrafish model 
in the field.  
 
1.1 Structure and function of the lymphatic system vasculature in mammals 
The lymphatic vasculature is composed of a network of blind-ended vessels lined by a single layer 
of overlapping endothelial cells. The lymphatic vasculature is independent of the blood vascular 
system and therefore does not contain any red blood cells.  Lymphatic vessels transport lymph 
(containing tissue fluid, immune cells and proteins), which flows unidirectionally from the tissues to 
the heart, where it reenters the bloodstream via the subclavian veins (Alitalo, 2011).  
 
In mammals, interstitial fluids enter the lymphatic vasculature via lymphatic capillaries that drain 
into pre-collecting lymphatic vessels. Pre-collecting lymphatics subsequently merge into secondary 
lymphatics that, unlike smaller capillaries, possess a continuous basal membrane and are 
surrounded by smooth muscle cells that provide contractile activity to assist lymph flow. 
Unidirectional flow of lymph is ensured by the presence of valves inside the collecting lymphatic 
vessels that prevent backward flow. Collecting lymphatic vessels deliver lymph to the lymph nodes, 
which are specialised structures enriched in white blood cells, designed to filter the lymph, identify 
and respond to all potential pathogens it may contain. The lymph then reenters the collecting 
lymphatic vessels, before ultimately being returned to the blood circulation (Butler et al., 2009; 
Schulte-Merker et al., 2011)(Figure 1.1).  
 
1.2.1 Cellular structure of adult lymphatic endothelial cells 
In capillary lymphatics, oak leaf-shaped endothelial cells are attached to the extracellular matrix via 
anchoring filaments. Interstitial fluid pressure tensions these filaments, pulling apart the endothelial 
cells and allowing for the entry of lymph. The button-like junctions present in between these cells 
allow for a directed lymph entry inside the lumen of the lymphatic capillary, while maintaining 
vascular integrity (Baluk et al., 2007). In collecting lymphatic vessels, endothelial cells present with 
a more elongated morphology and attach to their neighbors via continuous zipper-like junctions, 
which do not allow for the entry of interstitial fluids (Schulte-Merker et al., 2011).  In that sense, the 
very morphology and junctional identity of capillary and collecting lymphatic endothelial cells is a 
reflection of different physiological roles played by capillary and collecting lymphatic vessels, that 
is, respectively, the uptake and transport of lymph (Baluk et al., 2007)(Figure 1.1).  
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Figure 1.1. Organisation of the lymphatic vasculature. Sections 1.1/1.2 
(A) The lymphatic vasculature is independent of the blood vasculature. It transports lymph (tissue fluids, 
immune cells and proteins) unidirectionally from tissues to the heart where it reenters the bloodstream. 
Interstitial fluids enter the lymphatic vasculature via lymphatic capillaries that drain into collecting lymphatic 
vessels (greens arrows indicate the entry of lymph and the directionality of lymph flow). (B) Endothelial cells 
in lymphatic capillaries have a unique morphology that allows them to adapt to changes in external fluid 
pressure, and ensure the proper uptake of interstitial fluids and cells. Anchoring filaments attach the oak-
shaped endothelial cells to the extracellular matrix, which allows for the directed entry of lymph and prevent 
its return to the interstitial space. (C) In capillary lymphatic, endothelial cells are connected to one another 
via button like junctions, which allow for the entry of lymph while maintaining vascular integrity. Endothelial 
cells of collecting lymphatic vessels attach to their neighbors via regular zipper-like junctions, which do not 
allow for the uptake of extra cellular components. EC, endothelial cell. Figure from (Schulte-Merker et al., 
2011) 
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1.2 Lymphatic vessels in diseases  
1.2.1 Diseases of reduced lymphatic function 
 
1.2.1.1 Lymphedema 
Lymphedema is a chronic condition affecting 135 million people worldwide, with no cure yet in sight 
(Source: Stanford medicine research news). Recent reports suggest that around 300,000 
Australians will experience lymphedema at some point in their lifetime (source: Better health – 
Victorian Government). Lymphedema is the general term used to describe pathologies 
characterised by excessive interstitial accumulation of lymph caused by a dysfunction of the 
lymphatic vasculature, which progress to tissue fibrosis and inflammatory complications in chronic 
cases. Patients affected by lymphedema show regional inflammatory tissue response related to 
lymph fluid stasis, a result demonstrated in an experimental in vivo context (Rockson, 2001; 
Tabibiazar et al., 2006). It can be a primary (inherited) condition (such as in the autosomal 
recessive Hennekam syndrome where vessel dysplasia induces lymphedema in limbs (Alders et 
al., 2009; Hennekam et al., 1989) or a secondary (acquired) condition, as can occur after treatment 
of breast cancer, when the surgical removal of axillary lymph nodes is required (Rockson, 
2001)(Figure 1.2). 
 
1.2.1.2 Inflammatory response/disorders  
Lymphatic vessels play an active role in the transport of molecules and cells involved in the 
inflammatory response from peripheral tissues to lymph nodes and secondary lymphoid organs 
(Reviewed in (Tammela and Alitalo, 2010)). In particular, lymphocytes traffic from the periphery to 
the lymph nodes via the lymphatic vasculature during antigen presentation. Lymphangiogenesis is 
often induced in inflammation, as it is assumed to aid in the process, notably by reducing 
inflammation-induced oedema. (Karpanen and Alitalo, 2008b; Ristimaki et al., 1998).  
 
1.2.1.3 Lymphatic dysfunction and obesity 
The lymphatics of the mesentery are required for the drainage of dietary fatty acids and biological 
studies suggests a link with obesity. A link between lymphatic vessel leakage and adult-onset 
obesity was established in mouse models, where a mutation in Prox1, causing an abnormal 
patterning and rupture of lymphatic vessels, resulted in a correlated ectopic growth of fat cells in 
lymphatic rich tissues (Harvey et al., 2005). Harvey and colleagues hypothesised that the lymph 
may contain adipogenic factors and tested this by cultivating pre-adipogenic cells with lymph 
collected from newborns Prox-/- mice.  Potent adipogenic stimulation of the cultured cells 
demonstrated factors present in lymph were able to induce the accumulation of adipose tissue 
(Harvey et al., 2005).This research prompted us to reconsider the very etiology of obesity, as it 
raises the possibility that a lymphatic dysfunction might be a major underlying contributor to the 
pathology.  
12
  
 
 
Figure 1.2  - Diseases of reduced lymphatic function. Section 1.2.1 
Primary lymphedema are inherited pathologies characterised by abnormal lymphatic vessel morphology or a 
general reduction in the lymphatic vasculature. Secondary lymphedema are often the result of physical 
disruption of the lymphatic vasculature structure or integrity. Both lead to gross morphological defects, such 
as fluid retention in limbs.  
Figure from (Karpanen and Alitalo, 2008a). 
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1.2.2 Diseases of excess lymphatic function 
 
1.2.2.1 Cancer metastasis 
By the age of 85, 1 in 2 men and 1 in 3 women will have been diagnosed with cancer at some 
stage in their life. Cancer was responsible for a third of all deaths in 2010 (Source: National 
Institute of Health and Welfare, Cancer Report 2010). 
Tumour cells start to metastasise through the organism by invading either or both pre-existing 
blood and lymphatic vessels in the periphery of the tumour and by promoting neo-angiogenesis 
and neo-lymphangiogenesis (growth of lymphatic vessels from pre-existing lymphatic vessels) 
through the production of growth factors (VEGF-C/VEGF-D). When disseminating via lymphatics, 
these tumours then spread to the closest regional lymph node and further throughout the organism 
(reviewed in (Alitalo et al., 2005). Ninety percent of cancer mortality occurs due to cancer 
metastasis, rather than because of the primary tumour, which is often removed surgically or treated 
with chemotherapy (source: American Cancer Society, (Steeg, 2006)). Work by He and colleagues 
and Caunt and colleagues have shown that targeted inhibition of lymphangiogenesis impedes the 
spreading of tumour cells via metastasis (Caunt et al., 2008; He et al., 2002). In these particular 
studies, components of the Vegf-C/Vegfr-3 pathway were selectively inhibited, an approach that is 
currently used in multiple clinical trials (Vegenics annual report 2013)(Figure 1.3). 
 1.3 The cellular process of lymphatic vessel development 
Lymphangiogenesis is the formation of lymphatic vessels from pre-existing veins or lymphatic 
vessels and its mechanism is common in development and in disease. The investigation of the 
cellular origins and molecular regulation of the development of the lymphatic vasculature is 
therefore a necessary first step towards the discovery of novel therapeutic solutions to lymphatic 
pathologies.  
1.3.1 The venous origin of embryonic lymphatic vessels  
The chronology of embryonic lymphatic development starts with lymphatic endothelial cells 
emerging from the pre-existing venous endothelium to form primary lymphatic structures. These 
structures serve as origins for the further outgrowth of lymphatic vessels later maturing into a fully 
functional lymphatic vascular system. Over recent years, multiple reports have refined our 
understanding of this mechanism and its underlying cellular dynamics. One long-standing model, 
proposed over a century ago (Sabin, 1902) hypothesised that isolated primitive lymph sacs, 
primary lymphatic structures, bud from the endothelium of veins during early development; from 
these primary lymph sacs, the peripheral lymphatic system spreads by endothelial sprouting into  
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Figure 1.3 – Cancer metastasis. Section 1.2.2.1 
(A) Tumour can metastise through the blood and lymphatic vasculature. (B) Tumour can stimulate the 
formation of new lymphatic vessels from pre-existing ones (neo-lymphangiogenesis) and invade the 
lymphatic vasculature though intravasation. Lymphatic vessels are indicated in light green, and neo-formed 
vessels in dark green. When disseminating via lymphatics, these tumours then spread to the closest regional 
lymph node and further throughout the organism (reviewed in (Alitalo et al., 2005) Adapted from (Alitalo et 
al., 2005)                                                                                                                                                
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 tissues where local capillaries form. This theory was based on experiments involving dye injection 
into pig embryos and subsequent reconstruction of the lymphatic vasculature via careful 
sectioning. Despite an early controversy raised by the formulation of an alternative model by 
Huntington and McClure (stating that lymph sacs develop independently of the veins, arising in the 
mesenchyme (reviewed in (Huntington, 1914)), this venous endothelial origin of the lymphatic 
progenitor cells was very recently confirmed in zebrafish (Isogai et al., 2003; Kuchler et al., 2006; 
Yaniv et al., 2006) and mice (Srinivasan et al., 2007). 
 
In mouse, PROX1-/- animals were the first reported models of early lymphatic developmental arrest 
(Wigle and Oliver, 1999). These embryos had no lymphatic vasculature, suggesting Prox1 played a 
role in lymphangiogenesis (detailed in section 1.4.1.1). To analyse the expression of PROX1 
during development in mouse, Wigle and Oliver inactivated the Prox1 gene by in-frame insertion of 
the β-galactosidase gene, followed by X-gal staining. Prox1 expression was detected first in the 
embryonic veins and then became localised to the first developing lymphatic vessels (Wigle and 
Oliver, 1999). This expression pattern suggested a relationship between veins and the first 
developing lymphatics consistent with Sabin’s model.  
 
This result was later confirmed directly by cell lineage tracing experiments, with the use of a Prox1 
promoter driving the expression of a Tamoxifen-inducible Cre construct (Srinivasan et al., 2007). 
Using this transgenic mouse on the β-galactosidase (R26R line) background, Cre activity was 
induced at time points before the formation of lymphatics, when Prox1 is expressed exclusively in 
veins (from embryonic day 9.6 (E9.5) to E10.5). Once the embryos formed lymphatics, β-
galactosidase positive lymphatic vessels could be seen at later stages (from E11.5 to E15.5), 
demonstrating that venous embryonic endothelial cells directly give rise to lymphatic endothelial 
cells (LECs) (Srinivasan et al., 2007) (Figure 1.4). 
 
This work by Srinivasan was the second to demonstrate a venous origin of the lymphatic 
vasculature in vivo. In the zebrafish, described in details in section 1.5, Yaniv and Isogai also found 
that lymphatic precursors derive from veins (Yaniv et al., 2006). Using a transgenic zebrafish line, 
Tg(fli1a: nEGFP) y7, in which a pan-vascular promoter drives the expression of nuclear GFP, they 
performed time-lapse imaging of lymphatic development. These movies, when played backwards, 
allowed them to trace cells that contributed to lymphatics, finding that they had originated in veins.  
 
Both Srinivasan’s and Yaniv’s studies concluded that the emergence of lymphatic precursor cells 
occurs via sprouting from the cardinal vein, in a process by which migration occurs in a polarised 
manner. These emerging lymphatic precursor cells ultimately proliferate, migrate, and give rise to 
the mature lymphatic vasculature. 
16
  
 
 
 
 
Figure 1.4 – Lymphatic development in mouse. Section 1.3.1 
(A) Schematic representation of a E10.5 mouse embryo. The dashed box indicates the region of the embryo 
used to investigate lymphangiogenesis. (B) A sagittal cartoon view of the sprouting of lymphatic precursor 
cells (initial lymphatic endothelial cells, iLECs) from the cardinal veins, intersomitic veins (iSV) and the 
superficial venous plexus (sVP). (C) Confocal projection of a sagittal section in the jugular region shows the 
departure of iLECs (PROX1 positive – green) from the vein (ENDOMUCIN positive - blue). (D) Schematic 
representation of a E11.5 embryo. (E) A sagittal cartoon view shows that initial iLECs have reorganized in 2 
bilateral structures termed lymph sac (or pre-thoracic duct, pTD), and a posterior longitudinal lymphatic 
vessel (PLLV). The PLLV is ultimately the source of superficial lymphatic endothelial cells (sLECs), which are 
thought to contribute to the dorsal subcutaneous lymphatic plexus later during development. (F) Confocal 
projection of a sagittal section in the jugular region shows the different lymphatic endothelial cell populations 
in the trunk of a E11.5 embryo, immunostained for the lymphatic marker PROX1. S: Somite. Adapted from 
(Koltowska et al., 2013) 
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1.3.2 Migration of lymphatic precursor cells and maturation of the lymphatic network 
 
1.3.2.1 Francois (2012) and Yuan (2012) model. 
In recent times, a number of studies have refined the traditional model of murine lymphatic 
development championed by Sabin (Sabin, 1902). Van der Putte showed by section-based studies 
that blind-ended vascular outgrowths emerge from different parts of the major embryonic veins, 
before expanding centrifugally and fusing with adjacent outgrowths to form lymph sacs (van der 
Putte, 1975). In rather a similar way, Francois and colleagues described the emergence of 
primordial lymph sac from clusters of lymphatic precursors along the posterior cardinal vein in 
mice, via a ballooning process (François et al., 2012). These different primordial lymph sacs 
subsequently expand through their surrounding tissues and connect to adjacent lymph sacs to 
form a continuous lymphatic vascular system alongside the vein, connected to the blood vascular 
system only through the jugulo-subclavian region. The emergence of precursors cells from these 
pre-lymphatic clusters is temporally regulated from caudal to rostral. This work reconciled with the 
existing discrepancy that a stream of cells emerging from the vein to later coalesce into a hollow 
sac, despite evidence showing that these lymph sacs contain blood cells at an early stage, 
suggesting a connection with the vein (François et al., 2012). Francois and colleagues also 
described a population of NRP2-positive cells (a marker of migrating lymphatic cells (Yuan et al., 
2002)) emerging from the vein, which do not contribute to lymph sac formation (François et al., 
2012)(Figure 1.5).  
 
1.3.2.2  Hägerling model (2013) 
More recently, Hägerling and colleagues have further expanded the characterisation of primary 
lymphatic structures forming during murine embryogenesis, defining novel structures as well as 
identifying a potential new origin for a subgroup of lymphatic progenitor cells (Hagerling et al., 
2013). Hägerling and colleagues’ work is in agreement with that of Yang and colleagues in that 
both suggest the initial emergence of LEC from the venous vasculature occurs through budding 
rather than endothelial sprouting. In their view, initial LECs (iLECs) migrate away from the venous 
vasculature to form two distinct bilateral and symmetrical structures: the ventral primordial thoracic 
duct (pTD) and the peripheral lymphatic longitudinal vessel (PLLV). The pTD (a novel 
denomination regrouping all the initial lymph sacs previously thought to arise from the vein as 
individual structures) forms closer the cardinal vein, from the coalescing of a population of iLECs. 
This structure later connects to the cardinal vein, as suggested by the presence of erythrocytes 
within the pTD starting at 12 dpc despite the absence of erythrocytes enclosed by migrating iLECs. 
This result is in direct contradiction with the findings of Francois and colleagues, as it defines the 
connection to the vein as subsequent to the formation of the pTD. The study by Hägerling and  
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Figure 1.5 – Lymphangiogenesis models – Francois, Yang. Section 1.3.2 
(A) Model of early lymphangiogenesis as defined by Francois and colleagues. Francois and colleagues 
describe lymphatic precursor cells clusters along the cardinal vein, which give rise to primordial lymph sacs 
via a ballooning mechanism, and the sprouting of LECs contributing to the superficial lymphatic vasculature. 
Each of these clusters is characterised by a unique marker expression profile that correlates with their mode 
of detachment from the wall of the vein.  
(B) Model of early lymphangiogenesis as defined by Yang and colleagues. Yang and colleagues suggest a 
dual origin of LECs from both the cardinal vein (CV) and intersegmental veins (ISV), which both contribute to 
the formation of a lymph sac like structure (green) alongside the cardinal vein. Figures from (François et 
al., 2012; Yang et al., 2012) 
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colleagues also suggests that the formation of the lymphovenous connection is concomitant with 
the aggregation of iLECs into a lumenised pTD. Here, there remains some controversy about the 
details of how the first lymphatics arising from the vein give rise to the different structures that 
compose the lymphatic vasculature.  
 
The PLLV, a thin and convoluted lumenised structure is thought to arise from the aggregation of 
iLECs originating from both the CV and the superficial venous plexus (sVP). The PLLV is the 
primary source of superficial lymphatic endothelial cells (sLECs), which go on to form the 
subcutaneous lymphatic network. The sLECs acquire a different expression profile to iLECS and 
pTD forming cells, mirroring their morphological changes (Hagerling et al., 2013).  
 
Importantly, this is only the second study to provide evidence supporting the idea that LECs 
originate from a part the venous vascular tree that is not the cardinal vein. Hägerling and 
colleagues characterised the sVP, as being immediately medial to the myotome and above the 
cardinal veins, as an alternative source of lymphatic precursor cells. This conclusion was 
supported by the fact that, similar to what is observed within the cardinal vein (CV), an 
accumulation of Prox1-positive lymphatic progenitor cells can be detected in the ventral part of the 
sVP in mutants presenting with impaired migration of LECs from the CV (see section 1.4.2.1). In 
wild-type context, these Prox1 positive cells are observed to leave the sVP and, as mentioned 
earlier, contribute ultimately to the formation of the superficial lymphatic vasculature (Figure 1.6). 
Recent work from Yang and colleagues also demonstrated a second origin of LECs by identifying 
the presence of LEC progenitor cells within the intersegmental vein (ISV) (Yang et al., 2012). 
Together, these studies challenge the dogma presenting the CV as the only established source of 
LECs.  
 
One could argue that the major reason for the controversies surrounding the cellular dynamics 
underlying lymphangiogenesis in vivo stems from the limitations of the murine model. The 
observation of the early steps of lymphangiogenesis is somewhat limited in mice by the difficulty to 
achieve live in vivo imaging, restricting researchers to work on fixed sections. This imaging 
problem has been circumvented in another vertebrate developmental model, which also has more 
simple early developmental processes in lymphangiogenesis: the zebrafish. 
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Figure 1.6 – Lymphangiogenesis models  - Hägerling. Section 1.3.2 
Hägerling and colleagues describe the formation of two distinct lymphatic structures, the peripheral 
longitudinal lymphatic vessel (PLLV) and the pTD (primordial thoracic duct) from the coalescing of initial 
lymphatic endothelial cells (iLECs). iLECs emerge from 3 distinct vascular beds: the cardinal vein (CV), the 
intersomitic veins (ISV) and the SVP (superficial venous plexus). Superficial lymphatics (sLECs) emerge 
from the PLLV after E10 and are ultimately thought to contribute to the superficial lymphatic vascular 
network. (See also Figure 1.4). Adapted from (Hagerling et al., 2013) 
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1.4 Zebrafish: a model for the study of vascular development 
 
Since the 1930s the Zebrafish (Danio Rerio) was considered to be a potential developmental and 
embryological model, given the transparency of the embryo, its ex-utero development, and its easy 
cellular manipulation. However, it was not until 1996, when a compete issue of the journal 
Development was dedicated to report the isolation of hundreds of developmental mutants in 
zebrafish, that the model began to be widely used in the research community (Driever et al., 1996). 
The development of novel methods to label and visualise developing tissues, methods for reverse 
genetics, and genetic tools of a sophistication previously reserved for mouse or Drosophila studies 
(reviewed in (Lieschke and Currie, 2007)) also enhanced the popularity of the model. This can be 
quantified by a 40-fold increase in the number of zebrafish publications between 1990 and 2006 
(Lieschke and Currie, 2007).  
 
The ease with which the model can be manipulated and the relatively lower costs associated with 
the maintenance of zebrafish colonies, when compared to other animal models, allows for easy up 
scaling and extensive investigation of developmental pathways. These advantages, together with 
the fact that the basic biological processes are generally conserved between all vertebrates, 
means discoveries made in zebrafish are highly translatable. 
 
1.4.1 Identification of the zebrafish lymphatic vasculature 
Despite the advantages of the zebrafish model for understanding developmental processes, the 
study of lymphangiogenesis only recently started to benefit from the applications of this model. 
This is due to the fact that the zebrafish was long thought to lack a lymphatic system (Steffensen 
and Lomholt, 1992). The belief was that tissue fluid homeostasis would be regulated differently in 
aquatic habitats and anatomists were unable to identify discrete lymph nodes. In 2006, Küchler 
and colleagues and Yaniv and colleagues took advantage of the existence of the Tg(fli1: EGFP)yl 
line, to demonstrate the existence of a specific vessel that sits ventral to the dorsal aorta and is 
devoid of any blood flow (Kuchler et al., 2006; Yaniv et al., 2006). Both groups showed that this 
putative lymphatic vessel expressed genes identified as markers of lymphatic endothelium in 
mammals (prox1 and neuropilin-2), and that inhibition of Vegfc signaling, through Vegfc-specific 
morpholinos or by injection of a dominant negative form of VegfR3, resulted in an inhibition of 
lymphangiogenesis in vivo, indicating a conservation of the VEGFC/VEGFR3 signaling pathway, 
one of the major hallmarks of lymphatic vessels. 
 
A transmission electron micrograph of this vessel showed that it was composed of a thin single 
layer of endothelial cells, unlike the thicker and more complex posterior cardinal vein and dorsal 
aorta (Yaniv et al., 2006). Another line of evidence was the role of this newly found vessel in the 
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removal of interstitial substances. Subcutaneous injection of dye resulted in primary uptake by the 
putative lymphatic vessel, and subsequent distribution to the posterior cardinal vein (Kuchler et al., 
2006; Yaniv et al., 2006). Taken together, these findings confirmed that this vessel was the 
thoracic duct, a main collecting lymphatic vessel and was functionally active in fluid drainage and 
required known regulators of lymphangiogenesis (Kuchler et al., 2006; Yaniv et al., 2006) (Figure 
1.7). 
 
The development of new visualisation tools differentiating different lineages of the blood and 
lymphatic vascular system further helped the development of the zebrafish as a useful animal 
model to investigate lymphangiogenesis during embryonic development (Hogan et al., 2009a; 
Lawson and Weinstein, 2002).  
 
1.4.2 Development of the zebrafish lymphatic vasculature. 
In the zebrafish, lymphatic precursors start sprouting from the posterior cardinal vein (PCV) from 
1.5 days post fertilization (dpf) and migrate up to the horizontal myoseptum (HM) region to form 
parachordal lymphangioblasts, rather than a lymph sac as seen in mice, which despite being 
initially presented as a vessel (Yaniv et al., 2006), was convincingly demonstrated to in fact be a 
group of individual lymphatic precursor cells (Hogan et al., 2009a). These precursors cells 
subsequently migrate both dorsally and ventrally to form the dorsal longitudinal lymphatic vessel 
(DLLV), the intersegmental lymphatic vessels (ISLV) and the thoracic duct (TD) (see Figure 1.7). 
Using novel transgenic lines, this migration was recently examined in relation to other vessel 
subtypes (Bussmann et al., 2010b), and was suggested to be dependent upon a variety of extrinsic 
signals (see section 1.4.3).  An arterial endothelial marker transgenic line was crossed to an 
enhancer-trap line that specifically labels the lymphatic vasculature in the zebrafish trunk 
(Bussmann et al., 2010b). Time-lapse imaging of these two cell types during development led to 
the discovery that the migration of LECs from the HM to form the three types of lymphatic vessels 
of the zebrafish trunk (DLLV, ISLV and TD) occurs specifically along arterial endothelial cells as a 
migration substrate. 
 
It is of interest that Hagerling and colleagues, when describing their model for mouse 
lymphangiogenesis (presented in section 1.3.2), noted the similarities observed to the process of 
lymphangiogenesis in zebrafish, furthering the view that the zebrafish is a relevant model for the 
study of this developmental process. 
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Figure 1.7 – Lymphangiogenesis in zebrafish. Section 1.4.2 
Stepwise model of trunk lymphatic formation in zebrafish shows the emergence of lymphatic precursor cells 
(parachordal lymphangioblasts) from the cardinal vein at 32 hpf and their subsequent migration to the 
horizontal myoseptum (HM) between 32-60 hpf. PLs subsequently migrate specifically along arterial 
endothelial cells, both dorsally and ventrally to form the entire lymphatic vasculature in the trunk, composed 
of the dorsal longitudinal lymphatic vessel (DLLV), intersegmental lymphatic vessels (ISLV) and the thoracic 
duct (TD). 
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1.5 Genetic regulation of lymphangiogenesis 
 
A number of genes have been shown to have a crucial role in the specification and outgrowth of 
lymphatic vessels. In this section, some of the key genes and pathways will be reviewed. For 
reasons of accessibility, the regulation processes will be presented in two different sections: 
specification, migration and maturation, guidance. A general overview of the genetic underlying of 
specification and maturation of the lymphatic vasculature is presented in Figure 1.8. 
 
1.5.1 Specification and early maintenance  
 
1.5.1.1 PROX1 
In the same study in which Wigle and Oliver first described the expression of the prospero 
homeobox transcription factor Prox1 in the developing lymphatic vasculature (see section 1.3.1); 
they also examined the consequences of loss-of-function of Prox1 on the formation of the 
lymphatic vasculature. In Prox1 null embryos, which presented with a normal blood vasculature, 
endothelial cells were still budding from the cardinal veins, as shown by X-gal staining, but the 
expression of blood vascular endothelial cell (BEC) marker genes was retained although the 
expression of markers of differentiated LECs were notably absent in these cells (Wigle et al., 
2002). This result demonstrated that the key role of Prox1 is in the establishment of lymphatic fate 
of a specific population of endothelial cells as they bud from the vein; however, these findings also 
highlighted the fact that Prox1 is not necessary in the regulation of initial budding from the vein. 
The same group later published work suggesting that the cells observed outside of the CV in Prox1 
null embryos may not be located in the mesenchyme, but rather within the intersegmental veins 
(Yang et al., 2012), prompting the need for further investigation in the Prox1 mutant. 
 
In vitro experiments have shown that Prox1 is also sufficient to drive the specification of LEC fate. 
Adenoviral-mediated expression of Prox1 in cultured human BECs resulted in an up-regulation of 
lymphatic markers (such as Podoplanin and Vegfr-3) and reduced expression of BEC markers 
(Laminin and CD34) (Hong et al., 2002; Petrova et al., 2002). Later in vivo experiments 
demonstrated that ectopic expression of Prox1 under the control of an endothelial promoter (Tie1) 
also induced the expression of LEC markers in the blood vasculature (Kim et al., 2010).  
 
1.5.1.2 SOX18 
Sry-related HMG-box 18 (Sox18) is a member of the F-group of Sox transcription factors that was 
reported to have a role in arterio-venous specification in vivo (Cermenati et al., 2008; Herpers et 
al., 2008; Pendeville et al., 2008). Defects in Sox18 gene function are linked to the hypotrichosis-
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lymphedema-telangiectasia (HLT) human syndrome, which is characterised by lymphatic 
dysfunction (Irrthum and colleagues, 2003), consistent with a role for Sox18 in the development 
and/or maintenance of lymphatic vessels. 
 
Prior to Prox1 expression, at E9, expression of Sox18 is observed in endothelial cells lining the 
dorso-lateral sector of the cardinal vein (Francois et al., 2008). In Ragged Opposum (RaOp) mutant 
mice carrying a mutation in Sox18 which renders the protein dominant negative in nature, and 
models hypotrichosis-lymphedema-telangiectasia syndrome (Pennisi et al., 2000; Slee, 1957). In 
this mouse model, there is no initiation of Prox1 venous expression, which leads to arrested 
lymphatic vascular development. Sox18 knock-out mice (full loss-of-function) reproduced this 
lymphatic defect only when bred on a pure C57BL/6 background. When bred on a mixed genetic 
background, other SoxF family members are found to be expressed in LEC precursors (namely 
Sox17 and Sox7), indicating some redundancy in the Sox code during lymphangiogenesis 
(Hosking et al., 2009). 
 
François and colleagues went on to show that the Prox1 promoter region contains two conserved 
SoxF consensus-binding sites that are bound to Sox18 (Francois et al., 2008). After Sox18 binds to 
these sites, transactivation of the Prox1 promoter was observed both in vitro and in vivo. Further to 
this, lentiviral-mediated overexpression of Sox18 in mouse embryonic stem cells resulted in an up-
regulation of lymphatic vascular markers (Prox1, Podoplanin) but had no effect on general blood 
vascular endothelial cell markers (Francois et al., 2008). 
 
Although these results demonstrated that Sox18 is required to induce Prox1 expression in venous 
LEC progenitors in the wall of the vein, Sox18 is also known to be expressed in embryonic arteries 
(Pennisi et al., 2000) where it is insufficient to induce Prox1 expression. This suggests that one or 
more venous endothelial cell-specific markers may be required as a cofactor to allow Sox18 to 
upregulate Prox1. 
 
1.5.1.3 COUP-TFII 
Coup-TFII is expressed in embryonic veins from E8.5 and in LECs during embryogenesis (You et 
al., 2005). Endothelial cell specific knock-out of Coup-TFII between E10.5 and E12.5 has been 
shown to result in a significant reduction of lymphatic vessel numbers, and a size reduction and 
mispatterning of lymph sacs, suggesting the gene is involved in the regulation of the early steps of 
lymphangiogenesis (Srinivasan et al., 2010).  
 
Srinivasan and colleagues also showed that the binding of Coup-TFII to a conserved consensus 
Coup-TF responsive element in the Prox1 promoter was capable of driving Prox1 expression in 
vitro (Srinivasan et al., 2010). The co-expression of Prox1 and Coup-TFII at E11.5 in LECs in and 
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around the cardinal vein (previously shown in (Lee et al., 2009; Yamazaki et al., 2009)), suggests 
COUP-TFII directly regulates the expression of Prox1.  It is worth noting that previous work by 
Yamazaki and Lee also presented evidence of a direct physical interaction between COUP-TFII 
and PROX1 in cultured human LECs (Lee et al., 2009; Yamazaki et al., 2009). 
 
The observation of only mild lymphatic defects in mice where CoupTFII knock-out occurred after 
E13.5 is evidence to support the idea that a two-stage mechanism controls the expression of Prox1 
in lymphangiogenesis. This mechanism first requires the induction and early maintenance of the 
expression of Prox1, as regulated by Coup-TFII (from E10.5 to E12.5). Later, the maintenance of 
Prox1 expression becomes independent of Coup-TFII, as Prox1 is able to regulate its own 
expression to maintain LEC identity (Johnson et al., 2008; Srinivasan et al., 2010).  
 
The induction of Prox1 expression in LEC precursors in response to Coup-TFII and Sox18 
cooperation marks the specification of LEC fate. The fact that Coup-TFII expression is not 
polarised in the cardinal vein, in contrast to Sox18 and Prox1, suggests another, as yet unreported, 
polarisation factor may be present (You et al., 2005). Recent work by Bowles and colleagues 
suggests that a spatially restricted gradient of retinoic acid (RA) might be one such factor (Bowles 
et al., 2013).  
 
1.5.1.4 Retinoic acid 
Bowles and colleagues demonstrated that the expression of an RA degrading enzyme, Cyp26B1, 
is restricted to the dorsal region of the cardinal vein, from which LEC progenitor cells emerge. An 
increase of RA signaling in Cyp26B1-/- mice results in an increase of the number of LEC 
progenitors cells, as well as expansion of their region of expression in the cardinal vein, and an 
enlargement of primary lymphatic structures (such as lymph sacs). Interestingly, an overexpression 
of this enzyme activity also has a detrimental effect on lymphatic development, as Cyp26B1GOF 
embryos exhibit dramatically smaller lymph sacs than their wild type counterparts (Bowles et al., 
2013). These results suggest that a fine regulation of RA, both spatially and post-translationally, is 
necessary for the development of primary lymphatic structures during early lymphangiogenesis. 
Finally, the authors demonstrate that RA is likely to act as a regulator of lymphatic endothelial cell 
proliferation, rather than specification (Bowles et al., 2013). 
 
1.5.2 Migration and maturation of LECs  
 
1.5.2.1 VEGFC/VEGFR3  
The most well characterised pathway in lymphatic development, the VEGFC/VEGFR-3 pathway, is 
required for LEC precursors cells to migrate from the vein and form lymphatic vessels. Vascular 
endothelial growth factor receptor 3 (VEGFR3/FLT4) is a VEGF receptor, a family of proteins that 
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plays a major role in a multiplicity of angiogenic processes (Hoeben et al., 2004). The binding of 
the processed form of ligands VEGFC and VEGFCD activates VEGFR3. Kaipainen and colleagues 
have shown that from E12.5, Flt4 (Vegfr3) is expressed in the venous system and developing 
lymphatic endothelia, before being restricted to only lymphatics at subsequent developmental 
stages (Kaipainen et al., 1995). Mäkinen and colleagues have since reported that the expression of 
a soluble form of VEGFR3 (dominant negative) in the skin of transgenic mice results in an 
inhibition of lymphangiogenesis and a lymphedema-like phenotype (Mäkinen et al., 2001). 
Karkkainen and colleagues (Karkkainen et al., 2004) went on to confirm the importance of FLT4 
signaling in lymphangiogenesis, by showing that mice deficient for the VEGFR3 ligand VEGFC 
(Vegfc-/- mouse embryos) fail to develop lymph sacs and often died during embryogenesis. Vegf-
C+/- embryos that survived to full-term exhibited lymphedema due to a hypoplasia of lymphatic 
vessels (also observed in ear skin of adult Vegfc+/- embryos).  
 
Vegfc was found to be strongly expressed at E10.5 in the dorso-lateral part of the embryo, toward 
which lymphatic cells are migrating to form lymph sacs during lymphangiogenesis, indicating a 
classic morphogenic role of Vegfc in promoting LEC migration (Karkkainen et al., 2004). This 
hypothesis was in agreement with a previous report by Jeltsch and colleagues that Vegfc 
overexpression induces excessive lymphangiogenesis (Jeltsch et al., 1997).   
 
1.5.2.2 TBX1 
In 2010, Chen and colleagues reported the discovery of a novel regulator of VEGFC/VEGFR3 
signaling, T-box protein 1 (Tbx1) (Chen et al., 2010). Offspring of their pan-endothelial Tbx1 knock-
out mouse died perinatally and were devoid of mature lymphatic vessels in a wide range of tissues, 
indicating Tbx1 was likely to be critical for correct lymphangiogenesis. Transfection of human 
umbilical vein endothelial cells (HUVECS) with a Tbx1 construct increased the expression of a 
subset of pro-lymphangiogenic genes such as Vegfr3, Podoplanin and Vegf-D, but in vivo, only 
embryos with a Vegfr3 defect presented with a phenotypic readout similar to Tbx1 knock-out, 
which suggested a role of Tbx1 in regulating the VEGFC/VEGFR3 pathway. The authors found 
that Tbx1 binds to an enhancer region of Vegfr3 and activates its expression in endothelial cells 
(Chen et al., 2010), which defines Tbx1 as a direct regulator of lymphatic vessels morphogenesis.  
 
1.5.2.3 CCBE1  
Hogan and colleagues presented the first report of collagen and calcium-binding EGF domains 1 
(ccbe1) as a regulator of lymphangiogenesis. The full-of-fluid zebrafish lymphatic mutant model 
presents with a complete absence of secondary angiogenesis, affecting both the formation of 
intersegmental veins and parachordal lymphangioblasts (Hogan et al., 2009a). Within a few 
months of this initial report, Alders and colleagues demonstrated that mutations in the human 
CCBE1 gene was linked to autosomal recessive Hennekam syndrome, a form of inherited 
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lymphedema, in a subset of patients (Alders et al., 2009). This conserved role of Ccbe1 in 
lymphangiogenesis has subsequently been confirmed in mice: Bos and colleagues, and more 
recently Hägerling and colleagues, have demonstrated that a loss-of-function mutation in Ccbe1 
results in a complete absence of primary and mature lymphatic structures within the embryo (Bos 
et al., 2011; Hagerling et al., 2013). Interestingly, Hägerling and colleagues reported the formation 
of a Prox1 positive structure emerging, but not detaching, from the CV, ISVs and ventral part of the 
sVP, and forming abnormal bag-like sac structures in Ccbe1 null embryos.  
 
Bos and colleagues were the first to suggest a potential interaction between VEGFC/VEGFR3 
signaling and the action of CCBE1 (Bos et al., 2011). Bos and colleagues demonstrated that the 
conjunction of VEGFC and CCBE1 (albeit a truncated form) ectopic expression results in a local 
increase of lymphangiogenesis. Interestingly, they noted an increase in lymphangiogenesis with 
ectopic expression of CCBE1, but attributed it to the expression of VEGFC by local macrophage 
expected to migrate toward the ectopic expression of CCBE1, mediated by the implantation of a 
solid pellet. Their result also suggested that overexpression of CCBE1 in vivo had no effect on the 
activation of VEGFR3, which suggested to them that the interaction observed between the 
VEGFC/VEGFR3 pathway and CCBE1 was merely additive (Bos et al., 2011).  Similarly, Hägerling 
showed that compound Vegfc/Ccbe1 heterozygous embryos presented with an exacerbated 
vascular phenotype marked by abnormal Prox1-positive sprouts and ISV formation and a reduction 
in the number of iLECs (compared to individual heterozygous mice from each strain) (Hagerling et 
al., 2013).  
 
Le Guen and colleagues subsequently showed that ccbe1 knock down results in a rescue of the 
vegfc overexpression phenotype. Conversely, only the active processed form of Vegfc, but not its 
full-length form, can rescue the ccbe1 loss-of-function lymphatic phenotype. They also showed that 
ccbe1 knock down results in a reduction of Vegfr3-dependent signaling through ERK activation. 
Finally, they showed in vitro a noted enrichment of the processed form of VEGFC in cells 
transfected with CCBE1, achieving to underline CCBE1 role in VEGFC/VEGFR3 signaling (Jeltsch 
et al., 2014; Le Guen et al., 2014). 
 
Overall, Le Guen and colleagues convincingly demonstrated that Ccbe1 is a key member of 
VEGFC/VEGFR3 signaling, acting as a mediator of VEGFC processing toward its active form (Le 
Guen et al., 2014). Jeltsch and colleagues concomitantly demonstrated this result, and further 
elaborated on the mechanism of activation of VEGFC by CCBE1. They showed that CCBE1 does 
not directly process VEGFC but selectively interact with a protease, ADAMTS3, to mediate this 
process (Jeltsch et al., 2014).   
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 1.5.2.4 FOXC2 
Mutations in FoxC2 lead to lymphedema distichiasis in humans, a syndrome associated with 
primary lymphedema (Rockson, 2008). In mice, FoxC2, a forkhead transcription factor, was found 
to control the maturation of the primary lymphatic plexus into mature lymphatic collecting vessels.  
 
Initial results from Petrova and colleagues showed that FoxC2 knockout mice exhibit abnormal 
patterning and hyperplasia of cutaneous lymphatic vessels at E17.5 (Petrova et al., 2004). 
Dramatically, dermal lymphatic capillaries in FoxC2 mutants ectopically recruit smooth muscle cells 
and pericytes to the area surrounding capillary lymphatics. In these mutants, collecting lymphatic 
vessels were completely devoid of lymphatic valves – a characteristic symptom of lymphedema 
distichiasis. Norrmén and colleagues characterised the expression of FoxC2 during the formation 
of a mature collecting system (Norrmén et al., 2009). They demonstrated that FoxC2 is transiently 
up-regulated at 15.5 dpc in lymphatic vasculature, before being down-regulated and remaining 
expressed at levels comparable to Prox1 and Vegfr3 in the lymphatic collecting vessels and highly 
expressed in lymphatic valves, for the life of the animal. 
 
This late expression and relatively late lymphatic vessel phenotype suggest a role for FoxC2 (after 
the initial stages of specification and early differentiation) in the maturation of lymphatic vessels. 
With regard to the human and mouse pathologies associated with mutations in FoxC2 gene 
expression, it is suggested that FoxC2 plays a conserved role in lymphatic valve formation and 
recruitment of pericytes to lymphatic vessels (Petrova et al., 2004). 
 
1.5.2.5 NFATC1 
The discovery of a role for Foxc2 in valve formation led to the investigation of another regulator of 
valve development, NfatC1. NfatC1 is a calcium-sensitive transcription factor activated by 
calcineurin-dependent dephosphorylation, and is expressed in cardiac valves (reviewed in (Hogan, 
2003)). NfatC1 is also expressed in the Prox1-positive cells of the cardinal vein (from E10.5) and 
the endothelial cells of lymph sacs (from E12.5) (Kulkarni et al., 2009). NFATC1 activation, which 
triggers its nuclear localisation, is dependent on Calcineurin that dephosphorylates NFATC1 
(Kulkarni et al., 2009).  
 
Kulkarni and colleagues have shown that although Nfatc1 null mice are capable of forming lymph 
sacs, the morphology of said lymph sacs is abnormal and, in addition, a reduced number of Prox1-
positive cells is observed (Kulkarni et al., 2009). Consequently, NfatC1 mice display oedema 
typical of lymphatic vascular defects. In response to an inhibition of Calcineurin phosphatase 
activation by Cyclosporine A (CsA) treatment, mouse embryos exhibited a disorganisation of 
developing lymph sacs, which showed a decrease in lymphatic markers, but no change in Prox1 or 
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Vegfr-3 expression. These results support the idea that Nfatc1 acts independently or downstream 
of Prox1. It is of interest to note that recent work by Sabine and colleagues have shown that pan-
endothelial deletion of calcineurin activity does not affect the patterning of lymphatic capillaries, 
although still affecting valve formation. This suggest that the lymphatic patterning defects observed 
in Cyclosporin-A (inhibitor of calcineurin)-treated embryos, are due to a non-cell autonomous role 
of calcineurin/nfatc1 in vivo (Sabine et al., 2012). 
 
Foxc2 and NfatC1 are co-expressed in a subset of LECs and cooperation between the two genes 
was demonstrated by Norrmén and colleagues who showed that the loss of one allele of FoxC2 
enhanced the effect of NfatC1 pathway inhibition, suggesting a cooperative role in the process of 
differentiation and maturation of the lymphatic vessels (Norrmén et al., 2009). This pathway was 
recently elucidated further by Sabine and colleagues who demonstrated that Foxc2 actually acts in 
concert with Prox1 to regulate the activity of the NFATC1/CALCINEURIN pathway in the context of 
lymphatic valve morphogenesis. Prox1 and Foxc2 activity are responsible for the clustering of 
lymphatic valve cells, but the acquisition of a specific expression profile, including the activation of 
NFATC1/CALCINEURIN signaling, and morphological changes, is triggered by local alteration of 
flow exerted on these cells (Sabine et al., 2012). Finally, activity of the NFATC1/CALCINEURIN 
pathway is necessary for the maintenance of the valves within the lymphatic vasculature (Sabine et 
al., 2012).  
 
1.5.2.6 ANGIOPOIETIN/TIE pathway 
The ANGIOPOIETIN/TIE pathway has been thoroughly described within the context of blood 
vascular development, where it acts as a regulator of vessel remodeling and maturation (reviewed 
in (Augustin et al., 2009). TIE receptors and their corresponding ANGIOPOIETIN (ANG) ligands 
form, along with VEGF/VEGFR, another tyrosine kinase signaling system. Similar to the 
VEGF/VEGFR system, only particular subtypes of angiopoietin ligand and their associated 
receptor have so far been associated with lymphangiogenic defects. Ang2-deficient mice have 
severe lymphatic patterning defects that result in the limited uptake and transport of intestinal 
chyle, and lymph stasis throughout the organism (Gale et al., 2002). Abnormal remodeling of the 
skin lymphatic plexus, intestinal microvessel patterning and luminal valve formation defects were 
also observed in Ang2-/- animals (Dellinger et al., 2008; Gale et al., 2002). Phenotypically, 
lymphatic vessels are present in Ang2-/- embryos, but smooth muscle cell recruitment is abnormal, 
which would affect the vessels ability to function (Dellinger et al., 2008; Gale et al., 2002). Ang2 
deficiency can be specifically rescued by Ang1 in vivo, demonstrating their redundancy during 
lymphangiogenesis (Dellinger et al., 2008; Gale et al., 2002). Later work by Morisada and 
Tammela demonstrated the pro-lymphangiogenic role of Ang1 during development, which may 
partially act through the up-regulation of Vegfr-3 expression (Morisada et al., 2005; Tammela et al., 
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2005). Finally, mice deficient for orphan receptor Tie1 expression present with a mispaterning of 
lymph sacs and subcutaneous oedema from E13.5, which is consistent with the abnormal  
 
 
 
 
 
 
Figure 1.8 – Transcription factors regulating lymphangiogenesis. Section 1.5.1 
The expression level of multiple transcription factors is spatio-temporally regulated during 
lymphangiogenesis. From 9.5 dpc, a subpopulation of venous endothelial cells located on the dorsolateral 
part of the cardinal vein start expressing Prox1, a transcription factor which expression is directly regulated 
by Sox18 and CoupTF-II. These specified lymphatic precursor cells subsequently detach from the cardinal 
vein and migrate within the mesenchymal space. These cells progressively acquire a lymphatic specific 
expression profile and reorganise into diverse lymphatic structures (described in Figure 1.5,1.6). The 
maturation of these structures into a functional lymphatic vascular network is accompanied by expression of 
key transcriptional genes such as Nfatc1 and FoxC2, which play a role in valve morphogenesis within 
collecting lymphatic vessels, and Tbx1, which is involved in the remodelling of the lymphatic vascular 
network. Figure from (Francois et al., 2011) 
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development of the dorsal skin lymphatic vasculature observed at later time points (D'Amico et al., 
2010; Qu et al., 2010). Therefore, the ANGOPOIETIN/TIE pathway role in regulating lymphatic 
vascular morphogenesis is consistent with its previously reported role during blood vascular 
morphogenesis.  
 
1.5.3 External factors regulating lymphangiogenesis 
 
1.5.3.1 Chemokine signaling 
As presented in section 1.3.3, lymphatic endothelial cells emerging from the zebrafish posterior 
cardinal vein during secondary angiogenesis migrate along a well-established path. Despite 
definitive evidence presented by Lawson and colleagues and Hogan and colleagues that LECs 
emerging from the vein initially migrate to the HM irrespectively of the presence intersegmental 
blood vessels, the subsequent ventral migration giving rise to the thoracic duct is dependent upon 
the presence of arterial intersomitic vessels (aISV), which serve as a scaffold for directed migration 
(Bussmann et al., 2010b; Hogan et al., 2009a; Lawson et al., 2003). Cha and colleagues were the 
first to provide a mechanistic explanation for the observed migratory pattern (Cha et al., 2012). 
Chemokine receptors cxcr4a and cxcr4b are expressed in LECs and their respective ligands 
cxcl12a and cxcl12b in the surrounding environment. Disruption of chemokine signaling in 
morphants results in a significant reduction in thoracic duct formation. In cxcr4a and cxcl12a 
morphants, this reduction is preceded by a marked reduction in the number of parachordal 
lymphangioblasts at the HM. Accordingly, between 32 and 48 hours post fertilization (hpf), during 
initial migration of LECs to the HM, cxcl12a is expressed by the muscle cells of the HM. 
Subsequently, between 56 hpf to 4 dpf, during the migration of PLs away from the myoseptum, 
cxcl12b is expressed in aISV and dorsal aorta (DA). Concomitantly with the migration of PLs 
toward the region of the future thoracic duct, the expression of cxcl12a is extinguished from the HM 
and restricted to the PCV. These results strongly suggest that the extrinsic chemokine signal 
guiding the migration of the PLs during lymphangiogenesis is precisely spatio-temporally regulated 
(Figure 9).  
 
1.5.3.2 Neurons 
Making use of the fli1:EGFPy1 line (see section 1.3.3), Wilson and colleagues demonstrated the 
importance of Netrin1a in the formation of parachordal lymphangioblasts  at the level of the 
myoseptum (Wilson et al., 2006) (a hypomorphic phenotype was previously described in (Lu et al., 
2004). netrin1a is expressed by muscle pioneers (MPs) and was primarily described as a regulator 
of neuronal migration.  netrin1a is strongly expressed at the level of the floor plate of the neural 
tube and in the region of the horizontal myoseptum, towards which LECs migrates between 32 and 
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56 hpf, but only its expression at the level of the MPs is relevant to LECs migration to the 
myoseptum. Lim and colleagues indeed show that physical ablation of the MPs results in a 
defective migration of PLs to the myoseptum. Knockdown of netrin1a receptors unc5b and dcc in 
zebrafish and mice result in a similar phenotype, with lymphatic sprouts migrating toward the 
midline of the embryo, but unable to turn within the HM (Lim et al., 2011; Lu et al., 2004; 
Navankasattusas et al., 2008). Interestingly, the reduced number of PLs migrating to the HM in 
these morphants seems to be linked to a reduction in the formation of motoneurons which normally 
serve as guides to the emerging lymphatic sprouts. Ablations of motoneurons in the zebrafish trunk 
has been shown to result in a reduced number of PLs at the myoseptum (Lim et al., 2011). It is of 
interest to note that despite this indirect role in this context, reports have presented the idea that 
NETRIN1 might act cell autonomously in tandem with its receptor UNC5b, the expression of which 
can be detected in the vascular endothelium (Epting et al., 2010)  and promotes the correct 
migration of PLs to the HM (Epting et al., 2010). It is likely that this role would be mediated by the 
ELMO1/DOCK180 complex and subsequent activation of Rac1 within endothelial cells. 
The regulation of Rac1 activation by the ELMO1/DOCK180 complex was reported in vitro, but a 
role for Elmo1 in regulating lymphangiogenesis has also been observed in vivo, with both Elmo1 
and Dock180 expressed in the blood vascular endothelium prior to and during secondary 
angiogenesis (Epting et al., 2010)(Figure 1.9).  
 
1.5.3.3 Tissue fluid pressure  
Planas-Paz and colleagues have recently reported that a change in interstitial or extracellular fluids 
can affect the morphogenesis of the lymphatic vasculature during development (Planas-Paz et al., 
2012). The authors suggest a correlation between length of LECs, the interstitial fluid pressure and 
mechanical stress to which they are exposed. More specifically, an increase in interstitial fluid 
pressure, as observed transiently between E11 and E12, correlates with an extension of the length 
of LECs (using nuclear elongation as a proxy for measurement) and LEC proliferation. Conversely, 
a decrease in interstitial fluid pressure correlates with reduced LEC extension, as shown in vivo, 
between E12 and E12.5. A positive correlation also exists between the amount of interstitial fluid 
pressure in a tissue and activation of VEGFR3 signaling. This is suggested to be due to the 
activation of the mechanoreceptors presents on LECs, namely β1 integrin. Higher interstitial 
pressures and mechanical stress triggers activation of β1 integrin and partial co-localisation with 
VEGFR3. The authors propose that, through β1 integrin, the activation of VEGFR3 is triggered 
through phosphorylation of its tyrosine kinase domain (Planas-Paz et al., 2012). This proposed 
mechanism is consistent with previous reports of β1 integrin associating with VEGFR3 and 
mediating its activation via c-Src in vitro (Galvagni et al., 2010; Zhang et al., 2005). Planas-Paz 
and colleagues were able to experimentally reproduce these observations using a series of loss- 
and gain-of-fluid experiment in vivo (Planas-Paz et al., 2012).  
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Figure 1.9: chemokine signaling during lymphatic vascular development in zebrafish – Section 
1.5.3.1 
(A) Coronal view of the zebrafish trunk between 32 and 48 hpf. Rostral primary motoneurons (RoP MN - 
yellow) and parachordal lymphangioblasts (PLs-green) migrate dorsally and laterally from the posterior 
cardinal vein (PCV) into the horizontal myoseptum (HM).  
(B) The presence of RoP MN in the HM is necessary for the subsequent migration of PLs into this region. 
The migration of RoP MN to the HM is dependent upon the expression of netrin1a by the muscle pioneer 
cells in the HM, and its binding to its receptors unc5b and dcc at the surface of the motoneurons.  
(C) Migration of PLs into the HM is also promoted by the expression of chemokines receptors cxcr4a/b at 
their surface, binding to its ligand cxcl12a, which is expressed in the HM region at that timepoint.  
(D) Cross section of the zebrafish trunk between 56 hpf and 4 dpf.  
(E) Pls are migrating ventrally along the arterial intersomitic vessels toward the region under the dorsal aorta 
(DA), both expressing cxcr4a/b ligand cxl12b (albeit at a reduced level in the DA), and above the PCV 
(expressing cxcl12a dorsally).  
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 Background to the project 
 
We are constantly improving upon our understanding of the detailed cellular, chemical and genetic 
pathways that drive the formation of lymphatic vasculature during embryonic life. The emergence 
of multiple model organisms, and the ever-expanding number of tools available to delineate the 
action of these pathways promise to help us further understand not only how lymphatic endothelial 
cells interact with one another and their environment, but also how these interactions affect their 
morphology and physiology during specification, differentiation, sprouting and remodelling. With an 
increasing number of zebrafish lymphatic mutants described, novel molecular regulators are being 
identified and continue to drive discovery.  
 
The first forward genetic screen for zebrafish lymphatic mutants	  
Since the inception of chemically-induced forward genetic screening in zebrafish, the model has 
continued to assist researchers in the discovery of novel developmental genes. The first forward 
genetic screen for novel regulators of lymphangiogenesis, which occurred at the Hubrecht Institute 
in The Netherlands, between 2007 and 2009, continues to identify new regulators in 
lymphangiogenesis, and in turn improves our understanding of angiogenesis.  
 
This recessive N-ethyl-N-nitrosourea (ENU)-mutagenesis screen identified mutants with no 
thoracic duct. Thirty-one independent families were isolated (following the procedure described in 
Figure 1.10), two of which have been previously published, namely expando (flt4 mutant) and full 
of fluid (ccbe1). These mutants led to the isolation and characterisation of two conserved 
regulators of angiogenesis and lymphangiogenesis, and highlighted the potential of the approach 
to uncover genetic elements contributing to these processes. 
 
This thesis will describe the mapping and characterisation of two novel zebrafish mutants – from 
this original 31-mutant screen – which exhibited defects in lymphatic development and details. We 
provide insight into where and when these genes act during vascular development and present 
hypotheses as to their mode of action.  
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Figure 1.10 – Forward genetic screen for lymphatic mutants  
Heavily ENU (N-ethyl-N-nitrosourea, a point mutagen) mutagenised males were outcrossed to generate F1 
animals each carrying a unique series of unique germline mutations. Individuals from the F1 generation were 
outcrossed to the fli1a: EGFP endothelial marker strain to each generates an F2 family carrying any given 
recessive mutation with 50% frequency. F2 families were inbred and their progeny examined for the 
presence of the thoracic duct. This inbreeding strategy gives rise to 25 % of embryos homozygous for a 
particular mutation. 
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1.7 AIM OF THE PROJECT 
We aim to discover the genes linked to the observed mutant phenotypes in families isolated from 
the ENU screen, namely families 3.7.1 and 4.172, and the nature of the mutation affecting their 
potential function in lymphangiogenesis. 
 
Our final goal is to characterise the lymphatic phenotypes affecting the mutant family 3.7.1 and 
4.172 families through confocal imaging of their trunk vasculature at different key time points of 
lymphangiogenesis. Time-lapse imaging will help us defining precisely the time points at which the 
lymphangiogenesis process in mutant zebrafish starts to deviate from the traditional model. 
Establishment of mutant transgenic reporter fish lines will enable a precise discrimination between 
the different vessels composing the trunk vasculature. Alternative experimental models will be 
considered to support the conclusion of our studies. 
 
Our final goal is to integrate these results with the pathways known to regulate lymphangiogenesis 
in vivo. 
 
AIM 1: 
Positional cloning of new zebrafish lymphatic mutants 
 
AIM 2:  
Characterisation of the mutant lymphatic phenotype 
 
AIM 3:  
Integration of these results with the general pathways regulating lymphangiogenesis. 
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Chapter 2  
 
carbamoyl-phosphate synthetase 2, aspartate 
transcarbamylase, and dihydroorotase (cad) regulates 
Notch signaling and vascular development in zebrafish 
 
 
 
Results presented as published work in Developmental Dynamics 
 
This work is accessible at: 
http://onlinelibrary.wiley.com/doi/10.1002/dvdy.24209/abstract 
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Foreword: 
 
The hu10125 lymphatic mutant family was initially isolated during the Hubrecht forward genetic 
screen for lymphatic mutants (2007–2009). The hu10125 mutant embryos displayed a significant 
reduction in the extent of the thoracic duct formation at 4 dpf. Interestingly, this phenotype was 
combined with a progressive vascular hyperbranching phenotype from 2 dpf. In this mutant family, 
we found the vascular hyperbranching phenotype to be reminiscent of, yet not identical to, that 
exhibited by organisms deficient for Notch signalling. The Notch signalling pathway plays a central 
role in the limitation of endothelial sprouting during primary angiogenesis. Accordingly, in Notch 
signalling-deficient organisms such as DAPT-treated embryos or mindbomb mutants, embryos 
present with an excessive arterial angiogenesis in the dorsal part of the trunk vasculature (Itoh and 
Chitnis, 2003; Lawson et al., 2001; Lawson and Weinstein, 2002; Leslie et al., 2007; Ozbudak and 
Lewis, 2008; Schier et al., 1996; Therapontos and Vargesson, 2010), due to an increased 
sensitisation of the blood vascular endothelium to VEGFC/VEGFR3 signalling, normally supressed 
by Dll4/Notch signalling (Hogan et al., 2009b; Villefranc et al., 2013).  
 
Work by Geudens and colleagues has shown that, in addition to primary angiogenesis, Notch 
signalling also plays an active role in the formation of the lymphatic vasculature in zebrafish 
(Geudens et al., 2010). The authors demonstrated that a morpholino-mediated knockdown of 
multiple zebrafish Notch receptor orthologs, as well as ligands such as Jagged or Delta, leads to a 
significant reduction of parachordal lymphangioblasts (PLs) exiting the pre-existing blood 
vasculature. Interestingly, the authors report a concomitant increased number of venous 
intersomitic vessels (vISVs), suggesting that Notch signalling is required for the transition from 
blood vascular endothelial cell (VEC) to lymphatic endothelial cell (LEC) identity during secondary 
angiogenesis. The authors also presented evidence to support the idea that Notch signalling non 
cell-autonomously regulates the migration of PLs along arterial intersomitic vessels (aISVs) to 
contribute to the formation of the thoracic duct.  
 
Despite reporting the intriguing discovery of a novel developmental role for Notch signalling during 
vascular development, this study failed to address how Notch signalling regulates 
lymphangiogenesis. In fact, earlier work by Srinivasan and colleagues showed that in vivo 
knockout of Rbpj, a key mediator of canonical Notch signalling, does not affect LEC specification in 
mice (Srinivasan et al., 2010). These contradictory results may suggest a role for Notch in both the 
regulation of blood and lymphatic vessel development, upstream of canonical and non-canonical 
signalling pathways, which the hu10125 mutant family might help uncover. Given the importance of 
the pre-existing blood vasculature to the migration of PLs from the myoseptum to the formation of 
the thoracic duct (Bussmann et al., 2010b), it is conceivable that the LEC migration defects 
reported in Notch morphants might be secondary to morphological changes to the blood 
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vasculature. In this context, the decision to characterise the hu10125 mutant family was driven by 
the need to understand the genetic and cellular mechanisms underlying Notch signalling in the 
context of both blood vessel development and lymphangiogenesis. Excitingly, preliminary genetic 
mapping, prior to the beginning of this doctoral project, failed to identify any genetic linkages with 
known regulators of Notch signalling, suggesting that the hu10125 mutant family could lead us to 
the identification and characterisation of novel components of this well-established biological 
pathway in the regulation of both blood and lymphatic vessel formation.  
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Background: The interplay between Notch and Vegf signaling regulates angiogenesis in the embryo. Notch signaling limits
the responsiveness of endothelial cells to Vegf to control sprouting. Despite the importance of this regulatory relationship,
much remains to be understood about extrinsic factors that modulate the pathway. Results: During a forward genetic screen
for novel regulators of lymphangiogenesis, we isolated a mutant with reduced lymphatic vessel development. This mutant
also exhibited hyperbranching arteries, reminiscent of Notch pathway mutants. Positional cloning identiﬁed a missense muta-
tion in the carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (cad) gene. Cad is essential for
UDP biosynthesis, which is necessary for protein glycosylation and de novo biosynthesis of pyrimidine-based nucleotides.
Using a transgenic reporter of Notch activity, we demonstrate that Notch signaling is signiﬁcantly reduced in cadhu10125
mutants. In this context, genetic epistasis showed that increased endothelial cell responsiveness to Vegfc/Vegfr3 signaling
drives excessive artery branching. Conclusions: These ﬁndings suggest important posttranslational modiﬁcations requiring
Cad as an unappreciated mechanism that regulates Notch/Vegf signaling during angiogenesis. Developmental Dynamics
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Introduction
In the developing embryo, angiogenesis is a complex process
requiring precise and timely interplay of multiple signaling path-
ways and cellular processes. Blood vessels arise from preexisting
vessels in a spatio-temporally regulated process involving the
sprouting, migration, proliferation and patterning of endothelial
cells into mature, functional, vessel networks (Herbert and Stain-
ier, 2011). Distinct signaling pathways regulate the formation of
arteries and veins and both express a unique combination of
markers that reflects vessel function (Adams and Alitalo, 2007).
In the zebrafish, the formation of the initial artery-derived
intersegmental vessel network occurs from the dorsal aorta (DA).
This process is termed primary angiogenesis and involves the
dorsal sprouting of a wave of endothelial cells from the DA to
give rise to arterial intersegmental vessels (aISVs) from 19 hr
postfertilization (hpf) (Isogai et al., 2003). From 32 hpf, endothe-
lial cells emerge from the posterior cardinal vein (PCV), in a pro-
cess termed secondary angiogenesis to form intersegmental veins
(vISVs) and lymphatic vascular precursor cells which migrate to
the horizontal myoseptum where they are known as parachordal
lymphangioblasts (PLs) (Isogai et al., 2003; Hogan et al., 2009a;
Koltowska et al., 2013).
A large number of studies have shown that zebrafish primary
angiogenesis is regulated by Vegfa mediated signaling through
the receptors Kdrl and Kdr (Nasevicius et al., 2000; Habeck et al.,
2002; Covassin et al., 2006; Bahary et al., 2007). The Notch sig-
naling pathway suppresses Vegf-mediated signaling to limit
sprouting during primary angiogenesis (Siekmann and Lawson,
2007). As such, inhibition of Notch signaling in mutants, mor-
phants, or using chemical inhibitors in vivo results in abnormal
sprouting of arterial endothelial cells and embryos present with
hyperbranching aISVs (Lawson et al., 2001; Lawson and Wein-
stein, 2002; Leslie et al., 2007; Geudens et al., 2010). These hyper-
branching phenotypes can be rescued by loss of Vegfc or Vegfr3
(Siekmann and Lawson, 2007; Hogan et al., 2009b; Villefranc
et al., 2013).
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The many developmental roles of Notch signaling rely upon
several modulatory pathways to determine context-dependent
activity (Guruharsha et al., 2012). A subset of modulators act on
Notch signaling through receptor and ligand posttranslational
modifications, particularly ubiquitination and glycosylation
(Haines and Irvine, 2003; Kovall and Blacklow, 2010). Such mod-
ulators include the well described ubiquitin-ligases mindbomb
and neuralized (Yeh et al., 2001; Itoh et al., 2003) and the glyco-
syltransferase Fringe (Blair, 2000). Although studies have demon-
strated the importance of mindbomb-mediated ubiquitination
during zebrafish angiogenesis (Lawson et al., 2001; Lawson and
Weinstein, 2002), little is known about the roles of other post-
translational modifications, including glycosylation.
This study presents a zebrafish mutant identified due to a
reduction in the development of lymphatic vessels that also dis-
plays hyperbranching of intersegmental vessels. We find that the
causative mutation occurs in the carbamoyl-phosphate synthetase
2, aspartate transcarbamylase, and dihydroorotase (cad) gene.
Our findings show that this gene modulates Notch signaling.
Given the known role of Cad in UDP biosynthesis, upstream of
glycosylation events, we suggest that it likely acts during post-
translational glycosylation in the Notch pathway. This study
identifies an unappreciated level of regulation in zebrafish vascu-
lar development and identifies the UDP-biosynthesis pathway as
a potential target to modulate Notch activity in vivo.
Results
hu10125 Mutants Display Reduced Formation of the
Thoracic Duct and Hyperbranched Intersegmental
Arteries
During a forward genetic screen for novel zebrafish lymphatic
mutants, we isolated a mutant designated hu10125. This mutant
presented with a significant disruption in the formation of the tho-
racic duct at 4 days post fertilization (dpf) (Fig.F1 1A,B, asterisks, I).
We also observed hyperbranching of the aISVs in these mutants
(Fig. 1A,B,E,F, I) and increased formation of PLs in mutant
embryos (Fig. 1I). This phenotype was progressive with 30 hpf
ISVs appearing to be normal in mutants (Fig. 1C,D). The hu10125
vascular defects were also associated with notable morphological
defects in nonvascular tissues, including a smaller head and eyes
from 2 dpf onward and an atrophied lower jaw (e.g., Fig.F2 2F),
but not with any visible circulatory defects in the trunk at 4 dpf
(Supplementary movies 1 and 2).
To address the nature of hyperbranching in hu10125 mutants,
we took advantage of a transgenic line Tg(flt1:tomato) labeling the
arterial vasculature. Phenotypic analysis in this line demonstrated
that the hyperbranching phenotype affects the aISVs (Fig. 1E,F). We
subsequently set out to investigate whether the arterial hyper-
branching was a consequence of excessive proliferation of aISV
endothelial cells. Using a nuclear vascular endothelial reporter (fli1:
nucEGFP), we found that endothelial cell number dorsal to the hori-
zontal myoseptum was increased at 3 dpf in mutants compared with
controls, consistent with increased aISV proliferation (Fig. 1G–I).
A Mutation in the carbamoyl-phosphate synthetase 2,
aspartate transcarbamylase, and dihydroorotase (cad)
Gene Is Responsible for the hu10125 Phenotype
To characterize the mutated gene responsible for the phenotype,
traditional meiotic mapping was used to localize the genetic
lesion to a large region (6 Mb) on chromosome 20 (Fig. 2A). This
region contained the gene cad, for which the previously charac-
terized mutant perplexed had been described as displaying a strik-
ingly similar morphology to hu10125 (Willer et al., 2005).
Sequencing of cad identified a mutation substituting a conserved
residue in the linker region of the Cad protein (Fig. 2B–E). To test
whether the hu10125 mutant is allelic to perplexed, we generated
compound heterozygotes in a classical complementation assay
and observed that 22.5% of the embryos (n¼ 165) exhibited the
mutant phenotype at both the level of gross morphology and vas-
cular hyperbranching (Fig. 2F,G). This confirms the identity of
the mutated gene and we hereafter refer to hu10125 as
cadhu10125.
Cad is a rate-limiting enzyme required for the formation of
UDP sugar, upstream of two different metabolic pathways; the de
novo biosynthesis of pyrimidine and pyrimide-based nucleotides
(Jones, 1980), and the formation of UDP sugar intermediates,
required for UDP-dependent glycosylation events (Haines and
Irvine, 2003). Of interest, given the ubiquitous nature of UDP
function, in situ hybridization analysis of cad gene expression
during development showed highly regulated gene expression,
including in cells located in positions consistent with the location
of developing endothelial cells (ECs) (Fig. 2H–J). To investigate
further if Cad is indeed expressed in ECs, we used qPCR for cad
transcripts in cDNA isolated from FAC sorted populations of arte-
rial endothelial cells. We have previously published data using
the same FACs populations, the identity of which was verified
using known markers of arteries, veins and lymphatics (Coxam
et al., 2014; Kartopawiro et al., 2014). Analysis of cDNA from
arterial endothelial cells isolated at 36 and 60 hpf, showed cad
expression at levels similar to endothelial markers kdrl, flt1, and
dll4 (Fig. 2J,K). These cells did not express nonendothelial
markers ccbe1 (Fig. 2K) or pkd1b (data not shown). Hence these
data demonstrate that cad is expressed in arterial endothelium
and has the potential to play an autonomous role.
Knockdown of Vegfc/Vegfr3 Signaling Rescues the
cadhu10125 Artery Hyperbranching Phenotype
Intersegmental vessel hyperbranching such as that observed in
cadhu10125 mutants, has been previously associated with reduced
Notch signaling and subsequently increased Vegfc/Vegfr3 signal-
ing in zebrafish (Hogan et al., 2009b). Morpholino knockdown of
dll4 leads to aISV hyperbranching, which can be rescued (at least
in part) by the depletion or mutation of Vegfc or the injection of
a soluble, truncated form of Vegfr3 that acts as a ligand trap
(Siekmann and Lawson, 2007; Hogan et al., 2009b; Villefranc
et al., 2013). These findings revealed that during normal angio-
genesis the arterial response to Vegfc/Vegfr3 signaling is sup-
pressed by Dll4/Notch signaling.
We reasoned that if the cadhu10125 mutant phenotype was due
to perturbed activity of the Notch pathway, the inhibition of
Vegfc/Vegfr3 signaling would rescue the cadhu10125 phenotype. To
test this, we injected morpholino oligomers targeting, vegfr3 (flt4),
vegfc and ccbe1 (a regulator of Vegfc maturation; Jeltsch et al.,
2014; Le Guen et al., 2014) into embryos from incrosses of hetero-
zygous cadhu10125 carriers. We observed a significant and quantifi-
able rescue of the aISV hyperbranching phenotype in cad/MO-
ccbe1 and cad/MO-vegfc and cad/MO-vegfr3 embryos (Fig. F33A–F).
It should be noted that Vegfc/Vegfr3 signaling normally plays
no role in aISV formation, with validated mutants in this
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pathway failing to display aISV phenotypes except in genetically
sensitized backgrounds (Hogan et al., 2009b; Villefranc et al.,
2013; Le Guen et al., 2014). Hence, the rescue observed here is
not additive in nature. cadhu10125 mutant embryos likewise fail to
exhibit defects during early angiogenesis (Fig. 1C,D).
Notch Signaling is Reduced in cadhu10125 Mutants
Cad regulates the biosynthesis of UDP and hence both thymidine
levels and protein glycosylation. Extensive research has demon-
strated the importance of posttranslational glycosylation of the
Notch receptor on its activity (Haines and Irvine, 2003). This
raises the intriguing possibility that Cad may mediate Notch
function by means of glycosylation in the context of zebrafish
developmental angiogenesis. In support of this hypothesis, we
examined the vascular phenotype of the mutant tymshi3510Tg, a
thymidylate synthase mutant (Amsterdam et al., 2004), affecting
the synthesis of de novo thymidine nucleotide from UDP, down-
stream of Cad and independent of UDP-dependent glycosylation.
At 5 dpf, tymshi3510Tg present with a reduction in the size of their
head and eyes, phenocopying the eye defects in cadhu10125 as
previously described (Willer et al., 2005) but these mutants do not
present with aISV hyperbranching at 4 dpf (Fig. 3G,H). This find-
ing suggests that the vascular phenotype is not due to thymidine
synthesis defects, while the eye phenotype most likely is.
To determine if Notch signaling is perturbed in cadhu10125
mutants, we examined Tg(Tp1-MmHbb:EGFP) transgene expres-
sion, in which a Notch-responsive promoter (Tp1) drives the
expression of EGFP. This strain was examined in cadhu10125
mutants together with Tg(flt1:Tomato) which expresses Tomato
selectively in aISVs. We observed strong down regulation of
Notch activity throughout the whole embryo in cadhu10125
mutants (Fig. F44J). In particular, a strong reduction was observed
in the neural tube (Fig. 4A–D). The broad embryonic reduction in
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Fig. 1. hu10125 mutants present with lymphatic vascular deficiency and arterial hyperbranching. A,B: The vasculature Tg(fli1a:EGFP; flt1:tomato)
in wild-type siblings (A) and hu10125 embryos (B) at 4 dpf (white arrows indicate a thoracic duct, asterisk an absence of thoracic duct, and arrow-
heads indicate hyperbranching). C,D: The vasculature Tg(fli1a:EGFP; flt1:tomato) in wild-type siblings (n¼ 53) (C) and hu10125 (n¼ 12) embryos
(D) at 30 hpf. E,F: The arteries Tg(flt1:tomato) in wild-type siblings (C) and hu10125 (D) embryos at 3 dpf. G,H: Endothelial nuclei Tg(fli1:nucEGFP)
in wild-type siblings (G) and hu10125 (H) embryos at 3 dpf. I: Quantification of: thoracic duct extent (number of thoracic duct fragments visible
across 10 segments in the trunk) in WT (n¼ 20) and hu10125 (n¼ 21) (4 dpf); vascular hyperbranching (number of bilateral paired ISVs presenting
with extra branches across 10 segments in the trunk) in WT (n¼ 32) and hu10125 (n¼ 32) (4 dpf); parachordal lymphangioblasts (number of PLs
visible at the level of the horizontal myoseptum, across 10 segments in the trunk) in WT (n¼ 28) and hu10125 (n¼ 21) (56 hpf); and nuclei count
(in ISVs, scored dorsal to the horizontal myoseptum across 10 segments) in WT (n¼ 12) and hu10125 (n¼ 10) embryos (3 dpf).
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Notch activity was confirmed by Western blot detection of EGFP
expression in Tg(Tp1-MmHbb:EGFP) expressing mutant embryos
(Fig. 4J) and qPCR for Notch targets efnb2a and hey1 at 3 and 5
dpf. Furthermore, the arterial expression of Tg(Tp1-
MmHbb:EGFP) in mutant arteries was visualized by limiting
analysis in the Tg(Tp1-MmHbb:EGFP) strain to cells expressing
Tg(flt1:Tomato). In aISVs, we observed a significant reduction in
signal, as quantified by EGFP signal intensity relative to average
WT intensity (Fig. 4E–I). Overall, these observations demonstrate
that Cad is needed for Notch signaling in the developing embryo
including in aISVs.
Discussion
This study identifies an unappreciated modulator of the Notch
signaling pathway in zebrafish development. Cad is essential for
normal artery development at 3 and 5 dpf and for the formation
of the lymphatic vasculature. This mutant was initially isolated
for the lymphatic vessel defect. However, it seems likely that this
phenotype may be secondary to abnormal artery formation, par-
ticularly as the number of lymphatic precursor cells is initially
increased and the thoracic duct deficiency highly variable. We
demonstrate that the hyperbranching phenotype observed in
cadhu10125 mutant embryos results from increased artery VegfC
signaling. We suggest that a down-regulation of Notch activity,
which suppresses the response of arteries to signaling through
Vegfr3, is the underlying cause for this vascular phenotype.
Indeed, cadhu10125 mutant embryos exhibit a reduction of Notch
signaling activity observed in the Notch activity reporter line
Tg(Tp1-MmHbb:EGFP). We found reduced expression of Notch
target genes and also reduced EGFP in Tg(Tp1-MmHbb:EGFP) by
Western blot. The difference in the expression of Notch target
genes comparing DAPT-treated embryos and cadhu10125 mutant
embryos may reflect that Cad represents a partial loss of Notch
scenario, or only influences some receptor or ligand activities.
These observations are consistent with an embryo-wide reduction
in Notch signaling in both endothelial and nonendothelial tissues
as both EGFP and the marker genes used are expressed more
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Fig. 2. hu10125 is a cad (perplexed) mutant. A–E: Overview of the genetic mapping of cadhu10125 mutants. Recombinant embryos at multiple
simple sequence length polymorphism markers identified the critical genetic interval indicated (A). Sequencing of the cad gene identified the pres-
ence of a mutation (P1850T) in hu10125 cDNA (B,C), affecting a conserved residue in the linker region of Cad (D,E). F,G: Overall morphology of
wild-type siblings (77.5 % of the progeny) and cadhu10125; cadhi2694 embryos (22.5% of the progeny) at 4 dpf in a classical complementation assay
(n¼ 165 embryos scored) (F). Quantification of the number of intersegmental arteries per embryo (out of 10 segments) presenting with hyper-
branching in WT siblings (n¼ 21 scored) and cadhu10125;cadhi2694 (n¼ 19 scored) embryos at 4 dpf (G). H–J: In situ hybridization analysis of cad
expression shows ubiquitous expression at the 12-somite stage (H), enrichment in the trunk and neural tissues 30 hpf (I) and enrichment within
kidney and putative vascular tissues at 48 hpf (J). Arrows: putative vascular endothelial cells. K: Quantitative RT-PCR for markers of the blood vas-
culature in arterial endothelial cells (AECs) sorted based on TG(flt1:YFP) expression at 36 and 60 hpf: kdrl (expressed in all blood vascular endo-
thelial cells), flt1 and dll4 (restricted to arterial endothelial cells), ccbe1 (not expressed in the vascular endothelium) and cad. Gene expression
were normalised to rpl13.
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widely than just endothelium. The reduction includes a quantifi-
able reduction in aISVs themselves, which is consistent with the
hyperbranching phenotype in these cells and suggests an autono-
mous reduction in Notch signaling as the mechanism underpin-
ning the phenotype.
We have observed that vascular development proceeds nor-
mally in tymshi3510Tg mutants, arguing that the Thymidine nucle-
otide branch of UDP metabolism is probably not responsible for
the vascular phenotype observed in cadhu10125 mutants. A role
for glycosylation in the function of the Notch pathway is
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Fig. 3. cad artery hyperbranching is Vegfc/Vegfr3 dependent. A,B: The vasculature Tg(fli1a:EGFP) in wild-type sibling (A) and cadhu10125 (B)
embryos at 3 dpf. C–E: The vasculature Tg(fli1a:EGFP) in cadhu10125/MO-vegfc (C), cadhu10125/MO-ccbe1 (D), and cadhu10125/MO-vegfr3 (E)
embryos at 3 dpf. F: Quantification of the severity of vascular hyperbranching designated as mild or severe (where mild: 1–7 hyperbranched
arteries, and severe: 8 hyperbranched arteries along the entire embryo body axis) scored in WT (n¼ 16), MO-vegfc (n¼ 12), MO-ccbe1 (n¼ 10)
and MO-vegfr3 (n¼ 14) injected cadhu10125 embryos. G,H: The thymidylate synthase mutant tymshi3510Tg does not present with arterial hyper-
branching. G: Overall morphology of wild-type (n¼ 30/30) and tymshi3510Tg (n¼ 30/30) embryos at 4 dpf. H: The vasculature Tg(fli1a:EGFP) in wild-
type (n¼ 30/30) and tymshi3510Tg (n¼ 30/30) embryos at 4dpf. White arrowhead: thoracic duct, white arrow: example of normal aISV.
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Fig. 4. Notch signaling is reduced in cadhu10125 mutants. A–D: The vasculature Tg(flt1:tomato, Tp1-MmHbb:EGFP) in wild-type siblings (n¼ 43) and
cadhu10125 (n¼ 12) embryos at 4 dpf, (A,B), Tg(flt1:tomato); (C,D), Tg(Tp1-MmHbb:EGFP; flt1:tomato). E–H Computer assisted segregation of vascular
specific expression of (Tp1-MmHbb:EGFP) in Tg(flt1:tomato, Tp1-MmHbb:EGFP) wild-type siblings (n¼ 13 embryos, 40 aISVs analysed) and
cadhu10125 (n¼ 13 embryos, 38 aISVs analysed) at 4 dpf. E,G: aISVs, Tg(flt1:tomato, Tp1-MmHbb:EGFP) positive, in wild-type siblings (E) and
cadhu10125 embryos (G) at 4 dpf. F,H: aISVs-restricted expression of Tg(Tp1-MmHbb:EGFP) in wild-type siblings (F) and cadhu10125 embryos (H) at 4
dpf. Fluorescence intensity is displayed as a heat map, with a low to high color-coded from blue to white. I: Quantification of aISV-restricted Notch-
reporter intensity based on analysis displayed in (F) and (H) (P¼ 0.0012). Each point represents the average aISV signal intensity in individual WT sib-
ling embryos (n¼ 13 embryos, 40 aISVs analysed) or cadhu10125 embryos (n¼ 13 embryos, 38 aISVs analysed) normalised to average WT sibling sig-
nal intensity. J: Western blot detection of GFP expression in 48 hpf pooled embryos from WT and cadhu10125 Notch reporter transgenic embryos. The
level of GFP expression is significantly reduced in cadhu10125 embryos (P¼ 0.0274). The expression of actin was used to monitor protein input and
normalise GFP band intensity. K: Quantitative RT-PCR for the Notch target genes efnb2a, hey1, hey2, and nrarpa in embryos treated with 0.1%
DMSO (black columns) or 100 mM DAPT (white columns), shows that the expression of these genes is significantly reduced when Notch signaling is
inhibited from 24 hpf to 3dpf) (3 biological replicates, 10 embryos each). L,M: Quantitative RT-PCR for the Notch target genes efnb2a, hey1, hey2
and nrarpa in WT (black columns) and cadhu10125 (white columns) embryos at 3 dpf (WT, n¼ 5; cadhu10125, n¼ 5 biological replicates, 10 embryos
each)(L) and 5 dpf (WT, n¼ 5; cadhu10125, n¼ 4 biological replicates, 10 embryos each) (M). efnb2a reduction at 3 dpf, P¼ 0.0017, 5 dpf P¼ 0.0082.;
hey1 reduction at 5 dpf, P¼ 0.0437. Other trends nonsignificant in cadhu10125 mutants but significant in DAPT treated embryos.
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supported by numerous studies (reviewed in Haines and Irvine,
2003). The Notch receptor presents with multiple target sites for
UDP-dependent glycosylation events (Haines and Irvine, 2003).
These notably involve EGF repeats, which are key components of
the extracellular domain of the Notch receptor (Shao et al., 2002)
and crucially involved in ligand-receptor interactions. Hence, we
suggest that Cad and UDP-dependent glycosylation of the Notch
receptor is probably required for Notch activity and vascular
development.
As cadhu10125 embryos do not exhibit phenotypes equivalent
to pan-Notch deficiency such as those seen in mindbomb mutants
or early DAPT-treated embryos (Schier et al., 1996; Lawson et al.,
2001; Lawson and Weinstein, 2002; Itoh and Chitnis, 2003; Leslie
et al., 2007; Ozbudak and Lewis, 2008; Therapontos and Varges-
son, 2010), it is likely that early Notch signaling is either sup-
ported by maternally deposited UDP or maternally deposited Cad.
Consistent with this, is the progressive nature of the cadhu10125
artery phenotype, with no defects at 30 hpf, mild branching phe-
notypes at 2 dpf but gradually more severe hyperbranching as
development proceeds. This is likely observed progressively
because maternally deposited Cad or UDP is continually depleted
as development proceeds. The later stage hyperbranching may
also suggest that Notch suppression of Vegf-responsiveness is
ongoing, beyond just the process of angiogenic sprouting.
While the results presented here support the possibility that
posttranslational glycosylation of Notch plays a role in the regu-
lation of angiogenesis, we have not demonstrated actual func-
tionally important targets of Cad-dependent modifications in
vivo. It is, therefore, possible that the effect could be indirect,
with other undetermined modulators of Notch activity requiring
Cad or UDP. Our findings now mandate a further in-depth bio-
chemical assessment of UDP-dependent glycosylation in this
pathway. Though assessing the glycosylation state of the multiple
components of the Notch pathway is technically challenging, and
most knowledge in the field relies on in vitro assays (Bruckner
et al., 2000; Moloney et al., 2000a,b; Panin et al., 2002), this new
model may prove amenable to investigation in vivo in zebrafish,
particularly in the context of angiogenesis.
Therapeutic strategies targeting angiogenic pathways have
begun to move laterally toward broadly-acting cellular and meta-
bolic pathways within endothelial cells (Bottsford-Miller et al.,
2012; De Bock et al., 2013). Alternative target pathways to
manipulate the Notch/Vegf axis such as Cad or UDP-biosynthetic
enzymes have potential that is highlighted well by the dramatic
developmental angiogenesis phenotypes described here.
Experimental Procedures
Zebraﬁsh Strains
All animal use was approved by and conformed to ethical guide-
lines of the animal ethics committees at the University of Queens-
land and the Hubrecht Institute. Zebrafish were maintained using
standard husbandry procedures. ENU mutagenesis was performed
as previously described in (Wienholds et al., 2002). The cadhi2694,
Tg(fli1a:EGFP)y1 referred as Tg(fli1a:EGFP), Tg(26.5kdr-
l:mCherry)s916 referred as Tg(kdrl:mcherry), Tg(20.8flt1:tdToma-
to)hu5333Tg referred as Tg(flt1:tomato), Tg(EPV.Tp1-Mmu.Hb-
b:EGFP)um14 referred as Tg(Tp1-MmHbb:EGFP), Tg(fli1:nEGFP)y7
referred as Tg(fli1:nucEGFP), and Tg(flt1:YFP)hu4624 referred to as
Tg(flt1:YFP) lines are described in (Lawson and Weinstein, 2002;
Amsterdam et al., 2004; Siekmann and Lawson, 2007; Hogan
et al., 2009b; Parsons et al., 2009; Bussmann et al., 2010). The
cadhi2694 and tymshi3510Tg alleles were sourced through the Zebra-
fish International Resource Center.
Genetic Mapping
Meiotic mapping of the cad mutation in cadhu10125 embryos was
performed using the Ensembl database (http://www.ensembl.org),
release Zv9. The single sequence length polymorphism markers
used were: Z20582 (16 Mb. Zv9), Z26487 (22.9 Mb. Zv9),
Z23654 (33.1 Mb. Zv9), Z536 (39.1 Mb. Zv9), Z14605 (39.9 Mb.
Zv9).
Imaging and Analysis
For live confocal imaging, embryos were mounted as previously
described (Hogan et al., 2009b). Imaging was performed in the
Australian Cancer Research Foundation’s Dynamic Imaging
Facility at the Institute for Molecular Bioscience on a LSM Zeiss
510 NLO, META, or Zeiss 710 FCS confocal microscope using
10 or 20 dry objectives. Images were acquired with the Zeiss
Zen software and analyzed with Photoshop suite, Biplane IMARIS
and Fiji. Biplane IMARIS software was used to limit the analysis
in the Tg(Tp1-MmHbb:EGFP) strain to cells expressing
Tg(flt1:Tomato) (aISVs). Quantification of aISV fluorescence
intensity was performed using the Plot-profile plugin of Fiji
(ImageJ 1.47), applied on Z-axis maximum intensity projection
of 4 individual aISVs per embryo. The aISV-restricted fluores-
cence intensity of the Tg(Tp1-MmHbb:EGFP) reporter of both
wild-type and cadhu10125 mutant embryos was normalised to the
average fluorescence intensity measured in wild-type sibling
embryos, imaged under the same experimental settings.
Statistical Analysis
We used unpaired student t-tests using Prism (Graph Pad soft-
ware) for all Figures except Figure 3F, where an ANOVA was per-
formed. P-values are represented in the Figures as *P 0.05,
**P 0.01, ***P 0.001, and ****P 0.0001. Standard error of the
mean is represented in error bars.
DAPT Drug Treatment
Zebrafish embryos were exposed to DMSO and DAPT (Sigma,
D5942) at 0.1% and 100 mM, respectively, in E3 medium, from
24 hpf to 3 dpf. The treatment medium was changed once a day.
DAPT was stored according to manufacturer recommendations.
Western Blot
Zebrafish embryos were lysed in RIPA buffer containing 50 mM
Tris-HCl pH7.4, 1% Na-deoxycholate, 150 mM NaCl, 1 mM
EDTA, 1% Triton-X 100, 0.1% SDS, 1 mM PMSF and a protease
inhibitor cocktail (Sigma-Aldrich, P8340). Samples were resolved
by SDS-PAGE, transferred onto PVDF membrane (BIO-RAD,
170–4272), and blotted with antibodies against mouse anti-
chicken actin (EMD Millipore, MAB1501) and mouse anti-GFP
(Roche, 11814460001). Western blots were developed using the
ECL method (Western Blotting Analysis System, Sigma-Aldrich,
RPN2109). The intensity of the bands was quantified using
ImageJ (version 1.44) software.
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Whole-mount In Situ Hybridization and
Immunochemistry
Zebrafish cad full-length cDNA was amplified as a probe tem-
plate from stage mixed WT cDNA by PCR using the primers for-
ward: 50-cagctgcccaataacatcgc-30 and reverse: 50-ggatccatt
aaccctcactaaagggaacgcacattgcactcgatcacc-30. In situ hybridiza-
tion was performed essentially as previously described (Thisse
et al., 1993) with NBT/BCIP staining solution (Roche).
Morpholino Oligomers
Morpholino oligomers against vegfr3, vegfc, and ccbe1 were
described in (Hogan et al., 2009a) and were injected at 5 ng per
embryos. Injections were performed as described in (Hogan et al.,
2008).
Quantitative Real Time PCR Analysis
Cell isolation, RNA extraction and cDNA synthesis were per-
formed as described in (Coxam et al., 2014). A total of 30–50 ng
of amplified mRNA (FACs sorted cells) or 0.4 mg total RNA
(pooled WT and cadhu10125 mutant embryos) RNA was extracted
from FACS samples from 36 and 60 hpf Tg(flt1:YFP), Tg(kdrl:
mcherry) zebrafish, with the DsRed negative/YFP positive cells
corresponding to the arterial cell population.
Quantitative PCR was setup and results analysed as described
in (Coxam et al., 2014).The expression of rpl13 was used for nor-
malisation of gene expression in the aISVs. For FAC sorted cell
populations presented in Figure 2K. In WT and cadhu10125
embryos embryos treated or not with 0.1% DMSO, 100mM DAPT
(Fig. 4K–M), gene expression was normalised to the geometric
average of rpl13 and hprt1 expression, and presented as a ratio
to cdh5 normalised expression to take into account excessive
proliferation of aISVs in cadhu10125.
The following primers were used for RT-PCR:
hey1 Fwd: 50-CAAGCAAGAAAACGTCGCAG-30,
hey1 Rev 50-GTGCAGTCTCTGCTAGACATT-30,
hey2 Fwd 50-TGGGCAGCGAGAATAACTAC-30,
hey2 Rev 50-TTTTCAATGATCCCTCTCCGC-30,
nrarpa Fwd 50-AAGTGTGTCGTTTACTTGTCCT-30,
nrarpa Rev 50-TAAAACCAGTTTAGGCGCGT-30,
ephb2a Fwd 50-AGGAACAACCGTCCGAAATT-30,
ephb2a Rev: 50-GGAGAAGTCTGGTGTGCTAC-30.
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Chapter 3  
 
Pkd1 regulates lymphatic vascular morphogenesis 
during development 
 
 
 
Results presented as published work in Cell Reports 
 
This work is accessible at: 
http://www.sciencedirect.com/science/article/pii/S2211124714002605 
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Foreword:  
 
At the time when this study was first conceived, all reported zebrafish lymphatic mutants and 
morphant models were primarily characterised by a defective initiation of secondary angiogenesis; 
specifically, the number of lymphatic precursor cells exiting the pre-existing blood vasculature was 
significantly reduced (Hogan et al., 2009a; Hogan et al., 2009b; Le Guen et al., 2014; Villefranc et 
al., 2013). Initially isolated as a lymphatic mutant during the Hubrecht forward genetic screen for 
lymphatic mutants (2007–2009), lymphatic and cardiovascular defect 1 (lyc1) mutant embryos 
presented with a strikingly normal initiation of secondary angiogenesis and visibly unaltered blood 
vasculature, although exhibiting a significant reduction of the extent of the thoracic duct. At this 
time, it therefore constituted the only reported lymphatic zebrafish mutant model with an apparent 
primary defect in the migration of lymphatic precursor cells from the myoseptum to contribute to the 
lymphatic vasculature formation in the trunk. Interestingly, this mutant family also exhibited a 
specific heart phenotype, with the development of cardiac oedema from 4 dpf. This was not 
lymphedema, as other mutants devoid of lymphatic vessels (such as full-of-fluid or expando) do not 
display oedema before 6 dpf, suggesting that this phenotype was likely to be associated with 
developmental heart malformations. This cardiac defect was also thought to induce a third feature 
of the lyc1 phenotype – a general slowing of blood circulation from 4.5 dpf onwards. 
 
The conjunction of lymphatic and cardiac defects in the lyc1 mutants suggested that the underlying 
ENU-derived mutation affected a component of pathways regulating both cardiac and lymphatic 
development. Possible affected pathways included the Calcineurin/Nfatc1 or FoxC2-mediated 
pathways (Kulkarni et al., 2009; Norrmén et al., 2009; Sabine et al., 2012); however, the lymphatic 
phenotype exhibited by lyc1 mutant embryos occurred earlier than in Calcineurin/Nfatc1 or FoxC2 
loss-of-function models, suggesting that the genetic mutation underlying the phenotype did not 
affect a downstream component of these pathways. Excitingly, preliminary genetic mapping failed 
to identify linkage in any regions of the genome containing known regulator of lymphangiogenesis, 
including nfatc1 and foxc2. Investigating the lyc1 mutant family may therefore provide us with an 
opportunity to identify a novel joint regulator of lymphatic vessel maturation and remodelling, as 
well as cardiac morphogenesis. 
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Lymphatic vessels arise during development through
sprouting of precursor cells from veins, which is
regulated by known signaling and transcriptional
mechanisms. The ongoing elaboration of vessels to
form a network is less well understood. This involves
cell polarization, coordinated migration, adhesion,
mixing, regression, and shape rearrangements. We
identified a zebrafish mutant, lymphatic and cardiac
defects 1 (lyc1), with reduced lymphatic vessel devel-
opment. A mutation in polycystic kidney disease 1a
was responsible for the phenotype. PKD1 is the
most frequently mutated gene in autosomal domi-
nant polycystic kidney disease (ADPKD). Initial
lymphatic precursor sprouting is normal in lyc1
mutants, but ongoing migration fails. Loss of Pkd1
in mice has no effect on precursor sprouting but
leads to failed morphogenesis of the subcutaneous
lymphatic network. Individual lymphatic endothelial
cells display defective polarity, elongation, and
adherens junctions. This work identifies a highly
selective and unexpected role for Pkd1 in lymphatic
vessel morphogenesis during development.
INTRODUCTION
The lymphatic vasculature forms in the embryo as a result of
specification of lymphatic endothelial cell (LEC) fate, followed
by coordinated sprouting, morphogenesis, and network elabo-
ration. LEC fate is specified through key transcription factors,
which act in embryonic veins (Franc¸ois et al., 2008; Srinivasan
et al., 2010; Wigle and Oliver, 1999). LEC precursors subse-
quently sprout from veins and migrate through the embryo
(reviewed in Koltowska et al., 2013). This process is under the
control of VEGFC/VEGFR3 signaling (Karkkainen et al., 2004)5and its modulators (reviewed in Koltowska et al., 2013). In
mouse, lymphatic precursors form lymph sacs in the anterior
of the embryo (Franc¸ois et al., 2012; Yang et al., 2012), which
likely remodel into major lymphatic vessels (Ha¨gerling et al.,
2013). Superficial LECs (sLECs) migrate dorsally as loosely
attached individual cells to form the subcutaneous lymphatic
network (Ha¨gerling et al., 2013). Although several guidance mol-
ecules, cellular interactions, and extrinsic forces pattern embry-
onic lymphangiogenesis (reviewed in Koltowska et al., 2013),
much remains to be understood about the cellular mechanisms
that regulate LEC polarization, adhesion, outgrowth, remodeling,
and morphogenesis.
In zebrafish, there are strong parallels with mammals in the
processes that regulate lymphatic vascular development (Hogan
et al., 2009b; Ku¨chler et al., 2006; Yaniv et al., 2006). We have
used forward genetic screens to identify zebrafish mutants that
lack lymphatic vessels. Here, one zebrafish mutant uncovers a
surprising role for the ADPKD gene Pkd1 in lymphatic vascular
development. We show that this function of Pkd1 is conserved
and cell autonomous in endothelial knockout mice. Our findings
suggest a uniquely staged role for PKD1 in the regulation of
lymphatic vascular morphogenesis.
RESULTS
lyc1 Mutants Fail to Form a Lymphatic Vasculature
We identified a zebrafish mutant dubbed lymphatic and cardiac
defects 1 (lyc1). lyc1mutants exhibited a reduction or loss of the
main axial lymphatic vessel, the thoracic duct (TD) at 4 days post-
fertilization (dpf) as well as mild cardiac edema, while retaining
blood circulation (Figures 1A–1D and 1I). By 5 dpf, mutant blood
flow was reduced and cardiac edema increased in severity (Fig-
ure S1; data not shown). To determine the origins of the pheno-
type,weexaminedgeneexpression for arteriovenousgenes, lym-
phangiogenesis regulators (includingchemokinesand receptors),
and flow-induced pathways at 32 hr postfertilization (hpf), during
the initiation of lymphatic development. These markers were un-
changed in lyc1 embryos (Figure S1). In the zebrafish, precursorCell Reports 7, 623–633, May 8, 2014 ª2014 The Authors 623
8
Figure 1. lyc1 Mutants Display Reduced Lymphatic Development
(A and B) Overall morphology of wild-type siblings (A) and lyc1 mutants (B) at 4 dpf.
(C and D) The vasculature Tg(fli1a:EGFPy1; flt1:tomatohu5333Tg) of (C) wild-type (WT) (arrowheads indicate thoracic duct) and (D) lyc1 mutants at 4 dpf (asterisks
indicate absence of thoracic duct).
(E and G) The vasculature Tg(fli1a:EGFP y1; flt1:tomatohu5333Tg) in wild-type sibling (E) and mutant embryos (G) at 56 hpf (arrows indicate lymphatic precursors
known as parachordal lymphangioblasts, PLs).
(F and H) flt1:tomatohu5333Tg expression marks the arterial ECs, a loss of signal (brackets) indicating venous intersegmental vessels (vISVs).
(I–K) Quantification of (I) thoracic duct extent across ten somites (WT n = 40, lyc1 n = 17), (J) parachordal lymphangioblasts (WT n = 78, lyc1 n = 17), and (K) venous
sprouts (WT n = 40, lyc1 n = 15). DA, dorsal aorta; PCV, posterior cardinal vein.
Error bars indicate SEM. See also Figures S1 and S2.
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Figure 2. lyc1 Is a pkd1a Mutant
(A) Overview of positional cloning of lyc1. Individual recombinant embryos (labeled in red left [from 776 embryos analyzed], labeled in blue right [from 314 embryos
analyzed]) identify flanking polymorphic markers and limit the critical interval to a region containing partial sequences for pkd1a and tsc2.
(B) Sequence chromatograms showing the wild-type (upper) and pkd1a mutant (R3607X, lower) sequences.
(C) Overall morphology of 5 dpf WT, lyc1, MO-pkd1b, lyc1/MO-pkd1b, and MO-pkd2 embryos. The injection of MO-pkd1b into lyc1 mutants recapitulates the
published MO-pkd1a/1b double loss-of-function phenotype (Mangos et al., 2010).
(D) Expression pattern of pkd1a by in situ hybridization in the trunk of wild-type zebrafish at 24 hpf and 32 hpf.
(E) Quantitative RT-PCR for markers enriched in venous endothelial cells (VECs); kdrl, cdh5, LECs; prox1a, nfatc1, nrp2a; and both flt4 and lyve1 demonstrated
the purity of FACS-isolated populations at 5 dpf.
(F) Quantitative RT-PCR for pkd1a, pkd1b, and pkd2 transcripts in 3, 5, and 7 dpf VEC and LEC populations.
(G–I) The vasculature of 5 dpf WT, lyc1/MO-pkd1b and MO-pkd2 embryos (5 and 7.5 ng MO, respectively); asterisk indicates absence of thoracic duct in
Tg(fli1a:EGFP y1; kdrl:egfps843) embryos.
Error bars indicate SEM. See also Figures S3 and S4.LECs emerge from the posterior cardinal vein (PCV) during
secondary angiogenesis and migrate dorsally to the horizontal
myoseptum to form parachordal lymphangioblasts (PLs).
Concomitantly, venous sprouts form intersegmental veins
(vISVs). Strikingly, the numbers of vISVs and PLs were normal in
lyc1mutants (Figures 1E–1H, 1J, and 1K).
This phenotype differs from described mutants for vegfc,
vegfr3, or ccbe1 (Hogan et al., 2009a, 2009b; Le Guen et al.,
2014; Villefranc et al., 2013), which lack all venous sprouting.
Time-lapse imaging showed that the lymphatic defect resulted
from a block in themigration of PLs out of the horizontal myosep-
tum (Movies S1 and S2). Quantitative analysis of cell behavior
spanning this period of altered migration revealed that mutant
precursor LECs remain mobile but show altered exploratory
behavior and filopodial extension dynamics, consistent with
impaired directional migration (Movies S3 and S4; Figure S2).
A Loss-of-Function Mutation in pkd1a Is Responsible for
the lyc1 Phenotype
Meiotic mapping (see the Experimental Procedures) was used to
identify a region of chromosome 1 containing the lyc1 locus. The
critical interval (Figure 2A) contained two genes, tuberous
sclerosis 2 (tsc2) and polycystic kidney disease Ia (pkd1a). In
the zebrafish genome, pkd1 (encoding Polycystin1) is present6as duplicate genes, with pkd1a coding for a conserved 4281
amino acid protein. Sequencing revealed a mutation in pkd1a,
introducing a premature stop codon (R3607X) (Figure 2B). This
mutation was predicted to result in the failed translation of six
of the 11 transmembrane domains and essential C-terminal
cytoplasmic tail of the protein.
In humans,PKD1 and PKD2 (encoding POLYCYSTIN2) are the
most commonly mutated genes in ADPKD (for review, see
Chapin and Caplan, 2010; Zhou, 2009). PKD1 haploinsufficiency
and loss of function have also been frequently associated
with cardiovascular complications (reviewed in Rossetti and
Harris, 2013). In mammals, POLYCYSTIN1 protein localizes to
primary cilia, apical membranes, adherens, and desmosomal
junctions. It can act as a mechanosensory signaling protein,
transducing extracellular signals through its cytoplasmic C-ter-
minal domain (reviewed in Zhou, 2009). POLYCYSTIN1 binds
to POLYCYSTIN2 (a calcium pump) at the membrane to regulate
Ca2+ influx and signaling but also binds to E-cadherin, b-catenin,
and components/effectors of the planar cell polarity pathway
(Castelli et al., 2013; Lal et al., 2008; Roitbak et al., 2004).
Previous studies depleting Polycystin1 (a and b) in zebrafish
found that MO-pkd1a/b embryos exhibit a specific body curva-
ture phenotype (Mangos et al., 2010). We injected MO-pkd1b
into our pkd1a mutant embryos and robustly induced thisCell Reports 7, 623–633, May 8, 2014 ª2014 The Authors 625
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Figure 3. Pkd1 Cell-Autonomously Regulates Subcutaneous Lymphatic Vascular Development in Mice
(A–C) Morphology of WT, Pkd1KO, and Pkd1iDECKO embryos at 14.5 dpc (arrowhead indicates edema).
(D–F) Lymph sacs (LS) in WT, Pkd1KO, and Pkd1iDECKO embryos stained with endomucin, LYVE1, and PROX1. JV, jugular vein. Scale bar represents 100 mm.
(G–I) Hematoxylin and eosin staining in WT, Pkd1KO, Pkd1iDECKO embryos at 14.5 dpc. Lymph sacs (LS) indicated.
(J and K) Subcutaneous lymphatics in Sox18:GFP-Cre-ERT2, Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J costained with NRP2 and PROX1 (n = 663/1,138 scored
LECs were tdTOMATO positive (58.2%), from n = 2 embryos, 13.5 dpc).
(L–N) Subcutaneous lymphatic vasculature inWT, Pkd1KO, and Pkd1DECKOmutants at 14.5 dpc. Dashed line indicated the dorsal midline of the embryo. Scale bar
represents 400 mm.
(O–Q) Representative subcutaneous lymphatic sprout in WT, Pkd1KO, and Pkd1iDECKO mutants at 14.5 dpc.
(R and S) Quantification of branchpoints/area (2,0003 1,500 mm area on both sides of the midline) in (R) WT (n = 7 embryos) and Pkd1KO (n = 7 embryos) and (S)
WT (n = 8 embryos) and Pkd1iDECKO (n = 6 embryos) embryos at 14.5 dpc.
(legend continued on next page)
626 Cell Reports 7, 623–633, May 8, 2014 ª2014 The Authors
61
phenotype, confirming that the lyc1 mutation is a loss-of-func-
tion allele (Figures 2C and S3). Pkd1 and Pkd2 can modulate
extracellular matrix (ECM) formation (Mangos et al., 2010).
Importantly, even the most phenotypically penetrant pkd1a
mutants for lymphangiogenesis do not display the body curva-
ture associated with altered ECM.We examined several markers
and knockdown scenarios but found no evidence for increased
ECM or a role of altered matrix in the lyc1 lymphatic phenotype
(Figure S4).
pkd1a Is Expressed in Migrating LECs and Loss of
Function in the ADPKD Complex Mimics lyc1 Defects
We found that pkd1a expression was ubiquitous in the 24 hpf
embryo but was enriched in the trunk during secondary angio-
genesis at 32 hpf (Figure 2D). We saw no evidence for
nonsense-mediated decay in mutants using in situ hybridization
at 32 hpf (n = 130 embryos from a carrier incross analyzed; data
not shown). As in situ hybridization has proved insensitive in
LECs in older zebrafish (post 3 dpf), we isolated LECs using fluo-
rescence-activated cell sorting (FACS). Taking advantage of a
new transgenic line Tg(lyve1:DsRed2)nz101 (Okuda et al., 2012)
labeling embryonic veins and lymphatic vessels, crossed onto
the Tg(kdrl:egfp)s843 line (restricted to blood vessels; Jin et al.,
2005), we isolated LECs and venous ECs (VECs). We performed
quantitative PCR (qPCR) for knownmarkers, validating the spec-
ificity of cell populations (Figures 2E and S3). Consistent with the
timing of the lyc1 phenotype, pkd1a and pkd2were expressed in
VECs and LECs, with pkd1a in both populations at 3 dpf but
reduced in LECs at 5 dpf. pkd1b was expressed at low, almost
undetectable levels at all stages (Figures 2F and S3).
In endothelial cells, Polycystin1 can regulate calcium signaling
through Polycystin2 activity (Chapin and Caplan, 2010; Nauli
et al., 2003). To investigate this potential mechanism, we
knocked down Pkd2. Embryos depleted for Pkd2 exhibited a
phenotype similar to that of lyc1/MO-pkd1b embryos and
reduced TD extent (Figures 2G–2I and S3). We next treated
embryos with previously validated Ca2+ signaling antagonist
and agonists (North et al., 2009). These treatments generated
phenotypes highly reminiscent of the lyc1 phenotype (Figure S3).
Cacna1s, an L-type calcium channel targeted by the antagonist
Nifedipine, was expressed in ECs (Figure S3). Taken together,
these observations are consistent with Pkd1 functioning in the
canonical ADPKD complex.
Pkd1 Cell-Autonomously Regulates Development of the
Subcutaneous Lymphatic Vascular Network in Mice
Although most previous studies in mammalian models focus on
the role of Pkd1 in epithelia, Pkd1-null mice have been shown to
exhibit cardiovascular, skeletal, and renal defects (Boulter et al.,
2001; Kim et al., 2000; Piontek et al., 2004). Embryos devoid of
Pkd1 die after 15.5 days post coitum (dpc) displaying severe(T) Quantification of the average width of lymphatic vessels (mm) across the whol
embryos) embryos. The average is shown of n = 773, n = 354, and n = 250 measu
midline at 14.5 dpc.
(U) Quantification of nuclei/100 mm of vessel in WT (n = 12 embryos), Pkd1KO (n =
vessels counted per embryo) at 14.5 dpc.
Error bars indicate SEM. See also Figures S5 and S6.
6hemorrhaging and subcutaneous edema (Kim et al., 2000;
Muto et al., 2002), but a role for this gene in lymphangiogenesis
has yet to be reported.
We generated Pkd1 knockout embryos and examined their
overall morphology. We observed the previously described sub-
cutaneous edema, but not hemorrhaging (Figures 3A–3C).
Embryonic lymph sacs were present but were blood filled in
Pkd1 KO embryos (Figures 3D–3I). This phenotype suggests
that lymphatics in this mutant would not sustain fluid drainage
and may explain the subcutaneous edema. Interestingly, we
did not find any defect in lymphovenous valves at 14.5 dpc (Fig-
ure S5) perhaps suggesting that blood enters the mutant lymph
sacs early during morphogenesis, before valve maturation
(Franc¸ois et al., 2012). We next examined the developing subcu-
taneous lymphatic vasculature in dorsal embryonic skin, a useful
system to quantify lymphatic vascular phenotypes (James et al.,
2013; Kartopawiro et al., 2014). We found that Pkd1 KO embryos
exhibit defects in the morphogenesis of the lymphatic network,
with increased width of sprouting vessels, increased cell number
per vessel, and a significant reduction in network branching (Fig-
ures 3L, 3M, 3R, 3T, and 3U).
Previous studies reported that Tie2:Cre-mediated deletion of
Pkd1 did not lead to vascular abnormalities, and these knockout
mice did not display the edema observed in full knockout ani-
mals (Garcia-Gonzalez et al., 2010; Hassane et al., 2011). This
implies that the phenotypes that we observed may not reflect
endothelial autonomous function. To investigate this further,
we crossed the Tie2:Cre strain into a ROSA26r-LacZ back-
ground and examined Cre activity. Although active in blood ves-
sels, we could not detect activity throughout subcutaneous
lymphatic vessels (Figure S6). Hence, previous work would
not have uncovered function in these vessels. We generated
Tie2:Cre-mediated knockout embryos for Pkd1 and found no
subcutaneous lymphatic phenotype (Figure S5). Therefore, we
utilized Sox18:GFP-Cre-ErT2(GCE) as an additional endothelial
CRE strain (Kartopawiro et al., 2014). We validated the use of
Sox18:GCE on a Rosa26r-LacZ background, which demon-
strated activity throughout the vasculature (Figure S6). We also
used an inducible tdTomato reporter to quantify activity in sub-
cutaneous lymphatics by costaining with LEC markers NRP2
and PROX1. We found that induced Sox18:GCE was active in
58%of sprouting subcutaneous LECs at 13.5 dpc and frequently
in clonal regions spanning whole vessels (Figures 3J, 3K, and
S6H–S6Q; Movie S5).
We generated induced Pkd1 endothelial cell knockout
(iDECKO) embryos using this line. Pkd1iDECKO embryos dis-
played either mild or no subcutaneous edema at 14.5 dpc (Fig-
ure 3C), with lymph sacs present but not containing blood
(Figures 3I and 3F). In the subcutaneous lymphatic vasculature,
Pkd1iDECKO embryos displayed similar dramatic defects to germ-
line KO animals, if marginally milder on quantification (Figurese skin in WT (n = 15 embryos), Pkd1KO (n = 7 embryos), and Pkd1iDECKO (n = 6
rements, respectively, across leading lymphatic vessels from both sides of the
3 embryos), and Pkd1iDECKO (n = 6 embryos) (n = 5 representative leading edge
Cell Reports 7, 623–633, May 8, 2014 ª2014 The Authors 627
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3N, 3Q, 3T, and 3U).We examined the blood vasculature of Pkd1
KO embryos. Although we saw defects in Pkd1KO embryos,
these were at the dorsal midline associated with edema and
considered secondary to altered tissue architecture (Figure S5).
In contrast, Pkd1iDECKO embryos displayed normal blood vascu-
lature, including normal vessel width and branching (Figure S5).
Interestingly, Pkd1iDECKO embryos did not show reduced LEC
migration toward the midline (Figure 3N). This would be ex-
pected for mutants in known pathways such as VEGFC/
VEGFR3.
PKD1 Regulates Sprouting and Cell-Cell Junctions
In Vitro in Human LECs
Next, we examined the sprouting of human LECs in vitro in
response to VEGFC using a spheroid outgrowth assay. Small
interfering RNA (siRNA)-mediated knockdown of PKD1 in LECs
resulted in a reduced number of cells within individual spheroid
sprouts, with extensions exhibiting reduced length and abnormal
morphology (Figures 4A–4H; Figure S7). The efficacy of knock-
down with the siRNA mix was validated by qPCR, and the spec-
ificity was verified with an independent small hairpin RNA
(shRNA) knockdown (Figure S7). We examined the phenotype
of LECs in cultured monolayers and observed a rapid change
in morphology following PKD1 knockdown (Figures 4I–4P).
Stress fibers were disorganized in these cells (Figures 4I and
4M), and analysis of cell junctions revealed reduced VE-cadherin
and b-catenin and disorganized junctions following knockdown
(Figures 4J, 4K, 4N, and 4O). ZO-1 localization at tight junctions
was relatively unaffected in these assays, despite altered cell
morphology, suggesting a level of selectivity to adherens junc-
tions (Figures 4L and 4P). The levels of VE-cadherin were not
altered by western blot although b-catenin showed amild reduc-
tion (Figure S7), probably indicative of destabilized junctional
complexes.
Pkd1 Regulates Polarity and Cell-Cell Junctions during
Lymphatic Vessel Morphogenesis in Mice
Pkd1 has been implicated in the regulation of polarity in epithe-
lial cells and shown to regulate cellular convergent extension
and polarity during kidney tubule morphogenesis through
planar cell polarity (PCP) signaling (Castelli et al., 2013). PKD1
binds to PAR3 and aPKC as well as E-cadherin and b-catenin
therefore being associated with both polarity and junctional
components (Castelli et al., 2013; Lal et al., 2008; Roitbak
et al., 2004). Recently, the PCP pathway has been shown to
regulate junctional rearrangements in developing LECs, at least
during valve morphogenesis (Tatin et al., 2013).
We examined cell polarity in sprouting embryonic lymphatic
vessels. The Golgi apparatus orients toward the migration front
relative to the nucleus in many cell types including LECs (Fig-
ures 5A and 5C), serving as an ideal readout for polarity. We
quantified Golgi orientation in Pkd1 KO embryos and found it
to be significantly randomized in 14.5 dpc lymphatic vessels
compared with siblings (Figures 5A–5D and 5G). Furthermore,
this loss of polarity was associated with increased nucleus
sphericity in mutant vessels, a previously described proxy for
polarity and migratory behavior (Ha¨gerling et al., 2013)
(Figure 5H).628 Cell Reports 7, 623–633, May 8, 2014 ª2014 The Authors
63To determine the earliest defect, we performed detailed
phenotypic analysis at 10.5 and 11.5 dpc. At 10.5 dpc, analysis
of PROX1 expression indicated that cell migration from the cardi-
nal vein and nuclear morphology was normal in mutants (Figures
5I, S6G, and S6H). However, at 11.5 dpc, although the blood
vasculature was grossly normal (Figure S5), mutant LECs at the
sprouting vessel front displayed increased nucleus sphericity
(decreased elipticity) compared with wild-type (Figure 5J). We
assessedGolgi orientation at these stages, but the direction of in-
dividual cell migration events was not regular, and the midline
cannot be used as a direction of migration until later in develop-
ment (data not shown). These early leading vessels also exhibited
increased width and numbers of nuclei relative to vessel length
similar to later Pkd1KO vessels (Figures S5I–S5J).
Finally, we investigated cell shape and the morphology of
junctions within lymphatic vessels. At 14.5 dpc, VE-cadherin
highlighted cell shape and showed that mutant cells failed to
elongate along the plane of migration toward the midline
compared with wild-type vessels (Figures 5K, 5L, 5O, 5P, and
5S). At the level of individual junctional morphology, both VE-
cadherin and b-catenin expression identified junctions that
displayed immature morphology with irregular intracellular pro-
trusions (arrowheads in Figures 5M, 5N, 5Q, and 5R). These
phenotypes were only seen in phenotypically mutant vessels
and not morphologically wild-type mutant vessels (data not
shown; phenotypic variability shown in Figure 3). Quantification
of the number of cells displaying immature junctions showed a
significant phenotype from as early as 12.5 dpc (Figures 5T–5V).
DISCUSSION
Our results, along with those of Outeda et al. (2014) published
in this issue of Cell Reports demonstrate the surprising finding
that Pkd1 is a regulator of lymphatic vessel development. In
zebrafish, at the cellular level, Pkd1 regulates LEC migration
out of the horizontal myoseptum but not initial sprouting from
veins that is regulated by ccbe1/vegfc/vegfr3 (Hogan et al.,
2009a, 2009b; Le Guen et al., 2014; Villefranc et al., 2013).
pkd1a is expressed in lymphatic precursor cells when they are
actively migrating, consistent with the earliest cellular defects
in the mutant.
It was important, given the highly studied nature of Pkd1, to ask
if this function was conserved in mammals. In knockout mice,
early specification and initial sprouting of LECs occurs normally.
However, defects are seen in the morphology of migrating LECs
at 11.5 dpc with morphological defects in the subcutaneous
lymphatic network prominent by 14.5 dpc. This uniquely timed
requirement is distinct fromphenotypes in knownpathways, sug-
gesting that Pkd1 may act by an uncharacterized mechanism in
LECs. Interestingly, the lymph sacs were blood filled in full
knockout but not in endothelial knockout mice, which displayed
only mild edema. This may be due to the staging of tamoxifen
treatment to knockout Pkd1 function from 9.5 or 11.5 dpc,
when lymph sacs are already establishing (Ha¨gerling et al.,
2013). The observation that the lymphatic phenotype was
reproduced by deletion with Sox18:GCE, active in LECs, but not
Tie2:Cre, which we observed acts in BECs, suggests that Pkd1
functions in the LECs themselves during vessel morphogenesis.
Figure 4. PKD1 Regulates Sprouting and Cell-Cell Junctions in LECs In Vitro
(A–F) Morphology of human LEC spheroids treated with control and PKD1 siRNA (50 nM) in BSA or VEGFC-supplemented conditions, stained with F-ACTIN
(green) and DAPI (blue). Scale bar represents 100 mm in (A), (B), (D), and (E) and 30 mm in (C) and (F).
(G and H) Quantification of number of sprouts (G) and number of nuclei per 100 mm of sprouts (H) in spheroids treated with control or PKD1 siRNA in BSA or
VEGFC-supplemented conditions.
(I–P) Morphology of human LECs treated with control or PKD1 siRNA (50 nM) VEGFC-supplemented conditions, stained with DAPI (blue) and F-ACTIN (green)
(I and M), b-catenin (pink) (J and N), VE-cadherin (red) (K and O), or ZO-1 (L and P).
Error bars indicate SEM. See also Figure S7.Given the diverse functions of the protein, several hypotheses
could explain the observed migration and morphogenesis de-
fects. PKD1 has been previously reported to function at the pri-
mary cilium in endothelial cells (Nauli et al., 2008). However, we
found lymphatic vessels developed normally in a ciliogenesis
mutant (ift88; Huang and Schier, 2009), we saw no evidence
for altered ciliogenesis in lyc1 mutants, and overexpression of6a Pkd1a-YFP fusion protein, driven by the pkd1a promoter
(BAC clone), did not lead to cilium enrichment (Figure S8).
Hence, we find no supportive evidence that Pkd1 in zebrafish
lymphatic development functions at the cilium. Because Pkd1
can also localize to adherens junctions, desmosomal junctions,
and intracellular organelles and has a number of binding part-
ners, it has the potential to act at diverse locations.Cell Reports 7, 623–633, May 8, 2014 ª2014 The Authors 629
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Figure 5. Pkd1 Regulates Polarity and Cell-Cell Junctions in Mouse Embryonic Lymphatic Vessels
(A and B) Subcutaneous lymphatic vessels in skin of WT and Pkd1KO embryos at 14.5 dpc, stained with endomucin, NRP2, PROX1, and GOLPH4 (Golgi
apparatus), non-LEC GOLPH4 staining subtracted. Scale bar represents 20 mm.
(C and D) PROX1, GOLPH4 staining in WT and Pkd1KO lymphatic vessels. Arrowhead indicates Golgi; N, nucleus.
(legend continued on next page)
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The earliest consequences of loss of function are changes
in cell morphology during morphogenesis, including altered
polarity and adhesion. Cell polarity and adhesion are intimately
associated and must be carefully regulated to control tissue
morphogenesis. It is hard to determine which defect is pri-
marily regulated by Pkd1. However, parallels can be drawn
with recent findings in kidney tubule development where Pkd1
regulates cellular convergent extension during tube formation
through the PCP pathway (Castelli et al., 2013). Although it will
take further work to delineate the pathways modulated by
Pkd1 in LECs, the finding of a crucial role in lymphatic vascular
development is unexpected and serves as a unique entry point
to understand lymphatic vascular morphogenesis.
EXPERIMENTAL PROCEDURES
Zebrafish Strains, Mapping, and Genotyping
Animal use conformed to guidelines of the animal ethics committee at the
University of Queensland. Zebrafish were maintained and screening per-
formed as previously described (Hogan et al., 2009a). Mapping and genotyp-
ing was performed as previously described (Hogan et al., 2009a). Primers are
given in Supplemental Experimental Procedures. The lyc1 mutant allele is
formally designated pkd1ahu5855. The Tg(flt1:YFP)hu4624Tg, Tg(kdrl:egfp)s843,
Tg(fli1a:EGFP)y1, Tg(6.5kdrl:mcherry)s916, Tg(0.8flt1:tdTomato)hu5333Tg,
and Tg(lyve1:DsRed2)nz101 lines were previously described (Bussmann et al.,
2010; Hogan et al., 2009b; Jin et al., 2005; Krueger et al., 2011; Lawson and
Weinstein, 2002; Okuda et al., 2012).
Mouse Strains
We generated Sox18:GFP-Cre-ErT2(GCE), B6.129S4-Pkd1tm2Ggg/J (Pkd1f/f);
Rosa26rLacZ (C57BL/6 background) mice by crossing Pkd1f/f mice to both
Rosa26rLacZ and Sox18:GFP-Cre-ErT2 mice and breeding resulting carriers.
We generated Tie2:Cre, Rosa26rLacZ (C57BL/6 background) mice by crossing
Tie2:Cre mice to Rosa26rLacZ and breeding resulting carriers. We generated
Sox18:GFP-Cre-ErT2(GCE), Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J by cross-
ing Sox18:GFP-Cre-ErT2 mice to Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J
homozygous mice. We generated Pkd1/ embryos by crossing Pkd1f/f mice
to B6.C-Tg(CMV-cre)1Cgn/J and incrossing resulting progeny in subsequent
generations. Genotyping primers are described in Supplemental Experimental
Procedures.(E and F) Lateral view of (E) WT (n = 3) and (F) Pkd1KO (n = 2) bisected embryo
morphology of migrating sLEC nuclei (analyzed above dashed line). Scale bar re
(G and H) Quantification of nucleus-Golgi vector angle (G) in WT (n = 3 embryos, n
sphericity (width to length ratio) in WT (n = 7, n = 299 nuclei) and Pkd1KO (n = 7,
(I and J) Quantification of nucleus sphericity in (I) dorsal-most iLECs in WT (n = 5
sLECs in WT (n = 3, n = 131 nucleus) and Pkd1KO (n = 2, n = 93 nucleus) embryo
(K and O) Representative subcutaneous lymphatic vessels in (K) WT and (O) Pkd
Scale bar represents 20 mm
(L and P) Representative cell shape schematics based on vessels shown in (K) a
sided arrows indicate elongation axes.
(M and Q) WT and Pkd1KO mutant cells at 14.5 dpc stained with PROX1 and V
represents 5 mm.
(N and R) WT and Pkd1KO mutant cells at 14.5 dpc stained with PROX1 and
represents 5 mm.
(S) Quantification of the angle of cell elongation relative to the direction of mig
embryos).
(T) Quantification of the average number of cells with abnormal junctions (stained
(n = 4 embryos, n = 16 vessels) at 14.5 dpc.
(U) Quantification of abnormal junctions (stained with b-catenin) in WT (n = 3 em
(V) Quantification of the average number of cells with abnormal junctions (stained
(n = 3 embryos, n = 7 vessels) at 12.5 dpc.
iLECS, initial LECs; PLLV, peripheral longitudinal lymphatic vessel; sLECS, supe
6Imaging and Analysis
For confocal and spinning disk imaging, embryos were mounted as previously
described (Hogan et al., 2009b). Imaging was performed on a LSM Zeiss
510 NLO, META, or Zeiss 710 FCS confocal microscope with a 103, 203,
and 403 dry objective and 633 oil objective. Images were analyzed with the
Zen software, Biplane IMARIS, Photoshop, and ImageJ.
Morpholino Oligomers
Morpholino oligomers against pkd1a (morpholino oligomer [MO] ex8), pkd1b
(MO ex45), and pkd2 (MO ATG) were described in Mangos et al. (2010) and
were injected at 5, 7.5, or 10 ng/embryo as described (Hogan et al., 2008).
Quantitative Real-Time PCR
Procedures were performed in order to comply with MIQE guidelines (Bustin
et al., 2009) and are given in full in Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
eight figures, one table, and five movies and can be found with this article
online at http://dx.doi.org/10.1016/j.celrep.2014.03.063.
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Additional animal procedures 
For the induction of Cre-mediated recombination in embryos, 1.5 mg tamoxifen suspension in sunflower 
oil were injected intra-peritoneally into pregnant females at 9.5, 10.5 and 11.5 or 11.5, 12.5, 13.5 dpc in 
two separate regimes. 
 
GOLPH4 processing  - subtraction of background Golgi staining 
The nucleus-Golgi angle relative to the dorsal midline was measured by first using the NRP2 expressing 
tissues as a mask to remove non-endothelial GOLPH4 staining during processing. The angle was 
subsequently measured between the perpendicular to the midline and the nucleus-Golgi orientation 
vectors in endothelial cells. Sphericity was measured in nuclei located within 150 µm of the leading 
edge, on both side of the midline in 14.5 dpc embryos. At earlier stages (10.5 and 11.5dpc), polarity and 
nuclear sphericity were assessed in cells at the lymphatic vascular migratory front only.   
 
Statistical analysis  
We used a Mann-Whitney rank sum t-test using Prism (GraphPad software), for all figures except in 
Figure 2 (E), Figure 4 (G-H) and Supplementary Figure 3 and 9 where a two-tailed unpaired Student’s t 
test was used. P-values are represented in the Figures as *= P ≤ 0.05, **= P ≤ 0.01, ***= P ≤ 0.001 and 
****= P ≤ 0.0001. Standard error of the mean is represented in error bars. 
 
Whole-mount in situ hybridization and immunochemistry 
Primers used to amplify templates for riboprobe production are presented below. All probe template 
cDNAs were amplified from stage mixed WT cDNA by PCR and all PCR products, except for pkd1a, 
were subsequently cloned into pCS2+ plasmid (Turner and Weintraub, 1994). In situ hybridization was 
performed essentially as described in (Habeck et al., 2002; Thisse et al., 1993), with NBT/BCIP staining 
solution (Roche).  Expression analysis and plasmid probes for flt4, dab2, couptfII, ephrinb2a, vegfc 
probes has been previously described in (Aranguren et al., 2011; Hogan et al., 2009; Lawson et al., 	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2001; Song et al., 2004; Thompson et al., 1998). Antibodies and primers used in this study are reported 
below. 
 
Primers and antibody 
The antibodies used in this study are: ENDOMUCIN (sc-53941, Santa Cruz Biotechnology, 1/200), 
NRP2 (AF567, R&D systems, 1/200), PROX1 (AF2727, R&D systems, 1/200), PROX1 ( 11-002, 
Angobio Co, 1/200), GOLPH-4 ( ab28049, Abcam, 1/200), LYVE1 (Ab14917, Abcam, 1/200), LYVE1 
(Ab14917, Abcam, 1/200), β-CATENIN (C2206, Sigma, 1/200), VE-CADHERIN (sc-6458, Santa Cruz 
Biotechnology, 1/200),  Alexa fluor 647 ( A21247, Invitrogen, 1/200), Alexa fluor 546 (A11010, 
Invitrogen, 1/200), Alexa Fluor 488 (A11055, Invitrogen, 1/200), Acetylated-tubulin (T7451, Sigma, 
1/500). Primers used in this study are presented in Table 1.  
 
Quantitative real time PCR analysis 
Cell isolation, RNA extraction and cDNA synthesis: Zebrafish at 3 dpf and 5 dpf were deyolked by 
pipetting with 200 ul pipette tip and rinsed in Calcium free ringers solution.  Embryos were dissociated 
via treatment with 0.25% trypsin in PBS for early time points or a 1/35 dilution of liberase Tm (Roche) 
PBS at 28°C with repeated pipetting. For the venous/lymphatic comparisons RNA was extracted from 
FACS sorted samples from 3 and 5 dpf Tg(kdrl:GFP/lyve1:DsRed2) zebrafish, with the DsRed/GFP 
positive cells corresponding to the venous cell population and the DsRed positive and GFP negative 
population corresponding to the lymphatic cell population.  FACS analysis was performed at the 
Queensland Brain Institute (University of Queensland) using a Cytopeia Influx Cell Sorter (Cytopeia, 
Seattle USA).  RNA extraction and genomic DNA removal was performed using a QIAGEN RNeasy 
micro kit (Qiagen Inc., Chatsworth, CA, USA) as per manufacturers recommendations.  RNA was 
quantified using a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) 
and the integrity confirmed using an Agilent bioanalyser. RNA was amplified using the Agilent low input 
Quick Amp Labelling kit. For cDNA synthesis, residual genomic DNA was removed using the genomic 
DNA wipeout buffer included in the Quantitect reverse transcription kit (Qiagen Inc., Chatsworth, CA, 
USA). 30-50 ng of amplified mRNA was reverse transcribed into cDNA for 30 min at 42°C using a 
Quantitect reverse transcription kit (Qiagen Inc., Chatsworth, CA, USA) as per manufacturer's 	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recommendations. Specificity of the qPCR reactions was assessed in the absence of reverse 
transcriptase enzyme by including a no-transcript control (NTC). 
Quantitative PCR:  qPCR was performed using an Applied Biosystems Viia 7 384 well qPCR machine, 
Applied Biosystems). Each qPCR reaction mixture contained 7.5 µl 2 x ABI SYBR green master mix 
(Applied Biosystems), 5ul cDNA (80-fold dilution), and 500 nM each primer to a final volume of 15 µl. 
Amplification was performed in duplicate in 384 well plates (Applied Biosystems) with the following 
thermal cycling conditions: initial UDG treatment 50°C for 10 minutes, followed by 40 cycles of 15 s at 
95°C, 60 s at 60°C. Control reactions included a no template control (NTC) and a no reverse 
transcriptase control (-RT). Dissociation analysis of the PCR products was performed by running a 
gradient from 60 to 95°C to confirm the presence of a single PCR product. The efficiency of PCR 
amplification was determined using LinReg PCR (Ruijter et al., 2009). The stability of several reference 
genes was analysed including hprt1, ef1a, rps29, rpl13 and β-actin.  Reference gene stability was 
determined using GeNorm (Vandesompele et al., 2002).  The geometric average of rps29, rpl13 and 
ef1a was used for normalisation of gene expression, except in Figure 2F where rpl13 was used, these 
genes being validated as the most stable across the sample population. 
 
Primer design: Primers were designed using Primer blast (http://www.ncbi.nlm.nih.gov/tools/primer-
blast/) to have Tm of 60°C and to cross an exon-exon junction to avoid amplification of genomic DNA, 
whenever possible. Primers were used at a final concentration of 500 nM. 
 
Human lymphatic endothelial cells 
Human LECs were isolated and cultured as described (Norrmen et al., 2010). All experiments were 
performed with confluent  cells. 
 
PKD1 knockdown in human LECs 
siRNA transfection 
Human LECs were transfected with 50 nM of control siRNA (Qiagen, AllStars Negative Control siRNA) 
or PKD1 siRNA (ThermoScientific, SmartPool containg 4 different siRNAs) using Lipofectamine 
RNAiMAX (Invitrogen).  	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  shRNA transduction 
Lentiviral particles were prepared using PLKO.1 lentivector (Sigma) either empty as a control or carrying 
shRNA against PKD1. Two different constructs were used, shPKD1_a 
(TTGTAGACACAGAACTCCTCG) (Sigma, TRCN0000062320) and shPKD1_b 
(AATGTCTTGCCAAAGACGGAC) (Sigma, TRCN0000062322). shRNA sequences do not overlap with 
siRNAs used in the transfection experiments. Lentiviral particles were quantified using p24 Elisa kit 
(Gentaur) according to manufacturer’s instructions. Human LECs were transduced with a multiplicity of 
infection of 10. Three days post-transduction, cells were selected for two days  in 300 ng/ml puromycin.  
 
PKD1 knockdown validation 
Total RNA was isolated using Qiagen RNeasy Plus Mini Kit (Qiagen)  24h post-transfection or 3 days 
post-transduction. Reverse transcription was performed using Transcriptor First Strand cDNA Synthesis 
Kit (Roche Diagnostics). Real-time qPCR analyses were performed on StepOnePlus (Applied 
Biosystems) using SYBR Green PCR Master Mix (Applied Biosystems). Sequences of PCR primers are 
included in table 1. Analysis of PKD1 expression relative to 18s was carried out using the comparative 
Ct (ΔΔCt) method as described by the manufacturer. 
 
Lymphatic endothelial cell spheroid sprouting assay 
800 LECs were seeded in round-bottom 96-well plates as described previously (Korff et al., 1999). The 
spheroids were collected and embedded in fibrin gels (2.5 mg/ml fibrinogen, 0.625 U/ml thrombin and 
0.15 U/ml aprotinin), treated with 100 ng/ml BSA (Sigma) or ΔNΔC-VEGFC (kindly provided by Dr. M. 
Jeltsch and Dr. K. Alitalo) for 48 h. The spheroids were fixed in 4% PFA for 1 h at RT. Nuclei were 
stained with bis-Benzimide (Sigma) and F-actin cytoskeleton with Alexa 488-conjugated phalloidin 
(Molecular Probes). Spheroids (8 per condition) were imaged using Zeiss LSM 510 META scanning 
confocal microscope. The confocal images were processed using Bitplane IMARIS Suite 6.3.1 and 
Photoshop softwares. The number of sprouts, the cumulated length of sprouts, the average of sprout 
length and the density of nuclei composing the sprouts were measured for each spheroid using ImageJ 	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software. A two-tailed unpaired Student’s t test was used to analyze the statistical significance of the 
difference between BSA- and VEGFC-treated, or Control and PKD1-knockdown groups. 
 
Cell staining procedures and image acquisition 
Cells cultured on coverlips were fixed with 4% PFA, permeabilized with 0.1% Triton X-100 and blocked 
with 5% donkey serum. We used Alexa 488-conjugated phalloidin (Molecular Probes), rabbit anti-human 
β-CATENIN (Upstate), goat anti-mouse VE-CADHERIN (R&D systems) and rabbit anti-human ZO-1 
(Invitrogen). Coverslips were mounted using Prolong Gold anti-fade reagent containing Dapi (Invitrogen). 
Cells were imaged using Zeiss LSM 510 META scanning confocal microscope. The confocal images 
were processed using Bitplane IMARIS Suite 6.3.1 and Photoshop softwares. 
 
Western blotting 
Cells were lysed in a modified RIPA buffer, containing 50 mM Tris- HCl pH7.4, 0.25 mM Na-
deoxycholate, 150 mM NaCl, 2 mM EGTA, 0.1 mM Na3VO4, 10 mM NaF, 1 mM PMSF, 1% Triton-X 100 
and a complete protease inhibitor mixture (Roche). Protein concentration was measured using BCA kit 
(Pierce) and samples were resolved by SDS-PAGE, transferred onto Immobilon-P membrane (Millipore), 
and blotted with antibodies against rabbit anti-human GAPDH (Sigma), mouse anti-human β-CATENIN 
(BD transduction) and goat anti-mouse VE-CADHERIN (R&D systems). Western blots were developed 
using the ECL method (SuperSignal West Femto Maximum Sensitivity Substrate; Thermo Fisher 
Scientific). 
 
Calcium drug treatment 
Zebrafish embyos were exposed to DMSO, Nifedipine and Bayk8644 (Tocris Bioscience ref 1075 and 
1544 respectively) at the concentration indicated in E3 media, from 24 hpf to 4 dpf. The treatment media 
was changed twice a day.  Nifedipine and Bayk8644 were stored according to manufacturer 
recommendations.  	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SUPPLEMENTAL MOVIE LEGENDS 
 
 
Supplemental Movie S1. Related to Figure 1.  
Time-lapse visualization of PL (arrow) migration between 62 hpf and 92 hpf in the trunk of a WT embryo 
in Tg(fli1a:EGFP; flt1:tomato). The video was acquired using a 10x objective, one frame every 20 
minutes.  
 
Supplemental Movie S2. Related to Figure 1. 
Time-lapse visualization of PL (arrow) migration between 62hpf and 92hpf in the trunk of a lyc1 embryo 
in Tg(fli1a:EGFP; flt1:tomato). The video was acquired using a 10x objective, one frame every 20 
minutes.  
 
Supplemental Movie S3. Related to Figure 1.  
Spinning disk visualization of a parachordal lymphangioblast between 56 and 64 hpf in the trunk of a 
control (WT/MO-pkd1b) embryo (5ng MO), which develop wildtype lymphatics. The video was acquired 
using a 40x dry objective, one frame every 4 minutes.  
 
Supplemental Movie S4. Related to Figure 1. 
Spinning disk visualization of a parachordal lymphangioblast between 56 and 64 hpf in the trunk of a 
lyc1/MO-pkd1b embryo (5ng MO). The video was acquired using a 40x dry objective, one frame every 4 
minutes.  
 
Supplemental Movie S5. Related to Figure S7. 
Analysis of co-localisation of tdTOMATO with PROX1 and NRP2 during validation of the Sox18:GFP-
Cre-ERT2 using the Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J reporter strain.  Computational masking of the 
area spanned by NRP2 expression using Imaris software allows for removal of the majority of blood 
vascular tdTOMATO.  This identifies high activity of Sox18:GCE in LECs, allowing for counting of 
individual PROX1/tdTOMATO co-expressing LEC nuclei (CAG-tdTOMATO localizes strongly to nuclei) 
and revealing large clonal patches of CRE activity in subcutaneous lymphatic vessels.  	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Supplemental Figure S1: Further phenotypic analysis of lyc1. Related to Figure 1 
(A-B) Representative overall morphology of WT and lyc1 mutant embryonic hearts and pericardial 
cavities at 3 (A) and 5 dpf (B). Double-sided arrows indicate the distance between the pericardium and 
heart. Dashed line indicates the outline of the myocardium. 
(C) In situ hybridization analysis of flt4 (n=22), dab2 (n=16), coup-TFII (n=20), ephrinb2a (n=17) and 
vegf-c (n=28) in lyc1 mutant embryos revealed no alterations in normal expression patterns. N values 
indicate the total number of embryos examined from an incross of known heterozygotes (expected 25% 
lyc1 mutants). Individual genotype confirmed mutant embryos are shown in the right hand panels. (D) 
Expression of cxcr4a was unchanged at 32 hpf in control WT/MO-pkd1b (embryos show no phenotype 
after pkd1b knockdown only and internally control for MO toxicity) (n=39/40) compared with 
phenotypically mutant (based on body curvature in the presence of MO-pkd1b) lyc1/MO-pkd1b embryos 
(5ng MO) (n=16/16). Expression of cxcr4b was unchanged at 32 hpf in control (WT/MO-pkd1b) 
(n=36/38) compared with phenotypically mutant lyc1/MO-pkd1b embryos (5ng MO) (n=7/7). Expression 
of cxcl12a was unchanged at 32 hpf in control (WT/MO-pkd1b) (n=50/52) compared with phenotypically 
mutant lyc1/MO-pkd1b embryos (5ng MO) (n=14/14). Expression of cxcl12b was unchanged at 32 hpf in 
control (WT/MO-pkd1b)  (n=28/37) compared with phenotypically mutant lyc1/MO-pkd1b embryos (5ng 
MO) (n=6/7).  
(E) Expression of klf2a at 24 (n=10/10) and 32 hpf (n=9/10) is normal in WT embryos. Expression of 
klf2a at 24 hpf (n=14/14) and 32 hpf (n=19/20) in lyc1 mutant embryos.  	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Supplemental Figure S2: Parachordal lymphangioblasts fail to directionally migrate and display 
altered cell dynamics in the lyc1 mutant. Related to Figure 1.  
(A-B) Schematic overview of the movement of the leading front of individual parachordal 
lymphangioblasts (t=10.5h) from 56 hpf (scale bar: 10 µm) in (A) WT/MO-pkd1b (5ng MO) (n=3 
embryos, n=4 leading fronts) and (B) phenotypically mutant lyc1/ MO-pkd1b (5ng MO) (n=5 embryos, 
n=5 leading fronts).  
(C-D) Quantification of (C) movement of cell front and (D) origin to endpoint of cell front distance 
migrated by parachordal lymphangioblasts (t=10.5h) from 56 hpf in in WT/MO-pkd1b (5ng MO) (n=3 
embryos, n=4 leading front) and phenotypically mutant lyc1/ MO-pkd1b (5ng MO) (n=5 embryos, n=5 
leading fronts) (µm).  
(E) Quantification of duration of individual filipodial extensions in single parachordal lymphangioblasts at 
the horizontal myoseptum by time-lapse imaging (spinning disc). WT/MO-pkd1b (n=3) and 
phenotypically mutant lyc1/MO-pkd1b embryos (n=4) (5ng MO) were examined between 56-64 hpf (1 
time unit = 4 minutes).  
(F) Quantification of the number of filipodial extensions per parachordal lymphangioblasts by time-lapse 
imaging (spinning disc) in WT/MO-pkd1b (n=3) and phenotypically mutant lyc1/MO-pkd1b embryos 
(n=4) (5ng MO) between 56-64 hpf.  
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Supplemental Figure S3: The lyc1 mutant lymphatic phenotype is enhanced with MO-pkd1b 
injection and targeting calcium signaling results in a lymphatic phenotype. Related to Figure 2. 
(A) Quantitative real time PCR for kdrl, cdh5, prox1a, nfatc1, nrp2a, flt4 and lyve1 transcripts normalized 
expression at 3 dpf in sorted embryonic venous and lymphatic endothelial cells. Sorted cell populations 
display the predicted enrichment of marker genes.  
(B) Quantitative real time PCR for pkd1b transcript normalized expression against ef1a and rpl13 at 3 
dpf in WT and MO-pkd1a embryos at 24hpf. pkd1b is readily detectable in whole embryo cDNA but not 
altered by pkd1a knockdown. 
(C) Quantification of parachordal lymphangioblasts in WT (n=18), lyc1 (n=9) WT/pkd1b (5ng MO) (n=21), 
lyc1/MO-pkd1b embryos (5ng MO) (n=23) at 56hpf.  
(D-E) Quantification of thoracic duct extent in (D) WT (n=48), lyc1 (n=23), WT/MO-pkd1b (5ng MO) 
(n=24), lyc1/MO-pkd1b embryos (5 ng MO) (n=21), and (E) WT (n=50), MO-pkd2 embryos (7.5 ng 
MO)(n=136) at 4dpf.  
(F) Quantitative real time PCR for cacna1s transcript normalized expression at 30 hpf in sorted 
embryonic venous and arterial endothelial cells. Endothelial expression of this calcium channel and 
Nifedipine target is confirmed. 
(G-H) The vasculature of (G) DMSO 0.05% and (H) DMSO 0.05%/Nifedipine 25 µM treated embryos in 
Tg(fli1a:EGFP y1; kdrl:mcherry s916). The thoracic duct is markedly absent in the presence of a calcium 
signaling antagonist (Nifedipine). 
(I) Quantification of parachordal lymphangioblasts in DMSO 0.2% (n=62) and DMSO 0.2%/Nifedipine 
100µm treated embryos (n=101) at 56 hpf.  PLs are unchanged in the presence of a calcium signaling 
antagonist (Nifedipine).  
(J) Thoracic duct quantification in DMSO 0.05% (n=45) and DMSO/0.05%/Nifedipine 25 µM (n=68) at 5 
dpf. Thoracic duct reduction similar to lyc1 mutants is observed. 
(K) Quantification of thoracic duct extent in WT/MO-pkd1b/0.05% ethanol (5ng MO) (n=21), lyc1/MO-
pkd1b/0.05% ethanol (5ng MO) (n=21), MO-pkd1b/ethanol 0.05%/Bayk8644 (5ng MO) (n=28) and 
lyc1/MO-pkd1b /ethanol 0.05%/Bayk8644 (5ng MO)(n=15) embryos at 4dpf. A mildly penetrant lyc1 
carrier was used. Remarkably, a phenotypic interaction with the calcium agonist is observed only in the 
mutant animals and not in the wildtype siblings. This suggests a sensitivity of mutant cells to further 
fluctuations in Ca2+ signaling. 	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 Supplemental Figure S4: The lyc1 lymphatic vascular phenotype is independent of collagen 
gene expression and ECM changes. Related to Figure 2. 
(A-C) Electron-microscopy imaging of the peri-notochordal region in WT, lyc1/MO-pkd1b (5ng MO) and 
MO-pkd2 embryos (7.5 ng MO). Nt=notochord, M=muscle. 
(D) Expression of col12a1, a vascular collagen, was unchanged at 24 and 32 hpf in control (WT/MO-
pkd1b) (n=27, n=37 respectively) compared with phenotypically mutant lyc1/MO-pkd1b embryos (5ng 
MO) (n=37, n=12 respectively).  
(E) Expression of col9a2 was unchanged at 48 hpf in control (WT/MO-pkd1b) (n=10) compared with 
phenotypically mutant lyc1/MO-pkd1b embryos (5ng MO) (n=10).  
(F-G) Overall morphology of (F) MO-pkd1a/MO-pkd1b (5ng MO each) and (G) MO-pkd1a/MO-
pkd1b/MO-col2a1a morphants (5,5,1 ng MO respectively). Knockdown of Col2a1a rescues the gross 
curvature phenotype as previously described (Mangos et al., 2010). 
(H). Quantification of col9a2 expression as the anterior posterior extent of expression in the notochord, 
delineated by somites boundaries.  No increase in col9a2 extent was observed. 
(I) Quantification of thoracic duct extent in MO-pkd1a/MO-pkd1b embryos (n=21) and 
pkd1a/pkd1b/col2a1a morphants  (n=19). Despite rescue of the gross curvature phenotype, TD extent is 
not rescued. 
(J) Quantification of the number of collagen fibers in the medial layer of the peri-notochordal region in 
WT (n=3), WT/MO-pkd2 (7.5 ng MO) (n=3), WT/MO-pkd1b (5 ng MO) (n=3) and lyc1/MO-pkd1b 
embryos (5ng MO)(n=3). No change was observed in peri-notochordal collagen.  
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Supplemental Figure S5: Endothelial knockout of Pkd1 does not affect blood vascular 
development and lymphatic morphological defects are observed in Pkd1KO embryos from 11.5 
dpc. Related to Figure 3.  
 (A-B) Overall morphology of lymphovenous valves in (A) WT (n=2) and (B) Pkd1KO (n=3) coronal 
sections stained with PROX1, LYVE1 and ENDOMUCIN based on previous studies (Srinivasan and 
Oliver, 2011). LS: Lymph sac; CV: Cardinal Vein. White arrow and inset indicate lymphovenous valve. 
Scale bar: 100 µm 
(C) Representative morphology of subcutaneous blood vascular network in WT (n=7), Pkd1KO (n=7), 
Pkd1iΔECKO (n=3) at 14.5 dpc, stained with ENDOMUCIN. Scale bar: 200 µm 
(D) Lateral views of the representative morphology of the blood vascular network in whole mount WT 
(n=5) and Pkd1KO  (n=5) embryos at 11.5 dpc, stained with ENDOMUCIN. Scale bar: 100 µm 
(E) Quantification of the width of subcutaneous vessels (µm) across the whole skin in WT (n=6), and 
Pkd1iΔECKO   (n=3) embryos (n=2398, n=1200 measurements respectively. Two areas of 2000*900 µm 
centered on the midline were used for quantification in every embryo). 
(F) Quantification of the number of branch points per area in WT (n=6) and Pkd1iΔECKO (n=3) embryos (3 
areas of 2000*500 µm centered on the midline were used for quantification in every embryo). 
(G,H) Representative lateral view of (G) WT (n=5) and (H) Pkd1KO (n=5) bisected embryos with at 10.5 
dpc stained with ENDOMUCIN and PROX1. Scale bar: 50 µm. CCV: common cardinal vein, iLECs: 
initial lymphatic endothelial cells.  
(I,J) Morphology of representative sLECs in (I) WT (n=5) and (J) Pkd1KO  (n=5) embryos stained for 
NEUROPILIN2. Scale bar: 10 µm 
(K) Quantification of the average width of leading sprouts (µm) in WT (n=5) and Pkd1KO (n=5), (n=18, 
n=27 measurements respectively, across leading lymphatic vessels, averaged) at 11.5 dpc.  
(L) Quantification of nuclei per µm of vessel in WT (n=5) and Pkd1KO (n=5) (n=39, n=66 measurements 
respectively) at 11.5dpc. 
 (M-N) Subcutaneous lymphatic vasculature in WT and Pkd1ECKO (Tie2:Cre+; Pkd1f/f) mutants at 14.5 
dpc.  
(O) Quantification of branch points/area (2000*1500 µm area on both sides of the midline) in WT (n=4 
embryos) and Pkd1ECKO (Tie2:Cre+; Pkd1f/f) (n=4 embryos) embryos at 14.5 dpc.  	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(P) Quantification of the average width of lymphatic vessels (µm) across the whole skin in WT (n=4 
embryos) and Pkd1ECKO (Tie2:Cre+; Pkd1f/f) (n=4 embryos) embryos. The average is shown of n=800 
and n=800 measurements respectively, across leading lymphatic vessels from both side of the midline at 
14.5 dpc.  
(Q) Quantification of nuclei/100 µm length of vessel in WT (n=4 embryos) and Pkd1ECKO (Tie2:Cre+; 
Pkd1f/f) (n=4 embryos) (n=10 representative vessels were counted per embryo at the leading edge and 
averaged) at 14.5 dpc. 	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Supplemental Figure S6: Validation of gene targeting. Related to Figure 3. 
(A-C) Whole mount X-gal staining of β-gal in Tie2:Cre-/-, Rosa26R-/- and Tie2:Cre+, Rosa26R+  embryos 
shows that the Cre activity in the subcutaneous vasculature is strong in the blood vascular endothelium 
but not the lymphatic vascular endothelium at 14.5 dpc.  
(D-E) Whole mount X-gal staining of β-gal in Sox18-CREert2, Rosa26R embryos show CREert2 activity 
in 10.5 and 14.5 dpc embryos.  
(F). Whole mount X-gal staining indicates CRE activity, which is selective for endothelial cells, 
recapitulating the Sox18 expression pattern.  Note that there is no co-stain to determine vessel identity in 
this experiment. 
(G) Genotyping of Pkd1iΔECKO with primers F4/R4 (Piontek et al., 2004) shows a band indicating a 
defloxing event (subsequently confirmed by sequencing). This shows that the Pkd1 locus is inactivated 
in a proportion of cells in the endothelial specific Sox18:GCE strain (DNA from whole tissue extract).  
(H-K) Subcutaneous vessels analysed in Sox18:GFP-Cre-ERT2, Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J 
co-stained with NRP2 and PROX1 to identify the lymphatic vessels at 13.5 dpc. H. Low magnification 
image of whole skin showing tdTOMATO expression in blood and lymphatic endothelial cells. I.  PROX1 
stains only the lymphatic vessels. J. Lymphatic vessels make up a proportion of total cells expressing 
tdTOMATO (indicated by the hashed lines). K. Image processing to remove most blood vascular 
tdTOMATO (by computational masking of NRP2 positive tissue using Imaris software) reveals strong 
activity of Sox18:GFP-Cre-ERT2 in cells of the lymphatic network. Scale bar: 200 µm 
(L-O). Example of a lymphatic vessel with tdTOMATO expression as analysed by Imaris image 
processing to remove non-lymphatic endothelial staining (eg, panels M-O). Inset in N and O are 
individual co-stained nuclei (PROX1 and tdTOMATO (CAG-tdTOMATO localizes to nuclei)) allowing 
precise cell counting. Quantification of whole skin as described in Figure 3 and related text, using this 
approach revealed that n=663/1138 LECs were tdTOMATO, PROX1 and NRP2 positive (58.2%).  
(P-Q) Alternative masking in Imaris using PROX1 expression as the mask identified the same co-
localisation as using an NRP2 mask (inset are individual nuclei). Scale bar: 10 µm 
(R-S) Sox18:GFP-Cre-ERT2, Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J co-stained with LYVE1 and PROX1 
at 11.5 dpc labels the cardinal vein from which early LECs derive. CV: Cardinal Vein, H: Heart. Scale 
bar: 300 µm 	  
88
BSA
Control
VEGFC
Control
BSA
shPkd1_a
VEGFC
shPkd1_a
shPkd1_b
BSA VEGFC
shPkd1_b
F-ACTIN   DAPI
Supplemental Figure 7
Co
ntr
ol
siP
KD
1
β-CATENIN
VE-CADHERIN
GAPDH0
20
40
60
80
100
120
Pk
d1
 m
RN
A 
lev
el
re
lat
ive
 to
 1
8s
 (%
)
Co
ntr
ol
siP
kd
1
*
2.4
1.8
1.2
0.6
0To
ta
l s
pr
ou
t l
en
gt
h 
/s
ph
er
oi
d 
(m
m
) *
*
*
*
*
shP
kd
1_a
BSA     VEGFC
2.0
Co
ntr
ol
1.5
1.0
0.5
0Me
an
 sp
ro
ut
 le
ng
th
/s
ph
er
oi
d 
(x1
00
 µ
m
)
shP
kd
1_b
* * *
0
20
40
60
80
100
120
Pk
d1
 m
RN
A 
lev
el
re
lat
ive
 to
 1
8s
 (%
)
Co
ntr
ol
shP
kd
1_a
shP
kd
1_b
*
20
15
10
5
0S
pr
ou
ts
/s
ph
er
oi
d *
*
*
BS
A
VE
GF
C
BS
A
VE
GF
C
4
3
2
1
0T
ot
al 
sp
ro
ut
 le
ng
th
 
/s
ph
er
oi
d 
(m
m
)
** ***
*****
Control siPKD1
A
B
C
D
E
F
G H I
J
*
*
89
Supplemental Figure S7: Validation of shRNA and siRNA targeting of PKD1 expression in LECs 
in vitro. Related to Figure 4. 
(A-C) Morphology of human LEC spheroids treated with control and two alternative PKD1 shRNA 
(shPkd1_a and shPkd1_b respectively) in BSA or VEGFC supplemented conditions, stained with F-
ACTIN (green) and DAPI (blue). Scale bar: 100 µm.  
(D-F) Quantification of number of sprouts (D), total sprout length (mm) (E) and number of nuclei per 100 
µm of sprouts (F) in spheroids treated with control or PKD1 targeting shRNA (shPkd1_a and shPkd1_b 
respectively) in BSA or VEGFC supplemented conditions.  
(G-H) Quantification of PKD1 mRNA expression level relative to 18s in human LEC spheroids treated 
with control and two alternative PKD1 shRNA (shPkd1_a and shPkd1_b respectively) (G) and with 
control and PKD1 targeting siRNA (H) in VEGFC supplemented conditions.  
(I) Western-blot quantification of β-CATENIN, VE-CADHERIN and GAPDH protein levels in cultured 
human LECs treated with control and PKD1 targeting siRNA.  
(J) Quantification of total sprout length (mm) in spheroid treated with control or PKD1 targeting siRNA in 
BSA or VEGFC supplemented conditions.  
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Supplemental Figure S8: No evidence for a contribution of primary cilia to lymphangiogenesis. 
Related to Discussion section.   
(A-B) The vasculature Tg(lyve1:DsRed2)nz101 in (A) wild-type sibling  and (B) ift88tz288 mutant embryos at 
56 hpf (arrowheads indicate parachordal lymphangioblasts and white arrows indicate venous sprouts).  
(C-D) Overall morphology of (C) wild-type siblings and (D) ift88tz288 mutants at 5 dpf. (E-H) The 
vasculature Tg(lyve1:DsRed2nz101; flt1:YFPhu4624Tg) of (E,G) WT and (F,H) ift88tz288 mutants at 5 dpf.  
(I-J) Quantification of (I) secondary sprouts in WT (n=12) and ift88tz288 (n=10) at 56 hpf and (J) thoracic 
duct extent in WT (n=16) and ift88tz288 (n=18).  
(K-N) Overview of primary cilia localization in the trunk of (K,M) WT (n=4) and (L,N) lyc1 mutants (n=3) 
embryos at 30 hpf, stained for blood vessels (Kdrl-Cherry), nuclei (DAPI) and primary cilia (Acetylated-
tubulin) markers. Arrowheads indicate example of discrete primary cilia.  
(O) An individual representative primary cilium in a lyc1 embryo.  
(P) Transient expression of a Pkd1-YFP BAC construct in an arterial intersegmental vessel and adjacent 
muscle cells at 4 dpf. DA: Dorsal Aorta, PCV: Posterior Cardinal Vein, TD: Thoracic duct 	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Table 1 Primers used in this study
Name Use Sequence direction Sequence
marker 1 - 54.65Mb polymorphic marker used for positional cloning F 5’-GACTACACCGGTTGTGTCTG-3’
R 5’-GTCCCTTCAGATCGGTCAC-3’
marker 2 - 54.73Mb polymorphic marker used for positional cloning F 5’-ACCACACAGACAAACTCTGG-3’
R 5’-CGTCACATGTTGATCACAGAC-3’
marker 3 - 54.77Mb polymorphic marker used for positional cloning F 5’-CAGAGGCTTCTCCTATCACAC-3’
R 5’-TGACAACCATGCTTTGAGTC-3’
marker 4 -  54.92Mb polymorphic marker used for positional cloning F 5’-TGAACAAATGGTCGCATGTT-3’
R 5’-ACTTTTCCATCTGCTGCTCC-3’
lyc1 mutation site sequencing lyc1 mutation (R3607X) F 5’-TTGCTATTCCTGTGTGTTCTG-3’
R 5’-ACATCAACCGTCTGACATC-3’
lyc1 mutation site Introduction of an Hinp1I restriction fragment Hinp1I-R 5’CGCACTCGGGGGATCCGCTGGACCACGC-3'
 length polymorphism by PCR for rapid genotyping
of lyc1 fish.  The presence of the lyc1 stop codon 
mutation in the pkd1a sequence removes 
the induced Hinp1I restriction cutting site.
pkd1a riboprobe riboprobe amplification with T3 polymerase Tag F 5'-ACGTGTGTGTGTCTCTGGAC-3'
R 5'GGATCCATTAACCCTCACTAAAGGGAACTGTACTCTGGGTATTGTGTGC-3'
cxcl12a cloning subcloning riboprobe in PCS2+ vector F 5'-GCGCGAATTCAAAAAGCCCAACAGCAGCAGG-3'
[restriction sites in bold] R 5'-GCGCCTCGAGACACGGAGCAAACAGGACTCC-3'
cxcl12b cloning subcloning riboprobe in PCS2+ vector F 5'-GCGCGAATTCTATTGCCCAGCAATGTTCGC-3'
[restriction sites in bold] R 5'-GCGCCTCGAGTGTGACCAGAGGGCTAGTGT-3'
cxcr4a cloning subcloning riboprobe in PCS2+ vector F 5'-GCGCGAATTCTGCTCACTCTGCCATTCTGG-3'
[restriction sites in bold] R 5'-GCGCCTCGAGACAGCAGTGAAAGTACGCGA-3'
cxcr4b cloning subcloning riboprobe in PCS2+ vector F 5'-GCGCGAATTCTCGCAGACCTCCTGTTTGTC-3'
[restriction sites in bold] R 5'-GCGCCTCGAGGCAGTGGAAATATGCCAGCG-3'
col9a2 cloning subcloning riboprobe in PCS2+ vector F 5'-GCGCGAATTCTTTCAGTGTCCAACCAACTG-3'
[restriction sites in bold] R 5'-GCGCCTCGAGGATCCTTGCATTCCCATC-3'
col12a1 cloning subcloning riboprobe in PCS2+ vector F 5'-GCGCGAATTCTCTGTATGCTGATGGAGAGG-3' 
[restriction sites in bold] R 5'-GCGCCTCGAGGCATCATACTGAGCGTAAACC-3'
Cre coding sequence gentoyping for the presence of Cre F 5'-CGAACGCACTGATTTCGACC-3'
R 5'-AACCAGCGTTTTCGTTCTGC-3'
Cre coding sequence 
(alternative) gentoyping for the presence of Cre F 5'-GTTTCACTGGTTATGCGGCG-3'
R 5'-GGTGCTAACCAGCGTTTTCG-3'
LacZ coding sequence genotyping for the precesence of LacZ F 5'-GGCGGCTTCGTCTGGGACTG-3'
R 5'-CAGGCGGCAGTAAGGCGGTC-3'
18S shRNA qPCR quantification of 18S expression F 5'-AGGAATTCCCAGTAAGTGCG-3'
R 5'-GCCTCACTAAACCATCCAA-3'
pkd1 shRNA qPCR quantification of PKD1 expression F 5'-CTTCCGGTGGACCATCAACG-3'
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4.1 Introduction 
 
Blood flow within the vasculature exposes the endothelium to different types of physical forces. 
Shear stress is one of the most studied physical forces, in particularly in relation to its effect on the 
behaviour of vascular endothelial cells both during development and under normal physiological 
conditions. Shear stress is defined as a frictional force applied at the surface of a cell and induced 
by flow. The physical characteristics of shear stress are dependent upon blood viscosity, velocity, 
and the local morphology of the endothelium (reviewed in (Ballermann et al., 1998)).  
 
There is much scientific evidence to support the idea that flow, particularly vascular flow, can affect 
embryonic morphogenesis. Many studies, both in vivo and in vitro, have emphasised the 
importance of blood flow in the remodelling of the blood vasculature during embryogenesis. Work 
in mice and chick yolk sac, has demonstrated that the perfusion of vessels, upon initiation of blood 
flow, directly regulates vascular remodelling and arterial-venous differentiation (le Noble et al., 
2004; Lucitti et al., 2007). Consistent with these findings is the observation that the formation of 
angiogenic sprouts in cultured endothelial cells is modulated by shear stress (Song and Munn, 
2011). In the last decade a number of flow-responsive pathways that regulate angiogenic 
processes such as vessel differentiation (Buschmann et al., 2010; le Noble et al., 2004), pruning 
(Chen et al., 2012), morphogenesis (Bussmann et al., 2011; Corti et al., 2011; Goetz et al., 2014; 
Yu et al., 2006) and maturation (Sabine et al., 2012) have been uncovered.  Examples of such 
pathways include Klf2a/nitric oxide, Nfatc1/Calmodulin and chemokine pathways (Bussmann et al., 
2011; Sabine et al., 2012; Wang et al., 2011a).  
 
Although a number of flow-dependent pathways have been identified, the cellular components 
underlying flow mechanosensation and mechanotransduction remain elusive. Mechanosensation is 
the ability to detect stimuli exerted onto the cell surface, while mechanotransduction is the ability to 
interpret these stimuli and translate them into a tangible intracellular event. At the level of cellular 
structures, caveolae and primary cilia are two key types of cellular organelles involved in a large 
array of embryonic developmental processes. These organelles have been suggested to act as 
mechanosensors in endothelial cells, and are capable of initiating flow mechanotransduction (Nauli 
et al., 2008; Yu et al., 2006). Endothelial specific expression of Caveolin-1 (Cav1), a protein 
necessary for the formation of caveolae, was shown to play a cell autonomous role in 
mechanotransduction and flow-dependent remodelling of the blood vasculature in vivo (Yu et al., 
2006). Flow-dependent remodelling and dilatation of vessels exposed to reduced or increased 
blood flow were significantly altered in Caveolin-1 knock out animals. In this context, the caveolae-
mediated morphological response to flow is propagated through the activation of endothelial nitric 
oxide signaling. 
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Nauli and colleagues showed that vascular endothelial cilia are mechanosensory organelles that 
are able to detect extracellular shear stress, and elicit the activation of calcium and nitric oxide 
signaling (Nauli et al., 2008). The authors showed a dramatic reduction of cytosolic nitric oxide and 
calcium levels in Polycystin-1 (Pkd1) null cells exposed to chronic and acute intraluminal flow, 
demonstrating that shear stress transduction is dependent upon the presence of Pkd1. The 
physiological phenocopy of the Pkd1 null phenotype in Tg737 null cells (lacking cilia) suggests that 
Polycystin-1 mediates the mechanosensory ability of cilia (Nauli et al., 2008). Further studies 
proposed that the ion channel Polycystin-2, which is directly activated by Polycystin-1, is able to 
mediate calcium and nitric oxide signaling in vascular endothelial cells (AbouAlaiwi et al., 2009; 
Hanaoka et al., 2000). More recently, Goetz and colleagues have highlighted another role of 
Polycystins on endothelial vascular cilia during vascular morphogenesis (Goetz et al., 2014). Using 
non-invasive visualisation of endothelial cilia, the authors demonstrated a direct correlation 
between the primary cilia physical bending in response to blood flow and the intensity of 
Polycystin-2 dependent calcium signaling. They showed that the remodelling of the venous caudal 
plexus in the zebrafish embryo is negatively affected by an abolition of blood flow or a reduced 
blood viscosity. 
 
In another cell type, in smooth muscle cells, Sharif-Naeini and colleagues have shown that 
Polycystin-1 and 2 interactively regulate pressure mechanotransduction. They demonstrated that 
the interaction between Polycystin-2, filamin-A and F-actin, two components of the cytoskeleton, is 
crucial to the process, as the disruption of any of these components results in an abnormal 
physiological response of the cells to external pressure (Sharif-Naeini et al., 2009). Interestingly, in 
this particular biological context, the interaction of Polycystin-1 with Polycystin-2 is suggested to 
reduce the intensity of the physiological response, a result that is diametrically opposed to what is 
seen during Polycystin1/2-dependent mechanotransduction in the vascular endothelium. 
 
Separate from these Polycystins complexes, cellular adhesion complexes also plays a central role 
in the mechanotransduction of shear stress. Tzima and colleagues have characterized a PECAM-
1/VE-CADHERIN/VEGFR2 multi-protein complex that mediates the response of vascular 
endothelial cells to shear stress (Tzima et al., 2005). By using the conformational activation of 
integrin and NF- κB as readout of cellular response to shear stress, they uncovered that this 
complex acts through a Src/PI(3)K signaling pathway, which in turn modulates the activity of flow-
responsive cellular effectors such as integrins and NF-κB.  
 
Although there is a lack of direct evidence linking shear stress and early lymphangiogenesis, the 
development of a mature functional lymphatic vasculature is a process that has been linked-both 
directly and indirectly to flow and fluid forces. Work by Planas-Paz and colleagues illustrate the 
correlation between lymphatic vessel expansion and interstitial fluid pressure in an in vivo setting, 
99
demonstrating the ability of lymphatic endothelial cells (LECs) to respond to changes in 
extracellular fluid pressure (Planas-Paz et al., 2012). In particular, they show that an increase in 
interstitial fluid pressure correlates with an extension of the length of local LECs and increased 
LEC proliferation.  The authors demonstrated that β1-integrins, also involved in lymphatic valve 
formation (Bazigou et al., 2009) are required for lymphatic vessel expansion, and mediate this 
process by direct interaction and activation of the VEGFR3 signaling pathway. In maturing 
lymphatic vessels, valve formation is directly regulated by local alteration of wall shear stress, 
especially in areas of disturbed flow such as vessel bifurcations (Bazigou et al., 2009). Disturbed 
flow has been shown to trigger the activation of the Nfatc1/Calcineurin pathway.   
 
Together, these data showed that shear stress is required for establishing blood and lymphatic 
vasculature during mouse development. On the molecular level, it is known that members of the 
flow mechanosensory pathways, including Polycystin1/2, Nfatc1, β1-integrins are active in LECs. 
In zebrafish the initiation of blood flow immediately precede secondary angiogenesis. However the 
role of mechanosensation during venous and lymphatic sprout formation has not been described. 
Here, we hypothesise that haemodynamic changes could be a primary factor promoting the 
emergence of lymphatic progenitors and intersomitic veins from the posterior cardinal vein.  
 
The main aim of this chapter is to determine the role of flow during secondary angiogenesis. In 
order to do so, we first investigated the consequence of altering the physical properties of blood 
flow in vivo prior to, and during secondary angiogenesis, and observed the consequence of such 
alteration on the initiation of this process. This was achieved through the abolishment of blood flow, 
and both an increase and decrease of blood viscosity. Secondly we investigated the role of the 
primary cilium, one of the main mechanosensor organelle, by disturbing its formation and 
maintenance. We then investigated the role played by calcium and nitric oxide signaling, so often 
at the crux of shear stress mechanotransduction, during secondary angiogenesis. Finally, we 
examined the role of the flow-regulated genes nfatc1 and klf2a, known to play an active role in 
endothelial vascular mechanotransduction, on early lymphangiogenesis.  
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4.2 Results 
Alteration of the physical properties of blood flow disrupts secondary angiogenesis  
To address whether blood flow directly impacts on secondary angiogenesis, we have analysed the 
effects of physically altering haemodynamics on developing vasculature, using three different 
approaches.  
 
First, we knocked down the expression of the gene tnnt2 (silent heart), a gene coding for cardiac 
troponin T, which is essential for the establishment of cardiac contractility (Sehnert et al., 2002). 
This knockdown abolished heartbeat and therefore blood flow (as previously shown by (Sehnert et 
al., 2002; Stainier et al., 1996)). It is of note that tnnt2 expression is restricted to cardiomyocytes 
during development (Sehnert et al., 2002), suggesting that any vascular phenotype observed in 
silent heart morphants is related to haemodynamic changes brought by cardiac dysfunction and 
not to a cell autonomous role of tnnt2 in the endothelium.  To visualise secondary angiogenesis, 
we took advantage of the Tg(fli1a:eGFP; flt1:tdtomato) zebrafish line which allows us to distinguish 
arterial, venous and lymphatics endothelial cells at 56 hours post fertilization (hpf). We found that 
knocking down tnnt2 resulted in a significant decrease in the percentage of both venous sprouts 
(VS) and parachordal lymphangioblasts (PLs). These phenotypes were quantified by scoring the 
percentage of PLs per somites in the trunk region (Figure 4.1).  
 
 
 
Figure 4.1 Abolition of blood flow in zebrafish embryos reduces the numbers of secondary 
angiogenic sprouts 
(A) Quantification of venous sprouts in 56 hpf WT (n=33) versus MO-silent heart (1 ng MO; n=74) embryos. 
(B) Quantification of parachordal lymphangioblasts in 56 hpf WT (n=10) versus MO-silent heart (1 ng; n=14) 
embryos. Both are scored as a percentage of sprouts per somites, across 10 somites in the trunk. **** p ≤ 
0.0001,  
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We then investigated the consequence of reduced viscosity, and therefore endothelial shear 
stress, on secondary angiogenesis, while blood circulation is maintained. Work by Vermot and 
colleagues showed that a knock-down of gata-binding factor 1 (gata1), a gene regulating the 
formation of erythrocytes, resulted in a significant reduction in the number of circulating red blood 
cells (Vermot et al., 2009). This reduction in red blood cells was not reported to affect vascular flow 
velocity, but significantly decreased viscosity (Goetz et al., 2014; Vermot et al., 2009). In gata1 
morphants that demonstrated a clear loss of erythrocytes, we found a significant reduction of PLs 
numbers at 56 hpf (Figure 4.2). Similar to tnnt2, the expression profile of gata1 during zebrafish 
development, predominantly in erythroid progenitors cells, suggests that the angiogenesis defects 
observed in gata1 knock down scenario are not related to a cell autonomous role of gata1 in the 
endothelium. 
 
 
Figure 4.2 A decrease in intravascular shear stress reduces the formation of parachordal 
lymphangioblasts. 
Quantification of parachordal lymphangioblasts in 56 hpf WT (n=51) versus MO-gata1 (5ng) (n=46) embryos, 
scored as a percentage of sprouts per somites, across 10 somites in the trunk. **** p ≤ 0.0001,  
 
Having established the effects of decreased viscosity, we next aimed to artificially increase the 
amount of shear stress exerted on the vascular endothelium. The vascular injection of plasma 
expander has been demonstrated to increase vasodilation and cardiac output, which results in an 
increase in the speed of blood flow. Clinically, this effect is used to maintain the global oxygen 
delivery capacity in case of significant blood loss (Hightower et al., 2012). We injected a mixture of 
hydroxyethyl starch (Hetastarch, a high molecular weight sugar derived from plants) and 
fluorescent dye (fluorescein dextran) at the highest dose that allowed for the maintenance of 
normal blood flow, which we predict should increase the intensity of shear stress exerted on the 
blood vascular endothelium, as shear stress is a function of velocity, density, pressure and 
viscosity of blood (Hightower et al., 2012; Nauli et al., 2008). This experimental approach is in 
agreement with the work of Lucitti and colleagues, who made a similar use of hetastarch to 
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increase the viscosity of circulating blood (Lucitti et al., 2007). We injected the mixture into the 
zebrafish vascular system upon initiation of flow (28 to 30 hpf) and confirmed the success of the 
injections by angiography. Interestingly, the predicted increase in shear stress resulted in a 
reduction of PLs numbers at 56 hpf, but did not affect the number of VS (Figure 4.3).  
 
 
                  
Figure 4.3 Increased intravascular shear stress reduces the formation of parachordal 
lymphangioblasts 
(A) Quantification of venous sprouts in 56 hpf WT embryos (n=25) versus embryos injected with dextran 
fluorescein  (n=25) or a 2% hetastarch/dextran fluorescein mix (n=32). (B) Quantification of parachordal 
lymphangioblasts in 56 hpf WT embryos (n=28) versus embryos injected with dextran fluorescein (n=17) or a 
2% hetastarch/dextran fluorescein mix (n=28), to confirm the successful injection of hetastarch in the 
circulation. Both are scored as percentage of sprouts per somites, across 10 somites in the trunk. * p ≤ 0.05 
 
This series of experiments, using three complementary approaches, have shown that altering or 
nullifying haemodynamic results in a reduction of lymphatic sprouting. Interestingly, only a 
decrease, but not an increase, of shear stress seems to affect venous sprouting, suggesting that a 
different range of shear stress mediates both sprouting events. Together, our data suggests a 
limited but significant role of flow-induced shear stress in the regulation of secondary angiogenesis. 
 
Blood flow within the posterior cardinal vein generates luminal forces consistent with shear 
stress-induced response.  
In cultured endothelial cells, only a limited range of shear stress intensity can elicit morphological 
and physiological changes, which include the release of endothelial nitric oxide (NO) and calcium 
(Ca2+), cytoskeletal rearrangements, and an increase of endothelial cell endocytosis (Dewey et al., 
1981; Nauli et al., 2008). We therefore asked whether the intraluminal environment in the posterior 
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cardinal vein (PCV) immediately prior to secondary angiogenesis, is compatible with wall sheer 
stress intensity within the range reported to induce a tangible cellular response (Dewey et al., 
1981; Nauli et al., 2008).  
 
We used high-resolution confocal microscopy of zebrafish transgenic Tg(kdrl:mcherry) embryos, 
which express mCherry in the whole vasculature,  to build a topologically accurate three-
dimensional model of the posterior cardinal vein surface at 32 hpf, at the onset of secondary 
angiogenesis. Using previously reported physical characteristics of circulating blood in zebrafish 
embryos (Forouhar et al., 2006; Hove et al., 2003), we created a mathematical model to predict the 
intensity of shear stress exerted on the venous endothelium at the start of secondary 
angiogenesis.  The parameters used to give physically realistic results are presented in Figure 4.4, 
and are based on published observations (Forouhar et al., 2006; Hove et al., 2003). 
 
Our model shows a clear delineation of regions of high shear stress in the dorsal part of the PCV. 
Regions of high shear stress are also segmented, and are intriguingly reminiscent of the patterning 
of the blood vasculature during secondary angiogenesis, when venous sprouting can be seen at 
intervals coinciding with somite boundaries (Bussmann et al., 2010a) (Figure 4.5). Our model also 
predicts that the range of shear stress to which the venous endothelial cells of the PCV are 
exposed is compatible with an endothelial cellular response, as previously reported by Nauli and 
colleagues and Dewey and colleagues (Dewey et al., 1981; Nauli et al., 2008). These authors 
showed that endothelial cells subjected to shear stress ranging from 5 to 10 dynes/cm2 presented 
with an optimal physiological response, characterised by the release of Ca2+ and NO and 
morphological changes, with a peak response at about 7.5 dynes/cm2. Our model predicts that 
endothelial cells of the PCV are subjected to shear stress ranging from 2.5 to 12.5 dynes/cm2 in a 
segmented manner, suggesting that only some regions of the posterior cardinal vein are in fact 
exposed to a shear stress range compatible with peak physiological response. Interestingly, these 
peak response regions are segregated along the dorsal wall of the vein. 
 
However, the question remains as to how the stimulation provided by shear stress is detected to 
then induce downstream physiological and morphological changes within endothelial cells.  
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Figure 4.4  - Construction of a physical model to predict shear stress intensity in the posterior 
cardinal vein prior to the initiation of secondary angiogenesis 
(A) High resolution confocal image of a Tg(kdlr:mcherry) zebrafish posterior cardinal vein (PCV) at 32 hpf 
allows for a clear delineation of the vessel wall. (B-C) The confocal images were used to generate a three-
dimensional grid of the (B) inner and (C) outer surface of the vessel. These models were used as a 
framework to mathematically compute shear stress intensity in vivo. (D) Velocity (U), Shear viscosity (µ) 
used to calculate the intensity of Shear stress within our mathematical model. The initial velocity was 
predicted using values reported by Forouhar and colleagues in zebrafish (Forouhar et al., 2006). This value 
fluctuates depending on the local architecture of the vessel. The Shear viscosity of blood was reported by 
Hove and colleagues in zebrafish (Hove et al., 2003). 
 
105
 
 
 
Figure 4.5 The intensity of shear stress is patterned along the dorso-ventral and longitudinal axis at 
the time of secondary angiogenesis from the posterior cardinal vein. 
The predicted intensity of shear stress  (dynes.cm-2) exerted on endothelial cells of the PCV at 32 hpf shows 
local peak values on the dorsal side of the vessel, from which secondary sprouts emerge. The modeling is 
based on confocal images of the PCV in kdrl:mcherry embryos at 32 hpf and uses reasonable estimates of 
the physical characteristics of blood flow based on previously published work (presented in Figure 4.4). 
 
Disruption of primary cilia formation and maintenance does not impair secondary 
angiogenesis 
Cilia are small organelles found on most cells of the body, including vascular endothelial cells prior 
to the initiation of secondary angiogenesis (Davenport, 2005; Goetz et al., 2014) (Chapter 3). 
These organelles have been associated with a growing number of cellular processes, one of which 
is mechanosensation (Davenport, 2005; Goetz et al., 2014).  
 
Given the in vivo evidence presented in Chapter 3 for the presence of primary cilia in the zebrafish 
embryonic blood vasculature, we chose to investigate the potential role of these organelles in the 
flow-dependent initiation of secondary angiogenesis (Goetz et al., 2014). 
 
ift88 (polaris) is a major regulator of cilia formation and maintenance, and reports show that in its 
absence, ciliated zebrafish cells present with obvious structural and functional defects (Huang and 
Schier, 2009; Pazour et al., 2000; Tsujikawa and Malicki, 2004).  
 
To delineate arteries from lymphatic and venous endothelium, we crossed a loss of function 
zebrafish mutant for ift88 (ift88tz288) to the Tg(lyve1:DsRed2; flt1:YFP) transgenic line. At 56 hpf, we 
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found no difference in the number of secondary angiogenic sprout in the ift88 mutants compared to 
controls. At 5 dpf, ift88 mutant exhibited a thoracic duct extent similar to that of their wild type 
counterparts, although they displayed a curved body axis, which is consistent with an ift88 loss-of-
function mutation (Tsujikawa and Malicki, 2004) (Figure 4.6). These results suggest that ift88, and 
by extension primary cilia, play no role in secondary angiogenesis and the formation of the thoracic 
duct in the zebrafish.  
 
 
 
 
Figure 4.6. Disruption of primary cilia formation and maintenance does not impair secondary 
angiogenesis 
 (A-B) The vasculature Tg(lyve1:DsRed2) in (A) wild-type sibling  and (B) ift88tz288 embryos at 56 hpf 
(arrowheads indicate parachordal lymphangioblasts and white arrows indicate venous sprouts). (C-D) 
Overall morphology of (C) wild-type siblings and (D) ift88tz288 mutants at 5 dpf. (E-H) The vasculature 
Tg(lyve1:DsRed2; flt1:YFP) of (E,G) WT and (F,H) ift88tz288 mutants at 5 dpf. (I) Quantification of secondary 
sprouts in WT (n=12) vs ift88tz288 (n=10) at 56 hpf. (J) Quantification of thoracic duct extent in WT (n=16) vs 
ift88tz288 (n=18). Both TD extent and secondary sprouts were scored as percentage per somites, across 10 
somites in the trunk. TD: thoracic duct; DA: dorsal aorta; PCV: posterior cardinal vein. **** p ≤ 0.0001 
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 Ca2+ and NO signaling are dispensable for the initiation of secondary angiogenesis 
Nauli and colleagues demonstrated that endothelial cells subjected to a very specific range of 
shear stress respond physiologically by releasing NO and Ca2+ (Nauli et al., 2008). We therefore 
investigated the role of NO and Ca2+ signaling pathways in the initiation of secondary 
angiogenesis. As previously discussed in Chapter 3, treatment of zebrafish embryos with a known 
in vivo inhibitor of calcium signaling, Nifedipine, has no effect on the formation of secondary 
angiogenic sprouts (Figure 4.7). Using an NO agonist (L-NAME)(Pfeiffer et al., 1996), we found no 
evidence that nitric oxide signaling plays a role in the initial sprouting of lymphatic precursor cells 
from the vein (Figure 4.7), even when using the agonist at a concentration ten times that previously 
reported to have a biological effect (North et al., 2009). Together, our findings suggest that both 
nitric oxide and calcium-signaling pathways are dispensable for secondary angiogenesis. 
 
 
Figure 4.7. Ca2+ and NO signaling are dispensable for the initiation of secondary angiogenesis 
 Quantification of parachordal lymphangioblasts at 56 hpf in untreated (n=63), DMSO 0.2% (n=62), DMSO 
0.2%/L-NAME 100 µM treated embryos (n=103) and DMSO 0.2%/Nifedipine 100µm treated embryos 
(n=101) at 56 hpf, scored as a percentage of sprouts per somites, across 10 somites in the trunk. The 
number of PLs is unaffected in the presence of a nitric oxide signaling antagonist  (L-NAME) or a calcium 
channel blocker (Nifedipine). 
 
Effectors of flow-mediated shear stress regulate secondary angiogenesis 
We next turned our attention to two proteins, klf2a and nfatc1, which are known to be transcribed 
or activated in response to flow (Sabine et al., 2012; Vermot et al., 2009). Work by Nauli and 
colleagues has shown that upon detection of an extracellular mechanical stimuli, Polycystin-1 
triggered an influx of intracellular calcium, through the transactivation of the calcium permeable 
cation channel Polycysytin-2 and cytosolic calcium channels (Nauli et al., 2003; Nauli et al., 2008). 
The change in calcium homeostasis mediates the activation of downstream proteins. One such 
target being Nfatc1, whose activation is mediated by a Polycystin-2 dependent cytosolic calcium 
increase in vitro (Puri et al., 2004). The increase in intracellular calcium activates the protein 
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Calcineurin, an intermediate messenger protein, which triggers the dephosphorylation of Nfatc1 
(reviewed in (Hogan, 2003; Rusnak and Mertz, 2000)). This dephosphorylation leads to the 
translocation of Nfatc1 to the nucleus, where it acts as a transcription factor ((Beals et al., 1997), 
reviewed in (Hogan, 2003)).   
 
In the context of cardiovascular development, Nfatc1 plays a major role in cardiac and lymphatic 
valve morphogenesis, two processes that are heavily dependent upon developmental blood flow 
(Bazigou et al., 2011; Hove et al., 2003; Sabine et al., 2012; Tatin et al., 2013; Vermot et al., 2009). 
Nfatc1 also regulates the formation of primary lymphatic structures, such as lymph sacs, making it 
a compelling candidate to investigate in relation to the initiation of secondary angiogenesis in 
zebrafish.    
 
Another compelling candidate is the gene klf2a, the expression of which is dependent upon the 
initiation of blood flow. klf2a is involved in the blood flow dependent regulation of haematopoietic 
stem cell programming during zebrafish embryonic development through an NO-dependent 
pathway (Wang et al., 2011a). Downstream of blood flow, klf2a also regulates vascular 
haemodynamics in vivo and is central to the cardiovascular system development and its adaptation 
to luminal shear stress (Lee et al., 2006). Vermot and colleagues have subsequently described a 
flow dependent role of klf2a in cardiac valve formation, which raises the intriguing possibility that 
klf2a may act within the same signaling pathway as nfatc1, downstream of blood flow stimuli 
(Vermot et al., 2009).  
 
Knockdown of flow-sensitive gene klf2a impairs early lymphangiogenesis 
klf2a expression is dependent upon the initiation of blood flow and its expression seems to be 
restricted to the vascular endothelium, which is suggestive of a cell autonomous role in the 
vasculature (Figure 4.8A-B)(Dekker et al., 2002; Lee et al., 2006; Wang et al., 2011a). To assess 
whether klf2a might be acting downstream of shear stress we used a previously validated 
morpholino targeting klf2a in zebrafish. Upon injection of the morpholino, we observed a significant 
reduction in the number of PLs at 56 hpf (Figure 4.8C) in MO-klf2a embryos, which later lead to 
significant reduction in the extent of the thoracic duct compared to their wild-type counterparts 
(Figure 4.8D). This is the first evidence for a role of klf2a in lymphatic vascular development.  
Knockdown of nfatc1 impairs parachordal lymphangioblasts and thoracic duct formation 
The role of nfatc1 in lymphangiogenesis was presented in detail in section 1.4.2.5. Though its role 
in mice is well established, a role in zebrafish has never been documented. Its role in cardiac and 
lymphatic valve morphogenesis, a process that has already been shown to be extensively 
dependent upon flow dynamics, makes it a compelling candidate to be part of a stress-induced 
downstream pathway regulating lymphangiogenesis (Bazigou et al., 2011; Hove et al., 2003; 
Sabine et al., 2012; Tatin et al., 2013; Vermot et al., 2009). 
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Figure 4.8. klf2a expression is flow-dependent and its knock-down reduces the formation of 
parachordal lymphangioblasts and the thoracic duct 
(A-B) in situ hybridisation analysis of klf2a expression at 32 hpf in WT (n=142/150) and MO-silent heart 
(n=62/62) embryos (lacking blood flow) shows that its expression is dependent on blood flow. (C) 
Quantification of parachordal lymphangioblasts at 56 hpf in WT (n=51), MO-klf2a (5 ng; n=20) and MO-klf2a 
(10 ng; n=36) embryos. (D) Quantification of thoracic duct extent at 5dpf in WT (n=42), MO-klf2a (5 ng; 
n=56) and MO-klf2a (10 ng; n=18) embryos. Both TD extent and secondary sprouts were scored as 
percentage per somites, across 10 somites in the trunk. * p ≤ 0.05, **** p ≤ 0.0001 
 
Using a splice site targeting morpholino, we showed that nfatc1 knock-down in the zebrafish leads 
to a significant reduction in the number of PLs at 56 hpf (Figure 4.9A-C). This reduction was 
consistent with a significant reduction of the extent of the thoracic duct at 5 dpf (Figure 4.9D-F). 
Co-injections of nfatc1 morpholino with a p53 morpholino were not sufficient to rescue the 
lymphatic phenotype visible in MO-nfatc1 embryos at 5 dpf (Figure 4.9G), confirming that the 
lymphatic phenotype observed in nfatc1 morphants was specific rather then due to morpholino-
induced cell toxicity. Using gene specific primers, we also showed by qPCR that nfatc1 normalised 
expression is significantly reduced at 24 hpf in MO-nfatc1 embryos (Figure 4.9H), further validating 
the specificity of the morpholino. 
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Figure 4.9 - Specific knock down of nfatc1 expression in zebrafish reduces the formation of 
parachordal lymphangioblasts and the thoracic duct  
(A-B) The vasculature Tg(fli1:eGFP) of (A) WT and (B) MO-nfatc1(10 ng) embryos at 56 hpf (asterisk 
indicates an absence of parachordal lymphangioblast). (C) Quantification of parachordal lymphangioblasts in 
WT (n=51) versus MO-nfatc1 (5ng) (n=20) and MO-nfatc1 (10 ng; n=51) embryos at 56 hpf. (D-E) The 
vasculature Tg(fli1:eGFP; kdrl:mcherry) of (D) WT and (E) MO-nfatc1(10 ng) embryos at 56 hpf (asterisk 
indicate the absence of the thoracic duct). (F) Quantification of thoracic duct extent in WT (n=25) versus MO-
nfatc1 (n=11; 5 ng) and MO-nfatc1 (n=20)(10 ng) embryos at 5 dpf. (G) We show that the morpholino 
induced phenotype is not related to cell toxicity with co-injection of a p53 morpholino which does not rescue 
the lymphatic phenotype observed in MO-nfatc1 (10 ng) embryos at 5 dpf. Both TD extent and secondary 
sprouts were scored as percentage per somites, across 9 somites in the trunk (H) Quantification of nfatc1 
expression relative to the house keeping gene elf1a in WT (n=15 embryos were pooled for mRNA) versus 
MO-nfatc1 (n=15 embryos were pooled for mRNA) embryos using gene specific primers. * p ≤ 0.05, *** p ≤ 
0.001; **** p ≤ 0.0001. 
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4.3 Discussion 
 
This chapter presents the intriguing discovery that modification of vascular haemodynamics during 
early embryogenesis has a direct effect on secondary angiogenesis. This represents a novel facet 
of the role of blood flow in cardiovascular development (Bazigou et al., 2011; Hove et al., 2003; 
Lucitti et al., 2007; Planas-Paz et al., 2012; Sabine et al., 2012; Tatin et al., 2013; Vermot et al., 
2009).  
 
Mechanosensors in secondary angiogenesis  
We showed that ift88 loss-of function mutants do not exhibit any defect in the formation of 
secondary sprouts. A potential caveat to this conclusion however, comes from work by Tsujikawa 
and Malicki who show that ift88tz288 mutant present with normal ciliogenesis in a number of tissues 
during early embryogenesis (prior to 72 hpf), due to maternal mRNA deposition. We chose to 
address the question as to whether such a phenomenon could explain the absence of early 
vascular phenotype by knocking down ift88 protein translation using a previously validated ATG 
morpholino (Kramer-Zucker et al., 2005). Strikingly, this resulted in a significant decrease in both 
the number of PL at 56 hpf and in the extent of the thoracic duct at 5 dpf (Supplementary Figure 2). 
It is worth noting however that Tsujikawa and Malicki, and Kramer-Zucker and colleague report no 
difference in the intensity of the ciliary phenotype exhibited by ift88 null mutants and translation 
targeted ift88 zebrafish morphants. This either suggests that our morpholino vascular phenotype is 
non-specific, or that a difference exists within the vascular endothelium, which was not analysed by 
either author.  
 
Interestingly, Nauli and colleagues presented Polycystin-1 as a key mechanosensory protein acting 
at the level of the cilia, but it is unlikely to play a similar role in the initiation of secondary 
angiogenesis, as demonstrated in chapter 3 by the absence of secondary angiogenesis defects in 
all investigated pkd1 knock out models 
 
Although further investigation would have to be carried out to formally establish whether cilia are 
one of the mechanosensors involved in secondary angiogenesis, other mechanosensors might 
play a role in this context. Adherens junctions and the cytoskeleton could be of importance in 
secondary angiogenesis as recent results by Yang and colleagues have suggested that lymphatic 
precursor cells budding off the cardinal vein express high levels of VE-CADHERIN to maintain the 
integrity of the venous endothelium (Yang et al., 2012). Additionally, Tzima and colleagues showed 
that VE-CADHERIN is part of a mechanosensory complex downstream of PECAM-1 during shear 
stress mechanotransduction (Tzima et al., 2005). It would be of interest to investigate not only the 
dynamic of adherens protein in budding LEC progenitors, but also the vascular consequences of a 
PECAM-1 deletion prior to secondary angiogenesis.  
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 This chapter also does not address the potential role played by caveolae during secondary 
angiogenesis. Caveolae have been shown to modulate shear stress mechanotransduction through 
the activation of nitric oxide signaling (Yu et al., 2006). The absence of any visible lymphatic 
phenotype in embryos treated with L-NAME, a reported inhibitor of nitric oxide synthase (Pfeiffer et 
al., 1996), suggest that any role played by caveolae during the initiation of secondary angiogenesis 
would be independent from nitric oxide signaling. However, the ever growing range of signaling 
molecules known to interact with caveolae, including adherens junction proteins, and cytoskeletal 
complexes (reviewed in (Parton and del Pozo, 2013), warrants further investigation. 
 
A potential nfatc1-klf2a signaling pathway  
We present the first evidence of a novel role of two well known flow-regulated transcription factors, 
klf2a and nfatc1, in the regulation of secondary angiogenesis. We demonstrated that a knock-down 
of klf2a and nfatc1 expression resulted in a significant decrease in the formation of PLs. However, 
it remains to be seen whether both genes act within the same signaling pathway. Given the flow-
dependent expression of klf2a and the observed decreased secondary angiogenesis in embryos 
lacking blood flow, in future work we will attempt to rescue the vascular defects observed in in 
silent heart morphants by over-expressing klf2a. A rescue would firmly define klf2a as a direct 
effector of blood flow in this particular developmental context. Beals and colleagues have reported 
the sequence of a constitutively active form of Nfatc1, which translocates to the nucleus and is 
independent of calcineurin and calcium signaling (Beals et al., 1997). Expression of this particular 
form of nfatc1 in a similar no-flow context would support an angiogenic role of nfatc1. Finally, over-
expression of klf2a and constitutively active nfatc1 mRNA in both klf2a and nfatc1 morphants 
would allow us to investigate if both gene are likely to act in the same signaling pathway.  
 
Calcium signaling and secondary angiogenesis 
This chapter presents conflicting results as to which biochemical pathways mediate our reported 
flow-dependent secondary angiogenesis process. Both klf2a and nfatc1 have respectively been 
shown to act in concert with nitric oxide and calcium signaling during development (Sabine et al., 
2012; Wang et al., 2011a). In addition, calcium and nitric oxide signaling are two of the most 
studied pathways activated during the transduction of shear stress stimuli in endothelial cells. The 
well documented activation of Nfatc1 downstream of calcium signaling is at odds with the results 
presented here that the inhibition of calcium signaling in vivo does not affect the initiation of 
secondary angiogenesis, although Nfatc1 expression seems required in this process. However, it 
is worth noting that the calcium inhibitor used in this chapter to block calcium signaling, Nifedipine, 
is specific to a specific subtype of calcium channels (L-type). It is therefore possible that signaling 
through other calcium channels may be involved in secondary angiogenesis, upstream of Nfatc1.  
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Similarly there exists a discrepancy between the observed reductions in the numbers of PLs 
observed in MO-klf2a embryos and the absence of secondary angiogenesis defect in embryos 
treated with the nitric oxide inhibitor L-NAME. These results suggest that the klf2a-NO signaling 
cascade that underlies klf2a’s role in haematopoiesis, a developmental process heavily dependent 
on shear-stress-induced signaling (Wang et al., 2011a), is not involved in the initiation of 
secondary angiogenesis.  
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4.4 Experimental procedures 
 
Zebrafish strains, mapping and genotyping 
All experiments were conducted in accordance with Australia Code of Practice for the Care and 
Use of Animals for Scientific Purposes with approval form the University of Queensland Animal 
Ethic Committee. Zebrafish were maintained and mutagenesis screening performed as previously 
described (Hogan et al., 2009a). Genetic mapping was performed as previously described (Hogan 
et al., 2009a). The Tg(fli1a:EGFP)y1, Tg(-6.5kdr-l:mCherry), Tg(-0.8flt1:tdTomato) lines are 
previously described in  (Amsterdam et al., 2004; Bussmann et al., 2010b; Hogan et al., 2009b; 
Lawson and Weinstein, 2002)  
 
Imaging and analysis 
For live confocal and spinning disk imaging, embryos were mounted as previously described 
(Hogan et al., 2009c). Imaging was performed in the Australian Cancer Research Foundation’s 
Dynamic Imaging Facility at the Institute for Molecular Bioscience on a LSM Zeiss 510 NLO,META 
10X or 20X objectives. Images were analysed using the Zeiss Zen software, Photoshop suite and 
ImageJ. 
 
Statistical analysis 
We used a Mann-Whitney rank sum t-test in Figure 1,3,5 and a Kruskal-Wallis test with Dunn’s 
correction in Figures 2 and 7. Graph Pad prims software was used for all figures. p-values are 
represented in the Figures as *= p≤ 0.05, **= p ≤ 0.01, ***= p ≤ 0.001 and ****= p ≤ 0.0001. 
Standard error of the mean is represented in error bars. Figure 3, 8C and 9C use data collected 
from injections made in a similar pool of wild-type embryos. They therefore share identical control 
data (n=51 wild-type embryos). 
 
Shear stress modelling 
Fluid equations of motion:  
The motion of an incompressible, Newtonian fluid is governed by two equations:  
The Continuity equation:         
(1)  𝛁 ∙ 𝑼 = 0; 
 
and 
 
The Navier-Stokes equation;    
(2)  𝜌 !𝑼!" + 𝑼 ∙ 𝛁 𝑼 = −∇𝑝 + 𝜇∇!𝑼 
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where U is the velocity of the fluid, ρ is the fluid density, p is the fluid pressure, µ is the fluid ‘shear 
viscosity’, t is time and ∇ is the gradient operator.   
The shear stress 𝛕 on a surface with normal vector n can then be determined from the velocity U, 
via the following equation.   
            
(3)  𝛕 = 𝜇 𝒏 ∙ 𝛁 𝑼. 
 
Analytic solutions to these equations can be found in some simplified systems. For more complex 
systems, solutions can be approximated numerically.  
 
Three-dimensional images of zebrafish vessels used for modeling were generated from z-stack 
confocal images of 32 hpf Tg(kdrl:mcherry) embryos using ImageJ, Mesh Maker and OpenFOA M.  
 
Whole-mount in situ hybridization and immunochemistry 
The klf2a probe has been previously described in (Vermot et al., 2009). In situ hybridization was 
performed as previously described (Thisse et al., 1993) with NBT/BCIP staining solution (Roche).  
 
Morpholino oligomers 
Previously published morpholino against klf2, silent heart and ift88 (Kramer-Zucker et al., 2005; 
Sehnert et al., 2002; Wang et al., 2011b) were injected at 5 ng (klf2a), 1 ng (silent heart) and 0.5 
ng (ift88) per embryo. The sequence of the morpholino targeting the splice junction of nfatc1 
between exon 3 and intron 3 used was 5’-
GGGAGGTCATCCAGTGGTCCAGGTATCAGTTCACAATCTCTCACAAACAGGCTTT-3’. This 
morpholino was injected at 5 ng per embryo. Injections were performed as described in (Hogan et 
al., 2008). 
 
Nitric Oxide and calcium signaling inhibitor treatment 
Zebrafish embryos were exposed to DMSO, Nifedipine and L-NAME (Tocris Bioscience – 1075 
and 0665) at the concentration indicated in E3 media, from 24 hpf to 56 dpf. The treatment media 
was changed twice daily.  L-Name was stored according to the manufacturer’s recommendations.  
 
Quantitative PCR (qPCR):  
Each qPCR reaction mixture contained 12.5 µl ABI SYBR green master mix (Applied Biosystems), 
1 μl cDNA, and 1 μl primer mix (3.5 µM) (Forward: 5’- TATGAGACTGAAGGCAGCAG-3’, Reverse: 
5’-GCCTATGAACAGCTGTAGGG-3’, gives a 114 bp band) to a final volume of 20 µl. Amplification 
was performed in technical triplicate in 96 well plates (Applied Biosystems). 
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Chemical injections 
Dextran Fluorescein and Biotin, 10.000 MW, Anionic, Lysine Fixable (Mini-Emerald; Life 
technologies; D-7178) was diluted according to the manufacturer’s recommendations to a 
concentration of 1 mg/ml. Hydroxyethyl starch (Hetastarch ; Sigma ; H6382) was diluted 2 % in 
1mg/ml Dextran Fluorescein. Injections were made in the ducts of Cuvier at 30-32 hpf.  
 
4.5 Acknowledgements 
The model presented in figure 4.4 and 4.5 was designed and built by Tim Lamberton. 
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5. Concluding remarks 
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In this thesis, I have presented findings that extend our basic understanding of vascular 
morphogenesis during embryonic life. This work stems from a forward genetic screen aiming to 
isolate new regulators of lymphangiogenesis, which was performed at the Hubrecht Institute 
between 2007 and 2009. Given the multiplicity of mutants isolated during this screen that were 
linked to component of the VEGFC/VEGFR3 pathway, a conscious effort was made in trying to 
isolate and characterise mutants exhibiting unreported lymphatic developmental defects. In effect, 
both hu10125 and lyc1 mutant families were selected on the basis of their lymphatic phenotypes 
which diverged, to a significant extent, from those reported in known regulators of 
lymphangiogenesis. These mutants also exhibited cardiovascular phenotypic defects that 
potentially linked them to known developmental pathways such as NOTCH, 
NFATC1/CALMODULIN and FOXC2-dependent signaling pathways. This approach increased the 
potential of these mutants to lead to the identification of novel regulators of lymphangiogenesis and 
their integration within the cardio-vascular developmental framework.   
 
In effect, this PhD project led to the discovery of two novel genes involved in the regulation of 
developmental angiogenesis, and constitutes the first report of a flow-mediated regulation of the 
initiation of secondary angiogenesis.  
 
Cad is a novel post-translational regulator of Notch signalling 
The zebrafish mutant cadhu10125, presented in Chapter 2, was initially selected due to its defective 
lymphatic vascular development. This mutant eventually led us to the serendipitous discovery of a 
novel regulator of Notch/Vegfc signalling within the blood arterial vasculature: Carbamoyl-
phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (Cad). The investigation 
of a role for Cad in the blood vasculature originated from the observation that cad mutant embryos 
exhibited a specific vascular hyper-branching of intersegmental arteries, reminiscent of mutants in 
the Notch pathway (Hogan et al., 2009c). The rescue of this hyper-branching phenotype by 
selective knock-down of the VEGFC/VEGFR3 pathway, and the known role for Cad upstream of 
protein glycosylation, led us to hypothesise that Cad regulates Notch-mediated inhibition of the 
VEGFC/VEGFR3 pathway in intersomitic arteries by contributing to UDP-dependent glycosylation 
of Notch components, which are known to require glycosylation to function. Interestingly, cad 
mutants do not display a morphological phenotype equivalent to that exhibited by pan-Notch-
deficient models, such as mindbomb mutants or early DAPT-treated embryos (Itoh and Chitnis, 
2003; Lawson et al., 2001; Lawson and Weinstein, 2002; Leslie et al., 2007; Ozbudak and Lewis, 
2008; Schier et al., 1996; Therapontos and Vargesson, 2010). We propose that this is likely due to 
residual maternally-deposited cad, which would provide sufficient UDP for early development but 
not for later life. This decline in UDP supply would also be consistent with the progressive nature of 
the phenotype of the cadhu10125 animals. The results presented in this thesis support the novel 
possibility that post-translational glycosylation of Notch plays a role in the regulation of 
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angiogenesis. However, we have not yet been able to demonstrate the exact target of Cad-
dependent glycosylation in vivo. Though we demonstrate that Notch activity is down regulated in 
cad mutant embryos, it remains to be seen which components of Notch signalling are effectively 
targeted by UDP-dependent glycosylation. Although the Notch receptor presents with multiple 
target sites for UDP-dependent glycosylation events, making it a logical candidate, other 
downstream effectors of Notch signalling might be affected. Further in-depth biochemical 
assessment of UDP-mediated glycosylation will be necessary to fully understand how cad is able 
to modulate Notch activity.  
 
Pkd1 in lymphangiogenesis 
At the core of this thesis is the discovery that Pkd1 is a novel regulator of lymphatic vascular 
morphogenesis. Pkd1 has garnered much attention from the scientific community; the past 20 
years has seen the publication of more than 800 papers mentioning Pkd1 (source: ncbi). It initially 
drew researchers’ attention thanks to its role in polycystic kidney disease pathologies, and as such, 
many studies published to date have focussed on the role of Pkd1 in this context.  
 
The work presented in Chapter 3 of this thesis is the first to report a role for pkd1 in both the 
regulation of vascular endothelial cell morphology and dynamic behaviour during embryogenesis. 
Using a combination of models, both in vivo and in vitro, we demonstrate that Pkd1 cell-
autonomously regulates the polarity and cell-to-cell junctions of lymphatic endothelial cells. 
Evidence to support the importance of polarisation, adhesion, mixing and directed migration of 
vascular endothelial cells during blood vascular morphogenesis is amassing (Arima et al., 2011; 
Blum et al., 2008; Herbert and Stainier, 2011; Jakobsson et al., 2010), and the work presented in 
this thesis supports the idea that such mechanisms are likely to play a central role in the context of 
lymphangiogenesis as well. Specifically, this work adds new insight into how Pkd1 may modulate 
planar cell polarity (PCP) signalling during morphogenesis. Based on recent findings that Pkd1 
modulates cellular convergent extension through PCP signalling during kidney tubule development, 
as well as the finding that PCP pathway-mediated junctional rearrangement occurs during 
lymphatic vessel morphogenesis, our current work strongly suggests that loss of function of this 
pathway may mimic the Pkd1 lymphatic phenotype, characterised by an increased width of 
sprouting vessels, increased cell number per vessels and a significant reduction in network 
branching.  
 
Indeed, Pkd1KO LECs within maturing vessels display complete randomisation of their polarity and 
abnormal cell-to-cell junctions, which occur concomitantly with a significant reduction in the 
complexity of the vascular network of which these vessels are part. The existing interplay between 
cell polarity and cell-to-cell junctions during tissue morphogenesis made it difficult for us to identify 
which component is regulated primarily by Pkd1. At this point in time, the only real hint of the 
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mechanism underlying the role of Pkd1 during lymphangiogenesis comes from what is known 
about its interaction with components of the (PCP) pathway such as PAR3 and aPKC, and the 
adhesion proteins β-CATENIN and E-CADHERIN. Interestingly, the abnormal localisation of VE-
CADHERIN and β-CATENIN at cell-to-cell junctions in Pkd1KO embryos provides us with some 
indication of where to begin this investigation. 
 
The work presented in Chapter 3 also provides evidence to support the re-evaluation of many of 
the phenotypes of autosomal dominant polycystic kidney disease (ADPKD). ADPKD, a pathology 
affecting one in 1000 people (Chapin and Caplan, 2010), is primarily characterised by the 
formation of hepatic cysts and gross enlargement of the structures of the kidney. A mutation in 
Pkd1 is responsible for the onset of ADPKD in 85 cases out of 100 (Chapin and Caplan, 2010). 
The work presented in this thesis suggests that patients suffering from ADPKD might also present 
with previously unappreciated local lymphatic abnormalities contributing to the severity of the 
disease.  
 
Flow-induced secondary angiogenesis 
Initiated soon after the identification of the loss of function mutation in pkd1a in lyc1 embryos, the 
work presented in Chapter 4 developed independently, as it became increasingly clear during the 
lyc1 characterisation effort that the well-reported mechanosensory role of Pkd1 was unlikely to 
underlie its function in lymphangiogenesis. 
 
In Chapter 4, we present the discovery that intravascular shear stress is linked to secondary 
angiogenesis. We provide evidence supporting the idea than an alteration of flow dynamics, prior 
to the initiation of secondary angiogenesis, significantly reduces the number of angiogenic sprouts 
produced. We provide evidence to suggest that two proteins known to play a role during shear 
stress mechanotransduction, namely klf2a and nfatc1, are implicated in this process. This 
discovery is one of the first steps toward understanding how vascular endothelial cells are able, 
during angiogenesis, to integrate extracellular stimuli and translate it physiologically.  
 
Our results suggest the existence of a novel flow-dependent developmental process that regulates 
the initiation of secondary angiogenesis. Further investigation into the genetic and molecular 
pathways underlying this process might give us an explanation as to why only a subset of vascular 
endothelial cells give rise to secondary angiogenic sprouts. We can hypothesise that all vascular 
endothelial cells might share a similar genetic profile, making them susceptible to sprout from the 
venous endothelium, but only those exposed to a precise range of wall shear stress, dependent 
upon the local architecture of the vessel, will effectively emerge. In future work, it would be 
valuable to generate a shear stress map (similar to that presented in Figure 4.5) modelled 
continuously from the initiation of secondary angiogenesis to the end of the secondary angiogenic 
122
sprouting phase (32 to 48 hpf). Using a combination of transgenic lines to visualise both the 
structure of the posterior cardinal vein and secondary sprouts (such as Tg(kdrl:mCherry; 
fli1:eGFP)) would allow us to trace the origins of these sprouts and correlate them with a three-
dimensional model of predictive shear stress exerted on the wall of the vein.  
 
Zebrafish forward genetic screening 
The forward genetic screen for novel lymphatic mutants that constitutes the source of the lyc1 and 
cadhu10125 mutants used the absence of a thoracic duct as a hallmark of lymphatic deficiency. This 
approach stemmed from the relative difficulty to screen for defects in other lymphatic structures 
using conventional manual screening and the vascular transgenic lines available at that time. At 
the time of the initial screen, only the Tg(fl1:eGFP)y7 line allowed for the visualisation of the 
lymphatic vasculature. The recent publication, by Okuda and colleagues, of the lyve1:DsRed2 line, 
which specifically highlights the venous and lymphatic vasculature, provides a new opportunity for 
lymphatic researchers to investigate specialised structures other than the thoracic duct (Okuda et 
al., 2012). These structures, such as the recently discovered facial lymphatic complex, might 
present with alternative cellular origins and involve previously uncharacterised regulatory 
pathways. The use of this line, in conjunction with specific blood vascular transgenic lines, will 
allow for the isolation of a new range of lymphatic mutants, with potentially more selective 
phenotypes, that would not have been detected in the original studies. Hence, second generation, 
more sensitive screens may be warranted for gene discovery in the future. 
 
Basic scientific discoveries and translational potential  
The discovery and report of a novel developmental gene is only the starting point in a long pathway 
towards improving human health. A growing emphasis has been placed on the necessity to 
integrate these genes within known or novel genetic pathways, and provide evidence as to which 
cellular mechanism/s may underlie the developmental process they control. Classic forward 
genetic experiments are extremely labour intensive, and despite yielding a treasure trove of novel 
genes, are but the first step in the characterisation of genetic pathways. A combination of 
biochemical, cell biological and systems-level approaches is necessary to integrate the functions of 
novel genes isolated over the course of forward genetic processes.  
 
This thesis has taken advantage of the multiple models available, and has used both in vivo and in 
vitro techniques, to provide a comprehensive description of the role cad and pkd1 in the regulation 
embryonic vascular development, and to contribute to extending our understanding of how 
lymphangiogenesis is regulated at the cellular and tissue level during early embryogenesis.  A 
better understanding of the defining mechanisms underlying lymphangiogenesis is necessary 
before the development of therapeutic processes to treat diseases and pathologies, such as 
cancer metastasis, can be considered.  
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 When primary tumours form in close proximity to blood and lymphatic vessels, these vessels are 
known to be mediators of tumour metastasis. The lymphatic and haematogenous propagation of 
tumour cells is often preceded by the stimulation of de novo angiogenesis (Alitalo et al., 2005). 
These nascent vessels connect to the general circulation and provide unique access points to 
distant organs permeated by the lymphatic vasculature. Targeting this neo-angiogenic process 
offers hope for a new method by which tumour spread can be significantly reduced, and thus 
improve survival prognosis in cancer patients. Current anti-angiogenesis therapy, which exclusively 
targets the VEGF/VEGFR3 pathway, has so far had limited success (Vegenics annual report 
2013)(Bottsford-Miller et al., 2012; Welti et al., 2013), and it is becoming increasingly clear that 
targeting a combination of developmental pathways will be necessary to address these 
shortcomings. We hope that the work presented in this thesis will provide novel and interesting 
targets for future translational research. Although the far-reaching role of Cad, upstream of UDP-
dependent glycosylation and de novo pyrimidine synthesis makes it an inadequate target for anti-
angiogenic therapies, we hope that future work will identify which proteins in the Cad-mediated 
glycosylation pathway directly interact with Notch signalling, and may thus serve as more specific 
therapeutic targets. Finally, the characterisation of a putative role of Pkd1 in the formation and 
maturation of tumour-induced lymphatic vessels, and the identification of its interacting partners in 
this process, might also provide novel therapeutic targets to hinder metastasis.  
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Supplementary Figure 1.  
Knock-down of ift88 transcription results in a secondary angiogenic defect. 
(A) Quantification of secondary sprouts in WT (n=24) vs MO-ift88 (n=38). (B) Quantification of (thoracic duct 
extent in WT (n=14) vs MO-ift88 (n=24) TD: thoracic duct; DA: dorsal aorta; PCV: posterior cardinal vein. **** 
p ≤ 0.0001 
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